Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16295780,elimination of half life,"In vitro, the elimination of half life was achieved at 2.88+/-1.14 h for NAC and at 3.68+/-1.84 h for total NAC.",Effect of high-dose intravenous N-acetylcysteine on the concentration of plasma sulfur-containing amino acids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16295780/),h,2.88,772,DB00143,Glutathione
,16295780,elimination of half life,"In vitro, the elimination of half life was achieved at 2.88+/-1.14 h for NAC and at 3.68+/-1.84 h for total NAC.",Effect of high-dose intravenous N-acetylcysteine on the concentration of plasma sulfur-containing amino acids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16295780/),h,3.68,773,DB00143,Glutathione
,16295780,body clearances,"The body clearances were 1.23+/-0.77 L h(-1) kg(-1) and 0.56+/-0.27 L h(-1) kg(-1) and the volumes of distribution were 3.07+/-0.10 L kg(-1) and 3.00+/-0.11 L kg(-1), respectively.",Effect of high-dose intravenous N-acetylcysteine on the concentration of plasma sulfur-containing amino acids. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16295780/),[l] / [h·kg],1.23,774,DB00143,Glutathione
,16295780,body clearances,"The body clearances were 1.23+/-0.77 L h(-1) kg(-1) and 0.56+/-0.27 L h(-1) kg(-1) and the volumes of distribution were 3.07+/-0.10 L kg(-1) and 3.00+/-0.11 L kg(-1), respectively.",Effect of high-dose intravenous N-acetylcysteine on the concentration of plasma sulfur-containing amino acids. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16295780/),[l] / [h·kg],0.56,775,DB00143,Glutathione
,16295780,volumes of distribution,"The body clearances were 1.23+/-0.77 L h(-1) kg(-1) and 0.56+/-0.27 L h(-1) kg(-1) and the volumes of distribution were 3.07+/-0.10 L kg(-1) and 3.00+/-0.11 L kg(-1), respectively.",Effect of high-dose intravenous N-acetylcysteine on the concentration of plasma sulfur-containing amino acids. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16295780/),[l] / [kg],3.07,776,DB00143,Glutathione
,16295780,volumes of distribution,"The body clearances were 1.23+/-0.77 L h(-1) kg(-1) and 0.56+/-0.27 L h(-1) kg(-1) and the volumes of distribution were 3.07+/-0.10 L kg(-1) and 3.00+/-0.11 L kg(-1), respectively.",Effect of high-dose intravenous N-acetylcysteine on the concentration of plasma sulfur-containing amino acids. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16295780/),[l] / [kg],3.00,777,DB00143,Glutathione
,1549695,T1 relaxivity,With T1 relaxivity values of 8.7 L/mmol.,Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1549695/),[l] / [mM],8.7,5135,DB00143,Glutathione
,1549695,biliary transport maximum,"In rats, the biliary transport maximum was 5 mumol gadolinium/min.kg.",Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1549695/),g·μM,5,5136,DB00143,Glutathione
,25951660,total blood clearance,"Following intravenous administration of KUC-7322 (1 mg/kg), total blood clearance was 1.36 L/h/kg, suggesting that intrinsic hepatic clearance is the rate-limiting step in KUC-7322 excretion.","Absorption, disposition, metabolism, and excretion of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, in rats. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25951660/),[l] / [h·kg],1.36,5596,DB00143,Glutathione
,25951660,half-life (t 1/2),"KUC-7322 levels rapidly decreased, with a half-life (t 1/2) of 0.42 to 1.37 h thereafter.","Absorption, disposition, metabolism, and excretion of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25951660/),h,0,5597,DB00143,Glutathione
,25951660,half-life (t 1/2),"KUC-7322 levels rapidly decreased, with a half-life (t 1/2) of 0.42 to 1.37 h thereafter.","Absorption, disposition, metabolism, and excretion of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25951660/),h,1,5598,DB00143,Glutathione
,25951660,bioavailability,The bioavailability of KUC-7322 was estimated to be 4%.,"Absorption, disposition, metabolism, and excretion of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25951660/),%,4,5599,DB00143,Glutathione
,25951660,cumulative excretion,"The cumulative excretion of radioactivity in urine and feces were 28.7% and 68.3% of the dose, respectively, up to 120 h after administration.","Absorption, disposition, metabolism, and excretion of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25951660/),%,28.7,5600,DB00143,Glutathione
,25951660,cumulative excretion,"The cumulative excretion of radioactivity in urine and feces were 28.7% and 68.3% of the dose, respectively, up to 120 h after administration.","Absorption, disposition, metabolism, and excretion of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25951660/),%,68.3,5601,DB00143,Glutathione
,19703064,oral clearance (CL/F),"Using the population pharmacokinetic model, the estimated the mean oral clearance (CL/F) of pranlukast was 16.4 L/h, and the inter-individual variability was 30.1%.",Impact of pharmacokinetics and pharmacogenetics on the efficacy of pranlukast in Japanese asthmatics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703064/),[l] / [h],16.4,5880,DB00143,Glutathione
,17610527,clearance,"Estimated PC-SOD clearance was 2.54 ml min(-1)[95% confidence interval (CI) 2.07, 2.83].",The pharmacokinetics and effects of a long-acting preparation of superoxide dismutase (PC-SOD) in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610527/),[ml] / [min],2.54,7139,DB00143,Glutathione
,17610527,terminal half-life,"The terminal half-life was estimated to be 1.54 days (95% CI 0.93, 2.15).",The pharmacokinetics and effects of a long-acting preparation of superoxide dismutase (PC-SOD) in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610527/),d,1.54,7140,DB00143,Glutathione
,2900736,Total radioactivity,Total radioactivity in the major tissues was relatively constant from 2 to 24 hr.,Metabolism and disposition of n-butyl acrylate in male Fischer rats. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900736/),h,2 to 24,7680,DB00143,Glutathione
,9101035,basic levels,The mean basic levels of bromide in plasma of rats receiving vehicle were 0.075 +/- 0.036 mmol/l (n = 27).,Chlorodibromomethane metabolism to bromide and carbon monoxide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9101035/),[mM] / [l],0.075,8297,DB00143,Glutathione
,28807770,areas under the curve (AUCs),"The measured areas under the curve (AUCs) were within target (900 to 1500 µM/min) in 38.7% of patients after the administration of the first dose calculated based on age and weight, as locally recommended.",GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28807770/),[μM] / [min],900 to 1500,12741,DB00143,Glutathione
,7570594,Vmax,ACN elimination from blood was described by saturable P450 epoxidation (Vmax of 6.5 mg/hr/kg and Km of 1.5 mg/liter) and first-order GSH conjugation (30 hr-1/kg).,A physiologically based dosimetry description of acrylonitrile and cyanoethylene oxide in the rat. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570594/),[mg] / [h·kg],6.5,15363,DB00143,Glutathione
,7570594,Km,ACN elimination from blood was described by saturable P450 epoxidation (Vmax of 6.5 mg/hr/kg and Km of 1.5 mg/liter) and first-order GSH conjugation (30 hr-1/kg).,A physiologically based dosimetry description of acrylonitrile and cyanoethylene oxide in the rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570594/),[mg] / [l],1.5,15364,DB00143,Glutathione
,7570594,first-order,ACN elimination from blood was described by saturable P450 epoxidation (Vmax of 6.5 mg/hr/kg and Km of 1.5 mg/liter) and first-order GSH conjugation (30 hr-1/kg).,A physiologically based dosimetry description of acrylonitrile and cyanoethylene oxide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570594/),1/[h·kg],30,15365,DB00143,Glutathione
,7570594,hepatic extractions,"Calculation of hepatic clearance values shows first-pass hepatic extractions of 61 and 90% for ACN and CEO, respectively.",A physiologically based dosimetry description of acrylonitrile and cyanoethylene oxide in the rat. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570594/),%,61,15366,DB00143,Glutathione
,7570594,hepatic extractions,"Calculation of hepatic clearance values shows first-pass hepatic extractions of 61 and 90% for ACN and CEO, respectively.",A physiologically based dosimetry description of acrylonitrile and cyanoethylene oxide in the rat. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570594/),%,90,15367,DB00143,Glutathione
,9363839,Peak plasma concentrations,"Peak plasma concentrations of 2 mM (250 mg/kg) and 6 mM (750 mg/kg) L-CPA occurred within 1 h of dosing, and the compound was readily cleared from the plasma with a half-life of 2.6 h.",L-2-Chloropropionic acid metabolism and disposition in male rats: relevance to cerebellar injury. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9363839/),mM,2,16350,DB00143,Glutathione
,9363839,Peak plasma concentrations,"Peak plasma concentrations of 2 mM (250 mg/kg) and 6 mM (750 mg/kg) L-CPA occurred within 1 h of dosing, and the compound was readily cleared from the plasma with a half-life of 2.6 h.",L-2-Chloropropionic acid metabolism and disposition in male rats: relevance to cerebellar injury. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9363839/),mM,6,16351,DB00143,Glutathione
,9363839,half-life,"Peak plasma concentrations of 2 mM (250 mg/kg) and 6 mM (750 mg/kg) L-CPA occurred within 1 h of dosing, and the compound was readily cleared from the plasma with a half-life of 2.6 h.",L-2-Chloropropionic acid metabolism and disposition in male rats: relevance to cerebellar injury. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9363839/),h,2.6,16352,DB00143,Glutathione
,20016052,oral bioavailability,Anacetrapib exhibited a low clearance in both species and a moderate oral bioavailability of approximately 38% in rats and approximately 13% in monkeys.,"Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20016052/),%,38,16413,DB00143,Glutathione
,20016052,oral bioavailability,Anacetrapib exhibited a low clearance in both species and a moderate oral bioavailability of approximately 38% in rats and approximately 13% in monkeys.,"Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20016052/),%,13,16414,DB00143,Glutathione
,33128207,clearance (CL),Median typical clearance (CL) was 0.22 L/h/kg and median typical volume of distribution was 0.69 L/kg.,Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128207/),[l] / [h·kg],0.22,18787,DB00143,Glutathione
,33128207,volume of distribution,Median typical clearance (CL) was 0.22 L/h/kg and median typical volume of distribution was 0.69 L/kg.,Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128207/),[l] / [kg],0.69,18788,DB00143,Glutathione
,33128207,area under the concentration-time curve,"One study observed a cumulative area under the concentration-time curve over all days of treatment of between 78 and 101 mg/L·h, and two studies observed an average concentration at first dose of < 600 ng/mL improved overall survival, transplant-related mortality, or relapse.",Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128207/),[mg] / [h·l],78 and 101,18789,DB00143,Glutathione
<,33128207,concentration at first dose,"One study observed a cumulative area under the concentration-time curve over all days of treatment of between 78 and 101 mg/L·h, and two studies observed an average concentration at first dose of < 600 ng/mL improved overall survival, transplant-related mortality, or relapse.",Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128207/),[ng] / [ml],600,18790,DB00143,Glutathione
>,33128207,maximum busulfan concentration,One study observed increased sinusoidal obstructive syndrome with maximum busulfan concentration > 1.88 ng/mL.,Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33128207/),[ng] / [ml],1.88,18791,DB00143,Glutathione
,29469189,AUC24h,The ability to achieve the target AUC24h (3600-6000 μM min-1 ) was assessed by estimating the first dose based on the present PopPK model and by comparing the results with other available models in children.,Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29469189/),[μM] / [min],3600-6000,19782,DB00143,Glutathione
,9576812,beta-phase half-life,"Analysis of the pharmacokinetic behavior of ITs in Balb/c mice given intravenous bolus injections indicated that ITs with higher in vitro stability were eliminated more slowly; i.e., the disulfide bearing a methyl group doubled the beta-phase half-life (from 3.5 to 7.1 h) compared with that of the unhindered, while a geminal dimethyl protection increased the elimination phase to 24 h.",Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9576812/),h,3,20271,DB00143,Glutathione
,9576812,beta-phase half-life,The thioether linkage showed its intrinsic stability with a beta-phase half-life of 46 h.,Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9576812/),h,46,20272,DB00143,Glutathione
,9576812,distribution phase,The thioether linkage also increased the distribution phase from 17 to 32 min.,Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9576812/),min,17,20273,DB00143,Glutathione
,9576812,distribution phase,The thioether linkage also increased the distribution phase from 17 to 32 min.,Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9576812/),min,32,20274,DB00143,Glutathione
,22934681,half-life,The short infusion of DAMGO resulted in a fast decline of the peptide concentration in plasma with a half-life of 9.2 ± 2.1 min.,Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22934681/),min,9.2,20511,DB00143,Glutathione
,22934681,half-life,Encapsulation in GSH-PEG liposomes prolonged the half-life to 6.9 ± 2.3 h.,Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22934681/),h,6.9,20512,DB00143,Glutathione
,22934681,steady state ratio,"Free DAMGO entered the brain to a limited extent with a steady state ratio between unbound drug concentrations in brain interstitial fluid and in blood (Kp,uu) of 0.09 ± 0.04.",Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22934681/),,0.09,20513,DB00143,Glutathione
,22934681,"Kp,uu","GSH-PEG liposomes significantly increased the brain exposure of DAMGO to a Kp,uu of 0.21 ± 0.17 (p < 0.05).",Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22934681/),,0.21,20514,DB00143,Glutathione
,34371742,loading capacity (LC),"The loading capacity (LC) and encapsulation efficiency (EE) percentages for MTF-loaded LCS and MTF-loaded DPP microcapsules were 14.9% ± 0.7, 29.8 ± 0.8, and 15.2% ± 0.7, 30.3 ± 1.0, respectively.",Sustained In Vitro and In Vivo Delivery of Metformin from Plant Pollen-Derived Composite Microcapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34371742/),%,14.9,21067,DB00143,Glutathione
,34371742,encapsulation efficiency (EE),"The loading capacity (LC) and encapsulation efficiency (EE) percentages for MTF-loaded LCS and MTF-loaded DPP microcapsules were 14.9% ± 0.7, 29.8 ± 0.8, and 15.2% ± 0.7, 30.3 ± 1.0, respectively.",Sustained In Vitro and In Vivo Delivery of Metformin from Plant Pollen-Derived Composite Microcapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34371742/),%,15.2,21068,DB00143,Glutathione
,34371742,encapsulation efficiency (EE),"The loading capacity (LC) and encapsulation efficiency (EE) percentages for MTF-loaded LCS and MTF-loaded DPP microcapsules were 14.9% ± 0.7, 29.8 ± 0.8, and 15.2% ± 0.7, 30.3 ± 1.0, respectively.",Sustained In Vitro and In Vivo Delivery of Metformin from Plant Pollen-Derived Composite Microcapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34371742/),,30.3,21069,DB00143,Glutathione
,8125985,mean residence time (t 1/2),"Pharmacokinetic studies on one of the polyethylene-glycolated molecules (R313C) showed that the mean residence time (t 1/2) was prolonged to 72 min, compared to 20 min for unpolyethylene glycolated PE-Cys(R313C).",Pseudomonas exotoxin A mutants. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8125985/),min,72,21255,DB00143,Glutathione
,8125985,mean residence time (t 1/2),"Pharmacokinetic studies on one of the polyethylene-glycolated molecules (R313C) showed that the mean residence time (t 1/2) was prolonged to 72 min, compared to 20 min for unpolyethylene glycolated PE-Cys(R313C).",Pseudomonas exotoxin A mutants. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8125985/),min,20,21256,DB00143,Glutathione
,7288620,apparent half-life,Peak concentrations of acetaminophen were high in all tissues (1500-2000 nmol/g) and declined with an apparent half-life of 1 hr.,Levels of acetaminophen and its metabolites in mouse tissues after a toxic dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7288620/),h,1,21372,DB00143,Glutathione
,24512295,en,"Optimized RA-loaded SLNs using tween 80 (SLNPRT) have the mean size of (149.2 ± 3.2 nm), ZP (-38.27 mV) entrapment efficiency (61.9 ± 2.2%).","Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512295/),%,61.9,22238,DB00143,Glutathione
,24512295,brain drug concentration,"In the organ distribution study, brain drug concentration was found to be 5.69 µg, in pharmacokinetic study Cmax, tmax, t1/2, AUC values were found to be 0.284 µg/ml, 1.5 h, 3.17 h, and 1.505 µg/ml/h, respectively.","Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512295/),μg,5.69,22239,DB00143,Glutathione
,24512295,Cmax,"In the organ distribution study, brain drug concentration was found to be 5.69 µg, in pharmacokinetic study Cmax, tmax, t1/2, AUC values were found to be 0.284 µg/ml, 1.5 h, 3.17 h, and 1.505 µg/ml/h, respectively.","Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512295/),[μg] / [ml],0.284,22240,DB00143,Glutathione
,24512295,tmax,"In the organ distribution study, brain drug concentration was found to be 5.69 µg, in pharmacokinetic study Cmax, tmax, t1/2, AUC values were found to be 0.284 µg/ml, 1.5 h, 3.17 h, and 1.505 µg/ml/h, respectively.","Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512295/),h,1.5,22241,DB00143,Glutathione
,24512295,tmax,"In the organ distribution study, brain drug concentration was found to be 5.69 µg, in pharmacokinetic study Cmax, tmax, t1/2, AUC values were found to be 0.284 µg/ml, 1.5 h, 3.17 h, and 1.505 µg/ml/h, respectively.","Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512295/),h,3.17,22242,DB00143,Glutathione
,24512295,t1/2,"In the organ distribution study, brain drug concentration was found to be 5.69 µg, in pharmacokinetic study Cmax, tmax, t1/2, AUC values were found to be 0.284 µg/ml, 1.5 h, 3.17 h, and 1.505 µg/ml/h, respectively.","Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512295/),h,1.5,22243,DB00143,Glutathione
,24512295,t1/2,"In the organ distribution study, brain drug concentration was found to be 5.69 µg, in pharmacokinetic study Cmax, tmax, t1/2, AUC values were found to be 0.284 µg/ml, 1.5 h, 3.17 h, and 1.505 µg/ml/h, respectively.","Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512295/),h,3.17,22244,DB00143,Glutathione
,24512295,AUC,"In the organ distribution study, brain drug concentration was found to be 5.69 µg, in pharmacokinetic study Cmax, tmax, t1/2, AUC values were found to be 0.284 µg/ml, 1.5 h, 3.17 h, and 1.505 µg/ml/h, respectively.","Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512295/),[μg] / [h·ml],1.505,22245,DB00143,Glutathione
,30963629,AUC0-∞,"For the infant with unexpectedly high AUC0-∞ (2,591 μmol/L min), the GSTA1, M1, and T1 polymorphisms were wild type.",Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963629/),[μM] / [l·min],"2,591",22457,DB00143,Glutathione
,30963629,clearance,"On further analysis, the poor metabolizer group had lower clearance and higher AUC0-∞, except for the aforementioned patient, compared with the extensive metabolizer group (1,531 vs 1,010 μmol/L min; P < 0.01).",Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963629/),[μM] / [l·min],"1,531",22458,DB00143,Glutathione
,30963629,AUC0-∞,"On further analysis, the poor metabolizer group had lower clearance and higher AUC0-∞, except for the aforementioned patient, compared with the extensive metabolizer group (1,531 vs 1,010 μmol/L min; P < 0.01).",Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963629/),[μM] / [l·min],"1,010",22459,DB00143,Glutathione
,10581862,Half-lifes,"Half-lifes for phases I and II were 0.8 and 99 h, respectively.",The disposition and metabolism of naphthalene in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10581862/),h,0.8,22724,DB00143,Glutathione
,10581862,Half-lifes,"Half-lifes for phases I and II were 0.8 and 99 h, respectively.",The disposition and metabolism of naphthalene in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10581862/),h,99,22725,DB00143,Glutathione
,10581862,half-life,In erythrocytes 3H-decline was monophasic with the half-life of about 9 h.,The disposition and metabolism of naphthalene in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10581862/),h,9,22726,DB00143,Glutathione
,12825238,rate constant,Absorption of radioactivity into plasma was slow with a rate constant of 0.2 h-1.,Pharmacokinetic modeling of disposition and time-course studies with [14C]atrazine. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12825238/),1/[h],0.2,25069,DB00143,Glutathione
,12825238,Second-order rates of reaction,"Second-order rates of reaction of CI-TRIs with hemoglobin and plasma protein were estimated to be 0.008 L/mmol/h and 1.14 x 10(-7) L/mg/h, respectively.",Pharmacokinetic modeling of disposition and time-course studies with [14C]atrazine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12825238/),[l] / [h·mM],0.008,25070,DB00143,Glutathione
,12825238,Second-order rates of reaction,"Second-order rates of reaction of CI-TRIs with hemoglobin and plasma protein were estimated to be 0.008 L/mmol/h and 1.14 x 10(-7) L/mg/h, respectively.",Pharmacokinetic modeling of disposition and time-course studies with [14C]atrazine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12825238/),[l] / [h·mg],1.14 x 10(-7),25071,DB00143,Glutathione
,3439877,maximal metabolic rate (Vmax),The estimated maximal metabolic rate (Vmax) in mice for epoxybutene was only 350 mumol X h-1 X kg-1 (rats: greater than 2600 mumol X h-1 X kg-1).,"Inhalation pharmacokinetics of 1,2-epoxybutene-3 reveal species differences between rats and mice sensitive to butadiene-induced carcinogenesis. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3439877/),[μM] / [h·kg],350,25966,DB00143,Glutathione
greater,3439877,maximal metabolic rate (Vmax),The estimated maximal metabolic rate (Vmax) in mice for epoxybutene was only 350 mumol X h-1 X kg-1 (rats: greater than 2600 mumol X h-1 X kg-1).,"Inhalation pharmacokinetics of 1,2-epoxybutene-3 reveal species differences between rats and mice sensitive to butadiene-induced carcinogenesis. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3439877/),[μM] / [h·kg],2600,25967,DB00143,Glutathione
,3439877,metabolic clearance,"In the lower concentration range where first order metabolism applies (up to about 500 ppm) epoxybutene is metabolized by mice at higher rates compared to rats (metabolic clearance per kg body weight, mice: 24,900 ml X h-1, rats: 13,400 ml X h-1).","Inhalation pharmacokinetics of 1,2-epoxybutene-3 reveal species differences between rats and mice sensitive to butadiene-induced carcinogenesis. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3439877/),[ml] / [h],"24,900",25968,DB00143,Glutathione
,3439877,metabolic clearance,"In the lower concentration range where first order metabolism applies (up to about 500 ppm) epoxybutene is metabolized by mice at higher rates compared to rats (metabolic clearance per kg body weight, mice: 24,900 ml X h-1, rats: 13,400 ml X h-1).","Inhalation pharmacokinetics of 1,2-epoxybutene-3 reveal species differences between rats and mice sensitive to butadiene-induced carcinogenesis. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3439877/),[ml] / [h],"13,400",25969,DB00143,Glutathione
,1676661,partial clearance,"However, BSO exposure increased the partial clearance of acetaminophen to acetaminophen glucuronide by 47% (1.29 +/- 0.08 vs. 1.90 +/- 0.23 ml/min/kg; p less than 0.01) and significantly (p less than 0.02) increased the percentage of the dose recovered as the glucuronide conjugate from 17.6 +/- 2.5 to 26.5 +/- 0.6",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),[ml] / [kg·min],1.29,26054,DB00143,Glutathione
,1676661,partial clearance,"However, BSO exposure increased the partial clearance of acetaminophen to acetaminophen glucuronide by 47% (1.29 +/- 0.08 vs. 1.90 +/- 0.23 ml/min/kg; p less than 0.01) and significantly (p less than 0.02) increased the percentage of the dose recovered as the glucuronide conjugate from 17.6 +/- 2.5 to 26.5 +/- 0.6",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),[ml] / [kg·min],1.90,26055,DB00143,Glutathione
,1676661,percentage,"However, BSO exposure increased the partial clearance of acetaminophen to acetaminophen glucuronide by 47% (1.29 +/- 0.08 vs. 1.90 +/- 0.23 ml/min/kg; p less than 0.01) and significantly (p less than 0.02) increased the percentage of the dose recovered as the glucuronide conjugate from 17.6 +/- 2.5 to 26.5 +/- 0.6",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),,17,26056,DB00143,Glutathione
,1676661,partial clearance,"The partial clearance of acetaminophen to acetaminophen sulfate was decreased, although not significantly, from 4.46 +/- 0.62 to 3.39 +/- 0.82 ml/min/kg.",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),[ml] / [kg·min],4.46,26057,DB00143,Glutathione
,1676661,partial clearance,"The partial clearance of acetaminophen to acetaminophen sulfate was decreased, although not significantly, from 4.46 +/- 0.62 to 3.39 +/- 0.82 ml/min/kg.",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),[ml] / [kg·min],3.39,26058,DB00143,Glutathione
,15142875,clearance,"Pharmacokinetic analysis in these patients showed that the clearance of busulfan was higher and first-dose steady-state concentration was lower among those with HVOD (0.403 +/- 0.06 vs 0.33 +/- 0.071 L/h/kg, Student t test P value =.000 01; and 508 +/- 125 vs 656 +/- 255 ng/mL, t test P value =.001, respectively).",Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142875/),[l] / [h·kg],0.403,26164,DB00143,Glutathione
,15142875,clearance,"Pharmacokinetic analysis in these patients showed that the clearance of busulfan was higher and first-dose steady-state concentration was lower among those with HVOD (0.403 +/- 0.06 vs 0.33 +/- 0.071 L/h/kg, Student t test P value =.000 01; and 508 +/- 125 vs 656 +/- 255 ng/mL, t test P value =.001, respectively).",Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142875/),[l] / [h·kg],0.33,26165,DB00143,Glutathione
,15142875,first-dose steady-state concentration,"Pharmacokinetic analysis in these patients showed that the clearance of busulfan was higher and first-dose steady-state concentration was lower among those with HVOD (0.403 +/- 0.06 vs 0.33 +/- 0.071 L/h/kg, Student t test P value =.000 01; and 508 +/- 125 vs 656 +/- 255 ng/mL, t test P value =.001, respectively).",Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142875/),[l] / [h·kg],0.403,26166,DB00143,Glutathione
,15142875,first-dose steady-state concentration,"Pharmacokinetic analysis in these patients showed that the clearance of busulfan was higher and first-dose steady-state concentration was lower among those with HVOD (0.403 +/- 0.06 vs 0.33 +/- 0.071 L/h/kg, Student t test P value =.000 01; and 508 +/- 125 vs 656 +/- 255 ng/mL, t test P value =.001, respectively).",Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142875/),[l] / [h·kg],0.33,26167,DB00143,Glutathione
,15142875,first-dose steady-state concentration,"Pharmacokinetic analysis in these patients showed that the clearance of busulfan was higher and first-dose steady-state concentration was lower among those with HVOD (0.403 +/- 0.06 vs 0.33 +/- 0.071 L/h/kg, Student t test P value =.000 01; and 508 +/- 125 vs 656 +/- 255 ng/mL, t test P value =.001, respectively).",Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142875/),[ng] / [ml],508,26168,DB00143,Glutathione
,15142875,first-dose steady-state concentration,"Pharmacokinetic analysis in these patients showed that the clearance of busulfan was higher and first-dose steady-state concentration was lower among those with HVOD (0.403 +/- 0.06 vs 0.33 +/- 0.071 L/h/kg, Student t test P value =.000 01; and 508 +/- 125 vs 656 +/- 255 ng/mL, t test P value =.001, respectively).",Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142875/),[ng] / [ml],656,26169,DB00143,Glutathione
,2760849,biological half-life,"When cystathionine (100 mg/kg) was administered i.p. in rats, it was eliminated from rat serum with a biological half-life of 1.19 +/- 0.23 hr.",Hepatoprotective effects of cystathionine against acetaminophen-induced necrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760849/),h,1.19,26756,DB00143,Glutathione
,2760849,half-life,"Subsequent to the decrease of serum cystathionine, the concentration of cyst(e)ine increased up to 14.5 +/- 1.2 mg/l, and then decreased with a half-life of 4.12 +/- 0.82 hr.",Hepatoprotective effects of cystathionine against acetaminophen-induced necrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760849/),h,4.12,26757,DB00143,Glutathione
,2760849,half-life,"The concomitant administration of taurine (100 mg/kg) did not change the half-life of cystathionine (1.42 +/- 0.33 hr), but significantly increased the half-life of cyst(e)ine (19.1 +/- 0.56 hr).",Hepatoprotective effects of cystathionine against acetaminophen-induced necrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760849/),h,1.42,26758,DB00143,Glutathione
,2760849,half-life,"The concomitant administration of taurine (100 mg/kg) did not change the half-life of cystathionine (1.42 +/- 0.33 hr), but significantly increased the half-life of cyst(e)ine (19.1 +/- 0.56 hr).",Hepatoprotective effects of cystathionine against acetaminophen-induced necrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760849/),h,19.1,26759,DB00143,Glutathione
,3517077,maximum concentration (Cmax),"Mean values for the maximum concentration (Cmax) were 803 and 66.3 ng/mL for CAP and Me-CAP, respectively.",Pharmacokinetics of captopril in elderly healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),[ng] / [ml],803,27361,DB00143,Glutathione
,3517077,maximum concentration (Cmax),"Mean values for the maximum concentration (Cmax) were 803 and 66.3 ng/mL for CAP and Me-CAP, respectively.",Pharmacokinetics of captopril in elderly healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),[ng] / [ml],66.3,27362,DB00143,Glutathione
,3517077,time to maximum concentration (tmax),"Mean time to maximum concentration (tmax) was determined as 1.0, 1.4, and 1.0 for CAP, TOT, and Me-CAP, respectively.",Pharmacokinetics of captopril in elderly healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),,1.0,27363,DB00143,Glutathione
,3517077,time to maximum concentration (tmax),"Mean time to maximum concentration (tmax) was determined as 1.0, 1.4, and 1.0 for CAP, TOT, and Me-CAP, respectively.",Pharmacokinetics of captopril in elderly healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),,1.4,27364,DB00143,Glutathione
,3517077,areas under the plasma concentration-time curve (AUC),"Mean areas under the plasma concentration-time curve (AUC) were 1,394 hr-ng/mL (CAP, 0-8 hr) and 17,316 hr-ng/mL (TOT, 0-24 hr).",Pharmacokinetics of captopril in elderly healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),[hr-ng] / [ml],"1,394",27365,DB00143,Glutathione
,3517077,areas under the plasma concentration-time curve (AUC),"Mean areas under the plasma concentration-time curve (AUC) were 1,394 hr-ng/mL (CAP, 0-8 hr) and 17,316 hr-ng/mL (TOT, 0-24 hr).",Pharmacokinetics of captopril in elderly healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),h,0-8,27366,DB00143,Glutathione
,3517077,areas under the plasma concentration-time curve (AUC),"Mean areas under the plasma concentration-time curve (AUC) were 1,394 hr-ng/mL (CAP, 0-8 hr) and 17,316 hr-ng/mL (TOT, 0-24 hr).",Pharmacokinetics of captopril in elderly healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),[hr-ng] / [ml],"17,316",27367,DB00143,Glutathione
,3517077,areas under the plasma concentration-time curve (AUC),"Mean areas under the plasma concentration-time curve (AUC) were 1,394 hr-ng/mL (CAP, 0-8 hr) and 17,316 hr-ng/mL (TOT, 0-24 hr).",Pharmacokinetics of captopril in elderly healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),h,0-24,27368,DB00143,Glutathione
,3517077,half-life (t 1/2),"The mean estimated half-life (t 1/2) for CAP was 1.4 hr, and its renal clearance was 187 mL/hr/kg.",Pharmacokinetics of captopril in elderly healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),h,1.4,27369,DB00143,Glutathione
,3517077,renal clearance,"The mean estimated half-life (t 1/2) for CAP was 1.4 hr, and its renal clearance was 187 mL/hr/kg.",Pharmacokinetics of captopril in elderly healthy male volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),[ml] / [h·kg],187,27370,DB00143,Glutathione
,3517077,urinary excretion,"Mean urinary excretion over 24 hr was 20.8 and 53.1 for CAP and TOT, respectively.",Pharmacokinetics of captopril in elderly healthy male volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),,20.8,27371,DB00143,Glutathione
,3517077,urinary excretion,"Mean urinary excretion over 24 hr was 20.8 and 53.1 for CAP and TOT, respectively.",Pharmacokinetics of captopril in elderly healthy male volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),,53.1,27372,DB00143,Glutathione
,24438363,Half-life,Half-life of 1-BP in rats following inhibition of P450 (9.6 h) or depletion of GSH (4.1 h) increased relative to controls (2.0 h) at 800 ppm.,Species and sex-dependent toxicokinetics of 1-bromopropane: the role of hepatic cytochrome P450 oxidation and glutathione (GSH). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24438363/),h,9.6,28422,DB00143,Glutathione
,24438363,Half-life,Half-life of 1-BP in rats following inhibition of P450 (9.6 h) or depletion of GSH (4.1 h) increased relative to controls (2.0 h) at 800 ppm.,Species and sex-dependent toxicokinetics of 1-bromopropane: the role of hepatic cytochrome P450 oxidation and glutathione (GSH). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24438363/),h,4.1,28423,DB00143,Glutathione
,24438363,Half-life,Half-life of 1-BP in rats following inhibition of P450 (9.6 h) or depletion of GSH (4.1 h) increased relative to controls (2.0 h) at 800 ppm.,Species and sex-dependent toxicokinetics of 1-bromopropane: the role of hepatic cytochrome P450 oxidation and glutathione (GSH). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24438363/),h,2.0,28424,DB00143,Glutathione
,3292102,body clearance,"In healthy subjects given captopril intravenously, the body clearance of captopril and steady-state volume of distribution were about 0.7 L/h/kg and 0.8 L/kg, respectively.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),[l] / [h·kg],0.7,28702,DB00143,Glutathione
,3292102,steady-state volume of distribution,"In healthy subjects given captopril intravenously, the body clearance of captopril and steady-state volume of distribution were about 0.7 L/h/kg and 0.8 L/kg, respectively.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),[l] / [kg],0.8,28703,DB00143,Glutathione
,3292102,elimination half-life,The elimination half-life of unchanged captopril was approximately 2 hours.,Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),h,2,28704,DB00143,Glutathione
,3292102,bioavailability,"In healthy subjects, about 70 to 75% of an oral dose is absorbed and the bioavailability of captopril is approximately 65%.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),%,65,28705,DB00143,Glutathione
,12189531,100%,"Myeloid progenitors were more sensitive than erythroid progenitors, expressed as 100% inhibition of colony formation (68.7 +/- 7.5 microg.h/ml and 140.3 +/- 35.7, respectively).",The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189531/),[h·μg] / [ml],68.7,30874,DB00143,Glutathione
,12189531,100%,"Myeloid progenitors were more sensitive than erythroid progenitors, expressed as 100% inhibition of colony formation (68.7 +/- 7.5 microg.h/ml and 140.3 +/- 35.7, respectively).",The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189531/),,140,30875,DB00143,Glutathione
,26333006,EC50,"EC50 values for the in vitro antioxidant assay with DPPH were found to be 19.99, 15.94 and 13.5 for phyllanthin, CP-PC and CP-P-PC, respectively.",Antioxidant and hepatoprotective effects of mixed micellar lipid formulation of phyllanthin and piperine in carbon tetrachloride-induced liver injury in rodents. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333006/),,19.99,31354,DB00143,Glutathione
,26333006,EC50,"EC50 values for the in vitro antioxidant assay with DPPH were found to be 19.99, 15.94 and 13.5 for phyllanthin, CP-PC and CP-P-PC, respectively.",Antioxidant and hepatoprotective effects of mixed micellar lipid formulation of phyllanthin and piperine in carbon tetrachloride-induced liver injury in rodents. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333006/),,15.94,31355,DB00143,Glutathione
,26333006,EC50,"EC50 values for the in vitro antioxidant assay with DPPH were found to be 19.99, 15.94 and 13.5 for phyllanthin, CP-PC and CP-P-PC, respectively.",Antioxidant and hepatoprotective effects of mixed micellar lipid formulation of phyllanthin and piperine in carbon tetrachloride-induced liver injury in rodents. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333006/),,13.5,31356,DB00143,Glutathione
,9266803,maximum depletion,"It appeared that at a dose level of 250 mg/kg, hepatic GSH was completely depleted after 10 hr for man, whereas for the rat a maximum depletion of 75% was predicted, after 15 hr.","A physiologically based pharmacokinetic (PB-PK) model for 1,2-dichlorobenzene linked to two possible parameters of toxicity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9266803/),%,75,32189,DB00143,Glutathione
,28914978,steady-state trough concentrations,"Finally, a 12.5 and 10.6 mg/kg twice-daily DCA dose was optimal in achieving the target steady-state trough concentrations (5-25 mg/L) for EGT carrier and EGT noncarrier children, respectively.",Model Informed Dose Optimization of Dichloroacetate for the Treatment of Congenital Lactic Acidosis in Children. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28914978/),[mg] / [l],5-25,32393,DB00143,Glutathione
,8887460,Vmax,ACN elimination from blood was described by saturable P450 epoxidation (Vmax of 5.0 mg/hr/kg and K(M) of 1.5 mg/liter) and first-order GSH conjugation (73 hr(-1)/kg).,Refinement and verification of the physiologically based dosimetry description for acrylonitrile in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887460/),[mg] / [h·kg],5.0,32638,DB00143,Glutathione
,8887460,K(M),ACN elimination from blood was described by saturable P450 epoxidation (Vmax of 5.0 mg/hr/kg and K(M) of 1.5 mg/liter) and first-order GSH conjugation (73 hr(-1)/kg).,Refinement and verification of the physiologically based dosimetry description for acrylonitrile in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887460/),[mg] / [l],1.5,32639,DB00143,Glutathione
,8887460,first-order GSH conjugation,ACN elimination from blood was described by saturable P450 epoxidation (Vmax of 5.0 mg/hr/kg and K(M) of 1.5 mg/liter) and first-order GSH conjugation (73 hr(-1)/kg).,Refinement and verification of the physiologically based dosimetry description for acrylonitrile in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887460/),1/[hr·kg],73,32640,DB00143,Glutathione
,26052837,elimination phase half-life,The elimination phase half-life of NAC was approximately 34 min.,Intravenous Administration of Stable-Labeled N-Acetylcysteine Demonstrates an Indirect Mechanism for Boosting Glutathione and Improving Redox Status. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26052837/),min,34,32999,DB00143,Glutathione
,2029805,peak plasma concentration,After an oral dose of N-acetylcysteine 200 to 400 mg the peak plasma concentration of 0.35 to 4 mg/L is achieved within 1 to 2 hours.,Clinical pharmacokinetics of N-acetylcysteine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029805/),[mg] / [l],0.35 to 4,33002,DB00143,Glutathione
,2029805,volume of distribution,"The volume of distribution ranges from 0.33 to 0.47 L/kg and protein binding is significant, reaching approximately 50% 4 hours after the dose.",Clinical pharmacokinetics of N-acetylcysteine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029805/),[l] / [kg],0.33 to 0.47,33003,DB00143,Glutathione
,2029805,Renal clearance,Renal clearance has been reported as 0.190 to 0.211 L/h/kg and approximately 70% of the total body clearance is nonrenal.,Clinical pharmacokinetics of N-acetylcysteine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029805/),[l] / [h·kg],0.190 to 0.211,33004,DB00143,Glutathione
,2029805,terminal half-life,"Following oral administration, reduced N-acetylcysteine has a terminal half-life of 6.25h.",Clinical pharmacokinetics of N-acetylcysteine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029805/),h,6.25,33005,DB00143,Glutathione
,31347013,"Css,avg","Predictions resulted in the lowest Css,avg in the third trimester (median [interquartile range]: 4.5 [3.8-5.1] mg/L), while Css,avg was 6.7 [5.9-7.4], 5.6 [4.7-6.3], and 4.9 [4.1-5.5] mg/L in non-pregnant, first trimester, and second trimester populations, respectively.",Physiologically Based Pharmacokinetic Modeling to Characterize Acetaminophen Pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) Formation in Non-Pregnant and Pregnant Women. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31347013/),[mg] / [l],4.5,34782,DB00143,Glutathione
,31347013,"Css,avg","Predictions resulted in the lowest Css,avg in the third trimester (median [interquartile range]: 4.5 [3.8-5.1] mg/L), while Css,avg was 6.7 [5.9-7.4], 5.6 [4.7-6.3], and 4.9 [4.1-5.5] mg/L in non-pregnant, first trimester, and second trimester populations, respectively.",Physiologically Based Pharmacokinetic Modeling to Characterize Acetaminophen Pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) Formation in Non-Pregnant and Pregnant Women. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31347013/),[mg] / [l],6.7,34783,DB00143,Glutathione
,31347013,"Css,avg","Predictions resulted in the lowest Css,avg in the third trimester (median [interquartile range]: 4.5 [3.8-5.1] mg/L), while Css,avg was 6.7 [5.9-7.4], 5.6 [4.7-6.3], and 4.9 [4.1-5.5] mg/L in non-pregnant, first trimester, and second trimester populations, respectively.",Physiologically Based Pharmacokinetic Modeling to Characterize Acetaminophen Pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) Formation in Non-Pregnant and Pregnant Women. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31347013/),[mg] / [l],5.6,34784,DB00143,Glutathione
,31347013,"Css,avg","Predictions resulted in the lowest Css,avg in the third trimester (median [interquartile range]: 4.5 [3.8-5.1] mg/L), while Css,avg was 6.7 [5.9-7.4], 5.6 [4.7-6.3], and 4.9 [4.1-5.5] mg/L in non-pregnant, first trimester, and second trimester populations, respectively.",Physiologically Based Pharmacokinetic Modeling to Characterize Acetaminophen Pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) Formation in Non-Pregnant and Pregnant Women. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31347013/),[mg] / [l],4.9,34785,DB00143,Glutathione
,18242812,area-under-the-concentration-curve (AUC),"The HEDs for the dosimetrics, area-under-the-concentration-curve (AUC) for total and free DCA in plasma, AUC of DCA in liver and amount of DCA metabolized per day were 0.02, 0.1, 0.1 and 1.0mg/kg day, respectively.",Quantitative evaluation of dichloroacetic acid kinetics in human--a physiologically based pharmacokinetic modeling investigation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18242812/),[mg] / [d·kg],0.02,35616,DB00143,Glutathione
,18242812,AUC,"The HEDs for the dosimetrics, area-under-the-concentration-curve (AUC) for total and free DCA in plasma, AUC of DCA in liver and amount of DCA metabolized per day were 0.02, 0.1, 0.1 and 1.0mg/kg day, respectively.",Quantitative evaluation of dichloroacetic acid kinetics in human--a physiologically based pharmacokinetic modeling investigation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18242812/),[mg] / [d·kg],0.1,35617,DB00143,Glutathione
,18242812,AUC,"The HEDs for the dosimetrics, area-under-the-concentration-curve (AUC) for total and free DCA in plasma, AUC of DCA in liver and amount of DCA metabolized per day were 0.02, 0.1, 0.1 and 1.0mg/kg day, respectively.",Quantitative evaluation of dichloroacetic acid kinetics in human--a physiologically based pharmacokinetic modeling investigation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18242812/),[mg] / [d·kg],1.0,35618,DB00143,Glutathione
,8682153,basal plasma concentrations,The basal plasma concentrations of free GSH (3.3 +/- 1.3 vs.,Decreased release of glutathione into the systemic circulation of patients with HIV infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8682153/),,3.3,35805,DB00143,Glutathione
,8682153,input,The input of GSH into the circulation (12.9 +/- 5.7 vs. 30.1 +/- 11.7 mumol min-1; P < 0.01) and the clearance of GSH (25 +/- 7 vs. 35 +/- 7 mL min-1 kg-1) were significantly lower in patients with HIV-infection.,Decreased release of glutathione into the systemic circulation of patients with HIV infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8682153/),[μM] / [min],12.9,35806,DB00143,Glutathione
,8682153,input,The input of GSH into the circulation (12.9 +/- 5.7 vs. 30.1 +/- 11.7 mumol min-1; P < 0.01) and the clearance of GSH (25 +/- 7 vs. 35 +/- 7 mL min-1 kg-1) were significantly lower in patients with HIV-infection.,Decreased release of glutathione into the systemic circulation of patients with HIV infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8682153/),[μM] / [min],30.1,35807,DB00143,Glutathione
,8682153,clearance,The input of GSH into the circulation (12.9 +/- 5.7 vs. 30.1 +/- 11.7 mumol min-1; P < 0.01) and the clearance of GSH (25 +/- 7 vs. 35 +/- 7 mL min-1 kg-1) were significantly lower in patients with HIV-infection.,Decreased release of glutathione into the systemic circulation of patients with HIV infection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8682153/),[ml] / [kg·min],25,35808,DB00143,Glutathione
,8682153,clearance,The input of GSH into the circulation (12.9 +/- 5.7 vs. 30.1 +/- 11.7 mumol min-1; P < 0.01) and the clearance of GSH (25 +/- 7 vs. 35 +/- 7 mL min-1 kg-1) were significantly lower in patients with HIV-infection.,Decreased release of glutathione into the systemic circulation of patients with HIV infection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8682153/),[ml] / [kg·min],35,35809,DB00143,Glutathione
,3409442,plasma beta half-life,"The compound was relatively rapidly cleared from the plasma, with a plasma beta half-life of 2.3 h and 0.9 h and a gamma half-life of 16 h and 3 h in the dog and the mouse, respectively.","Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409442/),h,2.3,35926,DB00143,Glutathione
,3409442,plasma beta half-life,"The compound was relatively rapidly cleared from the plasma, with a plasma beta half-life of 2.3 h and 0.9 h and a gamma half-life of 16 h and 3 h in the dog and the mouse, respectively.","Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409442/),h,0.9,35927,DB00143,Glutathione
,3409442,gamma half-life,"The compound was relatively rapidly cleared from the plasma, with a plasma beta half-life of 2.3 h and 0.9 h and a gamma half-life of 16 h and 3 h in the dog and the mouse, respectively.","Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409442/),h,16,35928,DB00143,Glutathione
,3409442,gamma half-life,"The compound was relatively rapidly cleared from the plasma, with a plasma beta half-life of 2.3 h and 0.9 h and a gamma half-life of 16 h and 3 h in the dog and the mouse, respectively.","Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409442/),h,3,35929,DB00143,Glutathione
,3409442,gamma half-life,Sulfamic acid diester was taken up by blood cells and only slowly eliminated with a whole blood gamma half-life of 42 h in the dog and 32 h in the mouse.,"Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409442/),h,42,35930,DB00143,Glutathione
,3409442,gamma half-life,Sulfamic acid diester was taken up by blood cells and only slowly eliminated with a whole blood gamma half-life of 42 h in the dog and 32 h in the mouse.,"Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409442/),h,32,35931,DB00143,Glutathione
,3409442,clearance,"When sulfamic acid diester was infused i.v. to mice at 15 mg/kg over 8 h, the clearance for the parent drug was 13.2 ml/min kg from the plasma and 3.3 ml/min kg from the whole blood.","Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409442/),[ml] / [kg·min],13.2,35932,DB00143,Glutathione
,3409442,clearance,"When sulfamic acid diester was infused i.v. to mice at 15 mg/kg over 8 h, the clearance for the parent drug was 13.2 ml/min kg from the plasma and 3.3 ml/min kg from the whole blood.","Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409442/),[ml] / [kg·min],3.3,35933,DB00143,Glutathione
,14570776,maximum concentration,"The initial formation rate of ZP-SG was rapid and reached a maximum concentration of 0.24 +/- 0.03 nM after 4 min of incubation, then decreased, in a fairly linear fashion, to 0.07 +/- 0.03 nM after 60 min of incubation.",Identification of zomepirac-S-acyl-glutathione in vitro in incubations with rat hepatocytes and in vivo in rat bile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570776/),nM,0.24,37843,DB00143,Glutathione
,14570776,maximum concentration,"The initial formation rate of ZP-SG was rapid and reached a maximum concentration of 0.24 +/- 0.03 nM after 4 min of incubation, then decreased, in a fairly linear fashion, to 0.07 +/- 0.03 nM after 60 min of incubation.",Identification of zomepirac-S-acyl-glutathione in vitro in incubations with rat hepatocytes and in vivo in rat bile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570776/),nM,0.07,37844,DB00143,Glutathione
,14570776,apparent half-life,The product ZP-SG (1 microM) was shown to be unstable by undergoing rapid hydrolysis (apparent half-life approximately 0.8 min) in incubations with rat hepatocytes.,Identification of zomepirac-S-acyl-glutathione in vitro in incubations with rat hepatocytes and in vivo in rat bile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570776/),min,0.8,37845,DB00143,Glutathione
,3829578,time of peak excretion rate,"The mean time of peak excretion rate was 1.3 to 3.7 hours for acetaminophen, its glucuronide, sulfate, cysteine, mercapturate, and methoxy metabolites but 13.5 hours for methylthioacetaminophen.",Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829578/),h,1.3 to 3.7,37952,DB00143,Glutathione
,3829578,time of peak excretion rate,"The mean time of peak excretion rate was 1.3 to 3.7 hours for acetaminophen, its glucuronide, sulfate, cysteine, mercapturate, and methoxy metabolites but 13.5 hours for methylthioacetaminophen.",Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829578/),h,13.5,37953,DB00143,Glutathione
,3829578,half-life,The mean half-life of acetaminophen was 3.1 hours and the mean half-life of the metabolites other than methylthioacetaminophen ranged from 4.1 to 5.7 hours.,Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829578/),h,3.1,37954,DB00143,Glutathione
,3829578,half-life,The mean half-life of acetaminophen was 3.1 hours and the mean half-life of the metabolites other than methylthioacetaminophen ranged from 4.1 to 5.7 hours.,Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829578/),h,4.1 to 5.7,37955,DB00143,Glutathione
,7905404,dissociation half-life,"GST was found to react only with the aziridinium intermediate formed from melphalan and to dissociate slowly from the resultant GST-product complex (dissociation half-life, 1 hr at pH 7.4 and 3.5 hr at pH 6.5).","Kinetic analysis of the reaction of melphalan with water, phosphate, and glutathione. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905404/),h,1,39519,DB00143,Glutathione
,7905404,dissociation half-life,"GST was found to react only with the aziridinium intermediate formed from melphalan and to dissociate slowly from the resultant GST-product complex (dissociation half-life, 1 hr at pH 7.4 and 3.5 hr at pH 6.5).","Kinetic analysis of the reaction of melphalan with water, phosphate, and glutathione. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905404/),h,3.5,39520,DB00143,Glutathione
,30386887,terminal elimination half-life,"H3B-6545 had a terminal elimination half-life of 2.4 h in rats and 4.0 h in monkeys and showed low to moderate bioavailability, in line with the in vitro permeability assessment.","Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30386887/),h,2.4,39765,DB00143,Glutathione
,30386887,terminal elimination half-life,"H3B-6545 had a terminal elimination half-life of 2.4 h in rats and 4.0 h in monkeys and showed low to moderate bioavailability, in line with the in vitro permeability assessment.","Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30386887/),h,4.0,39766,DB00143,Glutathione
,28801971,time to peak concentration,The pharmacokinetic results indicated that olerciamide A was rapidly distributed with a time to peak concentration of 30 min after oral administration and presented a low oral absolute bioavailability of 4.57%.,Pharmacokinetics and metabolism of olerciamide A from Portulaca oleracea L. in rats by UHPLC-UV and UHPLC-ESI-Q-TOF/MS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801971/),min,30,40225,DB00143,Glutathione
,28801971,oral absolute bioavailability,The pharmacokinetic results indicated that olerciamide A was rapidly distributed with a time to peak concentration of 30 min after oral administration and presented a low oral absolute bioavailability of 4.57%.,Pharmacokinetics and metabolism of olerciamide A from Portulaca oleracea L. in rats by UHPLC-UV and UHPLC-ESI-Q-TOF/MS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801971/),%,4.57,40226,DB00143,Glutathione
,17513394,Concentrations,"Concentrations of AV-A, AV-B, and AV-C in the AEM were 154, 109, and 111 micromol/g, respectively.",Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17513394/),μ,154,41132,DB00143,Glutathione
,17513394,Concentrations,"Concentrations of AV-A, AV-B, and AV-C in the AEM were 154, 109, and 111 micromol/g, respectively.",Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17513394/),μ,109,41133,DB00143,Glutathione
,17513394,Concentrations,"Concentrations of AV-A, AV-B, and AV-C in the AEM were 154, 109, and 111 micromol/g, respectively.",Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17513394/),μ,111,41134,DB00143,Glutathione
,17513394,Maximum plasma concentrations,"Maximum plasma concentrations of AV (free + conjugated) after consumption of 0.5 and 1 g AEM were 112.9 and 374.6 nmol/L for AV-A, 13.2 and 96.0 nmol/L for AV-B, and 41.4 and 89.0 nmol/L for AV-C, respectively.",Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17513394/),[nM] / [l],112.9,41135,DB00143,Glutathione
,17513394,Maximum plasma concentrations,"Maximum plasma concentrations of AV (free + conjugated) after consumption of 0.5 and 1 g AEM were 112.9 and 374.6 nmol/L for AV-A, 13.2 and 96.0 nmol/L for AV-B, and 41.4 and 89.0 nmol/L for AV-C, respectively.",Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17513394/),[nM] / [l],374.6,41136,DB00143,Glutathione
,17513394,Maximum plasma concentrations,"Maximum plasma concentrations of AV (free + conjugated) after consumption of 0.5 and 1 g AEM were 112.9 and 374.6 nmol/L for AV-A, 13.2 and 96.0 nmol/L for AV-B, and 41.4 and 89.0 nmol/L for AV-C, respectively.",Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17513394/),[nM] / [l],13.2,41137,DB00143,Glutathione
,17513394,Maximum plasma concentrations,"Maximum plasma concentrations of AV (free + conjugated) after consumption of 0.5 and 1 g AEM were 112.9 and 374.6 nmol/L for AV-A, 13.2 and 96.0 nmol/L for AV-B, and 41.4 and 89.0 nmol/L for AV-C, respectively.",Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17513394/),[nM] / [l],96.0,41138,DB00143,Glutathione
,17513394,Maximum plasma concentrations,"Maximum plasma concentrations of AV (free + conjugated) after consumption of 0.5 and 1 g AEM were 112.9 and 374.6 nmol/L for AV-A, 13.2 and 96.0 nmol/L for AV-B, and 41.4 and 89.0 nmol/L for AV-C, respectively.",Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17513394/),[nM] / [l],41.4,41139,DB00143,Glutathione
,17513394,Maximum plasma concentrations,"Maximum plasma concentrations of AV (free + conjugated) after consumption of 0.5 and 1 g AEM were 112.9 and 374.6 nmol/L for AV-A, 13.2 and 96.0 nmol/L for AV-B, and 41.4 and 89.0 nmol/L for AV-C, respectively.",Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17513394/),[nM] / [l],89.0,41140,DB00143,Glutathione
,17513394,Times to reach the C(max),"Times to reach the C(max) for both doses were 2.30, 1.75, and 2.15 h for AV-A, AV-B, and AV-C and half times for elimination were 1.75, 3.75, and 3.00 h, respectively.",Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17513394/),h,2.30,41141,DB00143,Glutathione
,17513394,Times to reach the C(max),"Times to reach the C(max) for both doses were 2.30, 1.75, and 2.15 h for AV-A, AV-B, and AV-C and half times for elimination were 1.75, 3.75, and 3.00 h, respectively.",Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17513394/),h,1.75,41142,DB00143,Glutathione
,17513394,Times to reach the C(max),"Times to reach the C(max) for both doses were 2.30, 1.75, and 2.15 h for AV-A, AV-B, and AV-C and half times for elimination were 1.75, 3.75, and 3.00 h, respectively.",Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17513394/),h,2.15,41143,DB00143,Glutathione
,17513394,half times for elimination,"Times to reach the C(max) for both doses were 2.30, 1.75, and 2.15 h for AV-A, AV-B, and AV-C and half times for elimination were 1.75, 3.75, and 3.00 h, respectively.",Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17513394/),h,1.75,41144,DB00143,Glutathione
,17513394,half times for elimination,"Times to reach the C(max) for both doses were 2.30, 1.75, and 2.15 h for AV-A, AV-B, and AV-C and half times for elimination were 1.75, 3.75, and 3.00 h, respectively.",Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17513394/),h,3.75,41145,DB00143,Glutathione
,17513394,half times for elimination,"Times to reach the C(max) for both doses were 2.30, 1.75, and 2.15 h for AV-A, AV-B, and AV-C and half times for elimination were 1.75, 3.75, and 3.00 h, respectively.",Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17513394/),h,3.00,41146,DB00143,Glutathione
,17656487,T(max),"The T(max) for the oral exposure ranged from 5 to 30 min, and the C(max) ranged from 0.4 to 4.1 ng/l.",Disposition of bromodichloromethane in humans following oral and dermal exposure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17656487/),min,5 to 30,41166,DB00143,Glutathione
,17656487,C(max),"The T(max) for the oral exposure ranged from 5 to 30 min, and the C(max) ranged from 0.4 to 4.1 ng/l.",Disposition of bromodichloromethane in humans following oral and dermal exposure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17656487/),[ng] / [l],0.4 to 4.1,41167,DB00143,Glutathione
,10438721,clearance rate,17alpha-Ethinyl estradiol (EE) treatment resulted in a significant increase in the clearance rate of recombinant human t-PA in mice (0.46 mL/min in treated mice v 0. 32 mL/min in controls; P <.01).,Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0.46,44028,DB00143,Glutathione
,10438721,clearance rate,17alpha-Ethinyl estradiol (EE) treatment resulted in a significant increase in the clearance rate of recombinant human t-PA in mice (0.46 mL/min in treated mice v 0. 32 mL/min in controls; P <.01).,Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0. 32,44029,DB00143,Glutathione
,10438721,area under the curve [AUC],"The clearance of endogenous, bradykinin-released t-PA in rats was also significantly increased after EE treatment (area under the curve [AUC], 24.9 ng/mL. min in treated animals v 31.9 ng/mL. min in controls; P <.05).",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ng] / [min·ml],24.9,44030,DB00143,Glutathione
,10438721,area under the curve [AUC],"The clearance of endogenous, bradykinin-released t-PA in rats was also significantly increased after EE treatment (area under the curve [AUC], 24.9 ng/mL. min in treated animals v 31.9 ng/mL. min in controls; P <.05).",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ng] / [min·ml],31.9,44031,DB00143,Glutathione
,10438721,clearance,"Inhibition of LRP by intravenous injection of receptor-associated protein (RAP) as a recombinant fusion protein with Salmonella japonicum glutathione S-transferase (GST) significantly retarded t-PA clearance in control mice (from 0.41 to 0.25 mL/min; n = 5, P <.001) and EE-treated mice (from 0.66 to 0.35 mL/min; n = 5, P <.005), but did not eliminate the difference in clearance capacity between the 2 experimental groups.",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0.41 to 0.25,44032,DB00143,Glutathione
,10438721,clearance,"Inhibition of LRP by intravenous injection of receptor-associated protein (RAP) as a recombinant fusion protein with Salmonella japonicum glutathione S-transferase (GST) significantly retarded t-PA clearance in control mice (from 0.41 to 0.25 mL/min; n = 5, P <.001) and EE-treated mice (from 0.66 to 0.35 mL/min; n = 5, P <.005), but did not eliminate the difference in clearance capacity between the 2 experimental groups.",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0.66 to 0.35,44033,DB00143,Glutathione
,10438721,clearances,"In contrast, administration of mannan, a mannose receptor antagonist, resulted in identical clearances (0.22 mL/min in controls and 0.24 mL/min in EE-treated mice).",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0.22,44034,DB00143,Glutathione
,10438721,clearances,"In contrast, administration of mannan, a mannose receptor antagonist, resulted in identical clearances (0.22 mL/min in controls and 0.24 mL/min in EE-treated mice).",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0.24,44035,DB00143,Glutathione
,27632696,critical micelle concentration,"PAAssVES was found to self-assemble into nanomicelles with diameter of about 130 nm, and a critical micelle concentration of about 6.3 μg/mL.",In vitro and in vivo evaluation of redox-responsive sorafenib carrier nanomicelles synthesized from poly (acryic acid) -cystamine hydrochloride-D-α-tocopherol succinate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27632696/),[μg] / [ml],6.3,48128,DB00143,Glutathione
,15657783,steady state,"Baseline NAC was on average 454 ng ml(-1); its concentration increased to 9,253 ng ml(-1) at the second infusion and attained a steady state between 14,000 ng ml(-1) and 17,000 ng ml(-1) at the fourth dose.",Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[ng] / [ml],"14,000",48595,DB00143,Glutathione
,15657783,steady state,"Baseline NAC was on average 454 ng ml(-1); its concentration increased to 9,253 ng ml(-1) at the second infusion and attained a steady state between 14,000 ng ml(-1) and 17,000 ng ml(-1) at the fourth dose.",Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[ng] / [ml],"17,000",48596,DB00143,Glutathione
,15657783,C (max),"We observed a C (max) of 53,458 ng ml(-1) with a t (max) of 3.0 h.",Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[ng] / [ml],"53,458",48597,DB00143,Glutathione
,15657783,t (max),"We observed a C (max) of 53,458 ng ml(-1) with a t (max) of 3.0 h.",Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),h,3.0,48598,DB00143,Glutathione
,15657783,Plasma clearance,Plasma clearance was 1.25 l h(-1) and dialytic clearance 5.52 l h(-1).,Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[l] / [h],1.25,48599,DB00143,Glutathione
,15657783,dialytic clearance,Plasma clearance was 1.25 l h(-1) and dialytic clearance 5.52 l h(-1).,Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[l] / [h],5.52,48600,DB00143,Glutathione
,15657783,total body clearance,"The dialytic clearance is effective, the total body clearance being reduced to 1.25 l h(-1).",Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657783/),[l] / [h],1.25,48601,DB00143,Glutathione
less,2758557,half-life,"Carmethizole was relatively unstable in aqueous media, having a half-life of less than or equal to 1 h in 0.9% sodium chloride, human whole blood, human plasma, and dog urine at 37 degrees C.",Preclinical pharmacologic studies of the new antitumor agent carmethizole (NSC-602668) in the mouse and beagle dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758557/),h,1,49753,DB00143,Glutathione
,2758557,terminal half-life,"At these doses the terminal half-life was 39 and 46 min, respectively, and the respective total body clearance was 4.6 and 7.7 ml/min per kg.",Preclinical pharmacologic studies of the new antitumor agent carmethizole (NSC-602668) in the mouse and beagle dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758557/),min,39,49754,DB00143,Glutathione
,2758557,terminal half-life,"At these doses the terminal half-life was 39 and 46 min, respectively, and the respective total body clearance was 4.6 and 7.7 ml/min per kg.",Preclinical pharmacologic studies of the new antitumor agent carmethizole (NSC-602668) in the mouse and beagle dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758557/),min,46,49755,DB00143,Glutathione
,2758557,total body clearance,"At these doses the terminal half-life was 39 and 46 min, respectively, and the respective total body clearance was 4.6 and 7.7 ml/min per kg.",Preclinical pharmacologic studies of the new antitumor agent carmethizole (NSC-602668) in the mouse and beagle dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758557/),[ml] / [kg·min],4.6,49756,DB00143,Glutathione
,2758557,total body clearance,"At these doses the terminal half-life was 39 and 46 min, respectively, and the respective total body clearance was 4.6 and 7.7 ml/min per kg.",Preclinical pharmacologic studies of the new antitumor agent carmethizole (NSC-602668) in the mouse and beagle dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758557/),[ml] / [kg·min],7.7,49757,DB00143,Glutathione
,2758557,half-life,"Elimination of carmethizole from the plasma of mice following an i.v. bolus dose of 115 mg/kg was monoexponential, with a half-life of 11.6 min and a total body plasma clearance of 43.6 ml/min per kg.",Preclinical pharmacologic studies of the new antitumor agent carmethizole (NSC-602668) in the mouse and beagle dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758557/),min,11.6,49758,DB00143,Glutathione
,2758557,total body plasma clearance,"Elimination of carmethizole from the plasma of mice following an i.v. bolus dose of 115 mg/kg was monoexponential, with a half-life of 11.6 min and a total body plasma clearance of 43.6 ml/min per kg.",Preclinical pharmacologic studies of the new antitumor agent carmethizole (NSC-602668) in the mouse and beagle dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758557/),[ml] / [kg·min],43.6,49759,DB00143,Glutathione
,2758557,total body clearance,"When the drug was infused at 230 mg/kg over 8 h into mice, the total body clearance was 40.8 ml/min per kg.",Preclinical pharmacologic studies of the new antitumor agent carmethizole (NSC-602668) in the mouse and beagle dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758557/),[ml] / [kg·min],40.8,49760,DB00143,Glutathione
,12915100,volume fraction,The median volume fraction was 0.045% in control rats and was significantly elevated in TCDD treatment groups.,"Area under the curve as a dose metric for promotional responses following 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915100/),%,0.045,51855,DB00143,Glutathione
less,12064344,half-life,Catechins from the extract were excreted into urine with a half-life of less than 2 h in accordance with the short-term effects on plasma antioxidant capacity.,Green tea extract only affects markers of oxidative status postprandially: lasting antioxidant effect of flavonoid-free diet. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12064344/),h,2,52123,DB00143,Glutathione
,26861689,Cmax,"The pharmacokinetic analysis of CAL compared with chlorogenic acid (CA), showed a higher value of Cmax(6.42 ± 1.49 min versus 3.97 ± 0.39 min) and a delayed Tmax(15 min versus 10 min), with 1.29-fold increase in relative oral bioavailability.",Enhanced oral bioavailability and in vivo antioxidant activity of chlorogenic acid via liposomal formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861689/),min,6.42,52256,DB00143,Glutathione
,26861689,Cmax,"The pharmacokinetic analysis of CAL compared with chlorogenic acid (CA), showed a higher value of Cmax(6.42 ± 1.49 min versus 3.97 ± 0.39 min) and a delayed Tmax(15 min versus 10 min), with 1.29-fold increase in relative oral bioavailability.",Enhanced oral bioavailability and in vivo antioxidant activity of chlorogenic acid via liposomal formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861689/),min,3.97,52257,DB00143,Glutathione
,26861689,Tmax,"The pharmacokinetic analysis of CAL compared with chlorogenic acid (CA), showed a higher value of Cmax(6.42 ± 1.49 min versus 3.97 ± 0.39 min) and a delayed Tmax(15 min versus 10 min), with 1.29-fold increase in relative oral bioavailability.",Enhanced oral bioavailability and in vivo antioxidant activity of chlorogenic acid via liposomal formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861689/),min,15,52258,DB00143,Glutathione
,26861689,Tmax,"The pharmacokinetic analysis of CAL compared with chlorogenic acid (CA), showed a higher value of Cmax(6.42 ± 1.49 min versus 3.97 ± 0.39 min) and a delayed Tmax(15 min versus 10 min), with 1.29-fold increase in relative oral bioavailability.",Enhanced oral bioavailability and in vivo antioxidant activity of chlorogenic acid via liposomal formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861689/),min,10,52259,DB00143,Glutathione
,31532629,elimination half-life,"Interestingly, DTX-CMHN displayed a long elimination half-life of 5.75 h, in contrast to half-lives of 2.11 and 0.75 h for its non-cross-linked counterpart (DTX-MHN) and free DTX, respectively.",CD44-Targeted Multifunctional Nanomedicines Based on a Single-Component Hyaluronic Acid Conjugate with All-Natural Precursors: Construction and Treatment of Metastatic Breast Tumors in Vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31532629/),h,5.75,52423,DB00143,Glutathione
,31532629,half-lives,"Interestingly, DTX-CMHN displayed a long elimination half-life of 5.75 h, in contrast to half-lives of 2.11 and 0.75 h for its non-cross-linked counterpart (DTX-MHN) and free DTX, respectively.",CD44-Targeted Multifunctional Nanomedicines Based on a Single-Component Hyaluronic Acid Conjugate with All-Natural Precursors: Construction and Treatment of Metastatic Breast Tumors in Vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31532629/),h,2.11,52424,DB00143,Glutathione
,31532629,half-lives,"Interestingly, DTX-CMHN displayed a long elimination half-life of 5.75 h, in contrast to half-lives of 2.11 and 0.75 h for its non-cross-linked counterpart (DTX-MHN) and free DTX, respectively.",CD44-Targeted Multifunctional Nanomedicines Based on a Single-Component Hyaluronic Acid Conjugate with All-Natural Precursors: Construction and Treatment of Metastatic Breast Tumors in Vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31532629/),h,0.75,52425,DB00143,Glutathione
,28835099,IC50,HA-GS-MP exhibited obvious targetability and markedly enhanced antitumor effect to OCI/AML-2 human AML cells (IC50 = 16.9 μg 6-MP equiv./mL).,Glutathione-Sensitive Hyaluronic Acid-Mercaptopurine Prodrug Linked via Carbonyl Vinyl Sulfide: A Robust and CD44-Targeted Nanomedicine for Leukemia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28835099/),μg,16.9,53138,DB00143,Glutathione
,28835099,elimination half-life,The pharmacokinetic studies displayed that Cy5-labeled HA-GS-MP had a long circulation time in mice (elimination half-life = 4.37 h).,Glutathione-Sensitive Hyaluronic Acid-Mercaptopurine Prodrug Linked via Carbonyl Vinyl Sulfide: A Robust and CD44-Targeted Nanomedicine for Leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28835099/),h,4.37,53139,DB00143,Glutathione
,8613932,Cl(f),"In phenobarbital-induced rats receiving a nontoxic dose of APAP (100 mg/kg i.v.), a single dose of caffeine (100 mg/kg i.p.) co-administered with APAP increased the Cl(f) of NAPQI formation from 0.58 +/- 0.47 to 2.08 +/- 1.1 1 ml/min/kg (P = .01).",Effects of caffeine and theophylline on acetaminophen pharmacokinetics: P450 inhibition and activation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8613932/),[1·ml] / [kg·min],0.58,54661,DB00143,Glutathione
,8613932,Cl(f),"In phenobarbital-induced rats receiving a nontoxic dose of APAP (100 mg/kg i.v.), a single dose of caffeine (100 mg/kg i.p.) co-administered with APAP increased the Cl(f) of NAPQI formation from 0.58 +/- 0.47 to 2.08 +/- 1.1 1 ml/min/kg (P = .01).",Effects of caffeine and theophylline on acetaminophen pharmacokinetics: P450 inhibition and activation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8613932/),[1·ml] / [kg·min],2.08,54662,DB00143,Glutathione
,4015096,t1/2,The half-life and systemic clearance of plasma glutathione were found to be the same in selenium-deficient and control rats (t1/2 = 3.4 +/- 0.7 min).,Effect of selenium deficiency on the disposition of plasma glutathione. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4015096/),min,3.4,55480,DB00143,Glutathione
,28210753,half-life,"In the pharmacokinetic study, puerarin-7-O-glucuronide was cleared with a half-life of 0.94 h after intravenous administration.","Puerarin-7-O-glucuronide, a water-soluble puerarin metabolite, prevents angiotensin II-induced cardiomyocyte hypertrophy by reducing oxidative stress. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28210753/),h,0.94,55555,DB00143,Glutathione
,7039926,systemic bioavailability,"Following oral administration it is rapidly absorbed from the gastrointestinal tract, its systemic bioavailability being dose-dependent and ranging from 70 to 90%.",Clinical pharmacokinetics of paracetamol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),%,70 to 90,56310,DB00143,Glutathione
,7039926,volume of distribution,It distributes rapidly and evenly throughout most tissues and fluids and has a volume of distribution of approximately 0.9L/kg.,Clinical pharmacokinetics of paracetamol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),[l] / [kg],0.9,56311,DB00143,Glutathione
,7039926,plasma half-life,The plasma half-life in such subjects ranges from 1.9 to 2.5 hours and the total body clearance from 4.5 to 5.5 ml/kg/min.,Clinical pharmacokinetics of paracetamol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),h,1.9 to 2.5,56312,DB00143,Glutathione
,7039926,total body clearance,The plasma half-life in such subjects ranges from 1.9 to 2.5 hours and the total body clearance from 4.5 to 5.5 ml/kg/min.,Clinical pharmacokinetics of paracetamol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7039926/),[ml] / [kg·min],4.5 to 5.5,56313,DB00143,Glutathione
,21030608,influx rate constant k(in),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.65,56417,DB00143,Glutathione
,21030608,influx rate constant k(in),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,2.12,56418,DB00143,Glutathione
,21030608,elimination rate constant k(be),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.09,56419,DB00143,Glutathione
,21030608,elimination rate constant k(be),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.17,56420,DB00143,Glutathione
,21030608,efflux rate constant k(out),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.07,56421,DB00143,Glutathione
,21030608,efflux rate constant k(out),"The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k(in) (0.65 ± 0.09 vs. 2.12 ± 0.30) and elimination rate constant k(be) (0.09 ± 0.02 vs. 0.17 ± 0.04) compared with control rat group, whereas the efflux rate constant k(out) was greatly increased (0.07 ± 0.02 vs. 0.02 ± 0.01).",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.02,56422,DB00143,Glutathione
,21030608,extraction ratio,"Hepatic taurocholate extraction ratio in adjuvant-treated rats (0.86 ± 0.05, n = 6) was significantly reduced compared with 0.93 ± 0.05 (n = 6) in normal rats.",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.86,56423,DB00143,Glutathione
,21030608,extraction ratio,"Hepatic taurocholate extraction ratio in adjuvant-treated rats (0.86 ± 0.05, n = 6) was significantly reduced compared with 0.93 ± 0.05 (n = 6) in normal rats.",Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21030608/),,0.93,56424,DB00143,Glutathione
,2750198,elimination t 1/2,"3. Exposure of rats to 78, 155, or 404 ppm DCP gave an elimination t 1/2 of 17 h, independent of exposure concentration.","Pharmacokinetics of S-[3-chloroprop-2-enyl]glutathione in rats following acute inhalation exposure to 1,3-dichloropropene. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2750198/),h,17,56575,DB00143,Glutathione
,31740394,bioavailability,"The method was utilized in pharmacokinetic study which showed that the bioavailability of NACA is significantly higher than NAC (67% and 15%, respectively).",Pharmacokinetic profile of N-acetylcysteine amide and its main metabolite in mice using new analytical method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31740394/),%,67,57864,DB00143,Glutathione
,31740394,bioavailability,"The method was utilized in pharmacokinetic study which showed that the bioavailability of NACA is significantly higher than NAC (67% and 15%, respectively).",Pharmacokinetic profile of N-acetylcysteine amide and its main metabolite in mice using new analytical method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31740394/),%,15,57865,DB00143,Glutathione
,27430634,peak observed concentrations in the blood,2. Lumiracoxib achieved peak observed concentrations in the blood of 1.26 + 0.51 μg/mL 0.5 h (0.5-1.0) post-dose with an AUCinf of 3.48 + 1.09 μg h/mL.,Lumiracoxib metabolism in male C57bl/6J mice: characterisation of novel in vivo metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27430634/),[μg] / [ml],1.26,58088,DB00143,Glutathione
,27430634,AUCinf,2. Lumiracoxib achieved peak observed concentrations in the blood of 1.26 + 0.51 μg/mL 0.5 h (0.5-1.0) post-dose with an AUCinf of 3.48 + 1.09 μg h/mL.,Lumiracoxib metabolism in male C57bl/6J mice: characterisation of novel in vivo metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27430634/),[h·μg] / [ml],3.48,58089,DB00143,Glutathione
,27430634,terminal half-life,Concentrations of lumiracoxib then declined with a terminal half-life of 1.54 + 0.31 h.,Lumiracoxib metabolism in male C57bl/6J mice: characterisation of novel in vivo metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27430634/),h,1.54,58090,DB00143,Glutathione
,33141084,Tmax,Intranasal puerarin TISGs were absorbed quickly with a shorter Tmax (10.0 ± 5.7 min) compared to that of oral puerarin (36 ± 13.4 min).,Comparative study of oral and intranasal puerarin for prevention of brain injury induced by acute high-altitude hypoxia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33141084/),min,10.0,58160,DB00143,Glutathione
,33141084,Tmax,Intranasal puerarin TISGs were absorbed quickly with a shorter Tmax (10.0 ± 5.7 min) compared to that of oral puerarin (36 ± 13.4 min).,Comparative study of oral and intranasal puerarin for prevention of brain injury induced by acute high-altitude hypoxia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33141084/),min,36,58161,DB00143,Glutathione
,33141084,relative bioavailability,"In addition, the relative bioavailability of i.n. puerarin TISGs was high to 300% compared to oral administration of puerarin.",Comparative study of oral and intranasal puerarin for prevention of brain injury induced by acute high-altitude hypoxia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33141084/),%,300,58162,DB00143,Glutathione
,33141084,area under the curve (AUC),"The area under the curve (AUC) of brain after i.n. administration of puerarin TISGs was 954.5 ± 335.1 h.ng/mL, while no puerarin was detected in the brain after oral administration.",Comparative study of oral and intranasal puerarin for prevention of brain injury induced by acute high-altitude hypoxia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33141084/),[h·ng] / [ml],954.5,58163,DB00143,Glutathione
,7197922,half-life,"When yeast are grown in amino-acid-free medium, the half-life of glutathione was found to be 230 min.",The role of glutathione in amino-acid absorption. Lack of correlation between glutathione turnover and amino-acid absorption by the yeast Candida utilis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197922/),min,230,59170,DB00143,Glutathione
,6882466,half-life,"The mononitrates were eliminated with a half-life of 30-70 min, giving rise to the completely denitrated product, adenosine-5'-(N-ethyl-carboxamide) (NECA).","Metabolism and disposition of 2',3'-di-O-nitro-adenosine-5'-(N-ethyl-carboxamide) in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882466/),min,30-70,60525,DB00143,Glutathione
,6882466,half-life,The latter product was not further metabolized and was eliminated with a half-life of about 4 hr.,"Metabolism and disposition of 2',3'-di-O-nitro-adenosine-5'-(N-ethyl-carboxamide) in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882466/),h,4,60526,DB00143,Glutathione
,6882466,Urinary excretion,Urinary excretion averaged 50% of the administered dose within 4 days and was represented essentially by the completely denitrated drug.,"Metabolism and disposition of 2',3'-di-O-nitro-adenosine-5'-(N-ethyl-carboxamide) in dogs. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882466/),%,50,60527,DB00143,Glutathione
,6882466,Oral bioavailability,Oral bioavailability of the drug was about 90%.,"Metabolism and disposition of 2',3'-di-O-nitro-adenosine-5'-(N-ethyl-carboxamide) in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882466/),%,90,60528,DB00143,Glutathione
,29385232,plasma half-life,"2B3-201 was shown to have a plasma half-life between 24 and 37 h and caused a prolonged decrease in the lymphocyte count, adrenocorticotropic hormone and osteocalcin, and a rise in fasting glucose.",Glutathione-PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first-in-human study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29385232/),h,24 and 37,61204,DB00143,Glutathione
,29223921,bioavailability,"The bioavailability of AL-total (AL, AL-GSH, AL-Cys) and IAL-total (IAL, IAL-GSH, IAL-Cys) was, respectively, 8.39% and 13.07%, which was 3.62- and 6.95- fold that of AL (2.32%) and IAL (1.88%), respectively.",Metabolism and pharmacokinetics of alantolactone and isoalantolactone in rats: Thiol conjugation as a potential metabolic pathway. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29223921/),%,8.39,65194,DB00143,Glutathione
,29223921,bioavailability,"The bioavailability of AL-total (AL, AL-GSH, AL-Cys) and IAL-total (IAL, IAL-GSH, IAL-Cys) was, respectively, 8.39% and 13.07%, which was 3.62- and 6.95- fold that of AL (2.32%) and IAL (1.88%), respectively.",Metabolism and pharmacokinetics of alantolactone and isoalantolactone in rats: Thiol conjugation as a potential metabolic pathway. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29223921/),%,13.07,65195,DB00143,Glutathione
,29223921,bioavailability,"The bioavailability of AL-total (AL, AL-GSH, AL-Cys) and IAL-total (IAL, IAL-GSH, IAL-Cys) was, respectively, 8.39% and 13.07%, which was 3.62- and 6.95- fold that of AL (2.32%) and IAL (1.88%), respectively.",Metabolism and pharmacokinetics of alantolactone and isoalantolactone in rats: Thiol conjugation as a potential metabolic pathway. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29223921/),%,2.32,65196,DB00143,Glutathione
,29223921,bioavailability,"The bioavailability of AL-total (AL, AL-GSH, AL-Cys) and IAL-total (IAL, IAL-GSH, IAL-Cys) was, respectively, 8.39% and 13.07%, which was 3.62- and 6.95- fold that of AL (2.32%) and IAL (1.88%), respectively.",Metabolism and pharmacokinetics of alantolactone and isoalantolactone in rats: Thiol conjugation as a potential metabolic pathway. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29223921/),%,1.88,65197,DB00143,Glutathione
,3228667,maximum excretion rate,The maximum excretion rate occurred between 5-10 min in control rats and 10-15 min in rats with ARF.,Dibromosulphophthalein: its pharmacokinetics and binding to hepatic cytosol proteins in rats with acute renal failure. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3228667/),min,5-10,65945,DB00143,Glutathione
,3228667,maximum excretion rate,The maximum excretion rate occurred between 5-10 min in control rats and 10-15 min in rats with ARF.,Dibromosulphophthalein: its pharmacokinetics and binding to hepatic cytosol proteins in rats with acute renal failure. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3228667/),min,10-15,65946,DB00143,Glutathione
,1872890,half-maximal production (P50,"The O2 concentrations required for half-maximal production (P50 values) of glucuronide (2.3 microM O2) and sulfate (1.8 microM O2) conjugates in cells from hypoxic animals were lower than for control cells (5.3 microM and 3.9 microM O2 for glucuronide and sulfate conjugates, respectively).",Effect of chronic hypoxia on acetaminophen metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1872890/),μM,2.3,67266,DB00143,Glutathione
,1872890,half-maximal production (P50,"The O2 concentrations required for half-maximal production (P50 values) of glucuronide (2.3 microM O2) and sulfate (1.8 microM O2) conjugates in cells from hypoxic animals were lower than for control cells (5.3 microM and 3.9 microM O2 for glucuronide and sulfate conjugates, respectively).",Effect of chronic hypoxia on acetaminophen metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1872890/),,1,67267,DB00143,Glutathione
,1872890,half-maximal production (P50,"The O2 concentrations required for half-maximal production (P50 values) of glucuronide (2.3 microM O2) and sulfate (1.8 microM O2) conjugates in cells from hypoxic animals were lower than for control cells (5.3 microM and 3.9 microM O2 for glucuronide and sulfate conjugates, respectively).",Effect of chronic hypoxia on acetaminophen metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1872890/),μM,5.3,67268,DB00143,Glutathione
,1872890,half-maximal production (P50,"The O2 concentrations required for half-maximal production (P50 values) of glucuronide (2.3 microM O2) and sulfate (1.8 microM O2) conjugates in cells from hypoxic animals were lower than for control cells (5.3 microM and 3.9 microM O2 for glucuronide and sulfate conjugates, respectively).",Effect of chronic hypoxia on acetaminophen metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1872890/),μM,3.9,67269,DB00143,Glutathione
,1872890,P50,"In comparison, the P50 for glutathione conjugation (4.1 microM O2) was not statistically different from control (4.6 microM O2), but the maximal rate was 65% higher.",Effect of chronic hypoxia on acetaminophen metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1872890/),μM,4.1,67270,DB00143,Glutathione
,1872890,P50,"In comparison, the P50 for glutathione conjugation (4.1 microM O2) was not statistically different from control (4.6 microM O2), but the maximal rate was 65% higher.",Effect of chronic hypoxia on acetaminophen metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1872890/),μM,4.6,67271,DB00143,Glutathione
,20359856,half-life,"Non-linear pharmacokinetic modeling predicted that the estimated absorption and elimination rate constants correspond to a half-life of approximately 13 min with an AUC of 1.18 μgh/mL, a C(max) of 2.16 μg/ml and a volume of distribution of 42.61 L/kg.","Preclinical pharmacokinetic analysis of NOV-002, a glutathione disulfide mimetic. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20359856/),min,13,67777,DB00143,Glutathione
,20359856,AUC,"Non-linear pharmacokinetic modeling predicted that the estimated absorption and elimination rate constants correspond to a half-life of approximately 13 min with an AUC of 1.18 μgh/mL, a C(max) of 2.16 μg/ml and a volume of distribution of 42.61 L/kg.","Preclinical pharmacokinetic analysis of NOV-002, a glutathione disulfide mimetic. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20359856/),[μgh] / [ml],1.18,67778,DB00143,Glutathione
,20359856,C(max),"Non-linear pharmacokinetic modeling predicted that the estimated absorption and elimination rate constants correspond to a half-life of approximately 13 min with an AUC of 1.18 μgh/mL, a C(max) of 2.16 μg/ml and a volume of distribution of 42.61 L/kg.","Preclinical pharmacokinetic analysis of NOV-002, a glutathione disulfide mimetic. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20359856/),[μg] / [ml],2.16,67779,DB00143,Glutathione
,20359856,volume of distribution,"Non-linear pharmacokinetic modeling predicted that the estimated absorption and elimination rate constants correspond to a half-life of approximately 13 min with an AUC of 1.18 μgh/mL, a C(max) of 2.16 μg/ml and a volume of distribution of 42.61 L/kg.","Preclinical pharmacokinetic analysis of NOV-002, a glutathione disulfide mimetic. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20359856/),[l] / [kg],42.61,67780,DB00143,Glutathione
,31834435,clearance (CL),The PK of intravenous busulfan was described by one-compartment model with first-order elimination with estimated clearance (CL) of 14.2 L/h and volume of distribution of 64.1 L.,Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31834435/),[l] / [h],14.2,69247,DB00143,Glutathione
,31834435,volume of distribution,The PK of intravenous busulfan was described by one-compartment model with first-order elimination with estimated clearance (CL) of 14.2 L/h and volume of distribution of 64.1 L.,Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31834435/),l,64.1,69248,DB00143,Glutathione
,7182455,Distribution half-life,Distribution half-life was extremely rapid (2-5 min).,Pharmacokinetics of intravenous isosorbide-dinitrate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7182455/),min,2-5,69364,DB00143,Glutathione
,7182455,half-life,"Terminal disappearance had a half-life of 67 (62-75) min (mean, range).",Pharmacokinetics of intravenous isosorbide-dinitrate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7182455/),min,67,69365,DB00143,Glutathione
,7182455,Total plasma clearance,"Total plasma clearance was 1.6 (1.2-2.2) litres X min-1, thus approaching liver blood flow.",Pharmacokinetics of intravenous isosorbide-dinitrate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7182455/),[l] / [min],1.6,69366,DB00143,Glutathione
,7182455,absolute systemic availability (F),"Nevertheless, absolute systemic availability (F) or oral ISDN amounted to 22% (16-29%).",Pharmacokinetics of intravenous isosorbide-dinitrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7182455/),%,22,69367,DB00143,Glutathione
,7182455,liver blood flow,"Assuming that oral ISDN is completely absorbed and blood levels do not exceed serum levels, an upper limit of hepatic clearance (liver blood flow 1.5 litres X min-1 X (1-F/100)) can be estimated, which is significantly smaller (p less than 0.05) than the measured clearance.",Pharmacokinetics of intravenous isosorbide-dinitrate. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7182455/),[1-f·l] / [100·min],1.5,69368,DB00143,Glutathione
,21986257,elimination t(½),The elimination t(½) was 1-4h.,Role of iodine in the toxicity of diiodomethyl-p-tolylsulfone (DIMPTS) in rats: ADME. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21986257/),h,1-4,69733,DB00143,Glutathione
,21986257,bioavailability,"Dermally applied (14)C-DIMPTS remained undetectable in plasma with bioavailability ≈ 7%, only 5-7% of the dose was recovered in urine.",Role of iodine in the toxicity of diiodomethyl-p-tolylsulfone (DIMPTS) in rats: ADME. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21986257/),%,7,69734,DB00143,Glutathione
,10545412,peak levels,"In the case of skin and prostate, the peak levels of silibinin were 1.4 +/- 0.5 and 2.5 +/- 0.4, respectively, and were achieved 1 h after administration.","Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10545412/),,1.4,70929,DB00143,Glutathione
,10545412,peak levels,"In the case of skin and prostate, the peak levels of silibinin were 1.4 +/- 0.5 and 2.5 +/- 0.4, respectively, and were achieved 1 h after administration.","Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10545412/),,2.5,70930,DB00143,Glutathione
,10545412,elimination half-life (t((1/2))),The levels of both free and conjugated silibinin declined after 0.5 or 1 h in an exponential fashion with an elimination half-life (t((1/2))) of 57-127 min for free and 45-94 min for conjugated silibinin in different tissues.,"Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10545412/),min,57-127,70931,DB00143,Glutathione
,10545412,elimination half-life (t((1/2))),The levels of both free and conjugated silibinin declined after 0.5 or 1 h in an exponential fashion with an elimination half-life (t((1/2))) of 57-127 min for free and 45-94 min for conjugated silibinin in different tissues.,"Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10545412/),min,45-94,70932,DB00143,Glutathione
,2058179,plasma clearance,"2. Across all subjects acetaminophen plasma clearance was reduced from 0.249 +/- 0.061 to 0.217 +/- 0.066 l/min after disulfiram treatment (mean +/- SD, P less than 0.05).",The influence of disulfiram on acetaminophen metabolism in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058179/),[l] / [min],0.249,71004,DB00143,Glutathione
,2058179,plasma clearance,"2. Across all subjects acetaminophen plasma clearance was reduced from 0.249 +/- 0.061 to 0.217 +/- 0.066 l/min after disulfiram treatment (mean +/- SD, P less than 0.05).",The influence of disulfiram on acetaminophen metabolism in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058179/),[l] / [min],0.217,71005,DB00143,Glutathione
,26229435,molar percentage,The molar percentage of PEGylated glutathione varied from 0 mol% to 0.75 mol%.,Targeting brain cells with glutathione-modulated nanoliposomes: in vitro and in vivo study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26229435/),mol%,0,72783,DB00143,Glutathione
,26229435,molar percentage,The molar percentage of PEGylated glutathione varied from 0 mol% to 0.75 mol%.,Targeting brain cells with glutathione-modulated nanoliposomes: in vitro and in vivo study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26229435/),mol%,0.75,72784,DB00143,Glutathione
more,26229435,zeta potential,The size of glutathione-modulated nanoliposomes was <100 nm and the zeta potential was more than -65 mV.,Targeting brain cells with glutathione-modulated nanoliposomes: in vitro and in vivo study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26229435/),m,65,72785,DB00143,Glutathione
,26229435,cumulative release,The cumulative release reached 70% for certain formulations.,Targeting brain cells with glutathione-modulated nanoliposomes: in vitro and in vivo study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26229435/),%,70,72786,DB00143,Glutathione
,26229435,concentration efficiency,"An in vivo study showed that the relative efficiency was 2.632±0.089 and the concentration efficiency was 1.590±0.049, and also, the drug-targeting index was 3.670±0.824.",Targeting brain cells with glutathione-modulated nanoliposomes: in vitro and in vivo study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26229435/),,1.590,72787,DB00143,Glutathione
,26229435,drug-targeting index,"An in vivo study showed that the relative efficiency was 2.632±0.089 and the concentration efficiency was 1.590±0.049, and also, the drug-targeting index was 3.670±0.824.",Targeting brain cells with glutathione-modulated nanoliposomes: in vitro and in vivo study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26229435/),,3.670,72788,DB00143,Glutathione
,12885396,binding,"In vitro binding of INUdR to bovine serum albumin (BSA) was estimated using an ultrafiltration method to be 65 to 77%, depending on the INUdR concentration.",Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885396/),%,65,73271,DB00143,Glutathione
,12885396,elimination half-life (T(1/2),"The pharmacokinetics of INUdR following single intravenous bolus and oral doses of INUdR (40 mg/kg) to male Sprague-Dawley rats were characterized by a short elimination half-life (T(1/2) 0.27 h), a large steady-state volume of distribution (V(ss) 0.89 l/kg) and high oral bioavailability (F=0.95).",Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885396/),h,0.27,73272,DB00143,Glutathione
,12885396,steady-state volume of distribution (V(ss),"The pharmacokinetics of INUdR following single intravenous bolus and oral doses of INUdR (40 mg/kg) to male Sprague-Dawley rats were characterized by a short elimination half-life (T(1/2) 0.27 h), a large steady-state volume of distribution (V(ss) 0.89 l/kg) and high oral bioavailability (F=0.95).",Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885396/),[l] / [kg],0.89,73273,DB00143,Glutathione
,12885396,oral bioavailability (F,"The pharmacokinetics of INUdR following single intravenous bolus and oral doses of INUdR (40 mg/kg) to male Sprague-Dawley rats were characterized by a short elimination half-life (T(1/2) 0.27 h), a large steady-state volume of distribution (V(ss) 0.89 l/kg) and high oral bioavailability (F=0.95).",Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885396/),,0.95,73274,DB00143,Glutathione
,6694118,Biliary excretion,Biliary excretion of the various metabolites of acetaminophen increased from 20 to 49% as the dosage was increased from 37.5 to 600 mg/kg.,Glucuronidation and biliary excretion of acetaminophen in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694118/),%,20,73728,DB00143,Glutathione
,33295031,minimum particle size,"The high-pressure homogenization significantly reduced the particle size of perilla oil nanoemulsions and enhanced their stability, and the minimum particle size was 293.87 ± 6.55 nm at 120 MPa.",Effect of nanoemulsion particle size on the bioavailability and bioactivity of perilla oil in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33295031/),nm,293.87,73896,DB00143,Glutathione
,33295031,IL-8,"The IL-1β, IL-6, and IL-8 levels were 49.52 ± 14.06, 90.13 ± 6.04, and 419.71 ± 32.03 ng/L, respectively, in rats treated with perilla oil nanoemulsions prepared at 120 MPa.",Effect of nanoemulsion particle size on the bioavailability and bioactivity of perilla oil in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33295031/),[ng] / [l],419.71,73897,DB00143,Glutathione
,8047323,immunoreactive fraction,99Tcm-CC83 was eluted as intact immunoglobulin by FPLC analysis and the mean immunoreactive fraction was 0.49 +/- 0.15.,Immunoscintigraphy of human colon cancer xenografts in nude mice using a second-generation TAG-72 monoclonal antibody labelled with 99Tcm. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8047323/),,0.49,74570,DB00143,Glutathione
,8047323,Tumour uptake,Tumour uptake at 24 h postinjection was 11.2 +/- 4.1% i.d.g-1.,Immunoscintigraphy of human colon cancer xenografts in nude mice using a second-generation TAG-72 monoclonal antibody labelled with 99Tcm. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8047323/),%,11.2,74571,DB00143,Glutathione
,8047323,half-life,Radioactivity in the blood was eliminated rapidly with a half-life of 8 h and tumour:blood ratios were > 2:1 at 24 h postinjection.,Immunoscintigraphy of human colon cancer xenografts in nude mice using a second-generation TAG-72 monoclonal antibody labelled with 99Tcm. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8047323/),h,8,74572,DB00143,Glutathione
>,8047323,tumour:blood ratios,Radioactivity in the blood was eliminated rapidly with a half-life of 8 h and tumour:blood ratios were > 2:1 at 24 h postinjection.,Immunoscintigraphy of human colon cancer xenografts in nude mice using a second-generation TAG-72 monoclonal antibody labelled with 99Tcm. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8047323/),,2:,74573,DB00143,Glutathione
>,8047323,tumour:blood ratios,Radioactivity in the blood was eliminated rapidly with a half-life of 8 h and tumour:blood ratios were > 2:1 at 24 h postinjection.,Immunoscintigraphy of human colon cancer xenografts in nude mice using a second-generation TAG-72 monoclonal antibody labelled with 99Tcm. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8047323/),,1,74574,DB00143,Glutathione
,1993989,half-lives,"The half-lives of the urinary excretion were the same for the two mercapturates: 18 min and approximately 130 min, respectively, for the rapid and the slow phase.",The fate of diastereomeric glutathione conjugates of alpha-bromoisovalerylurea in blood in the rat in vivo and in the perfused liver. Stereoselectivity in biliary and urinary excretion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1993989/),min,18,74782,DB00143,Glutathione
,1993989,half-lives,"The half-lives of the urinary excretion were the same for the two mercapturates: 18 min and approximately 130 min, respectively, for the rapid and the slow phase.",The fate of diastereomeric glutathione conjugates of alpha-bromoisovalerylurea in blood in the rat in vivo and in the perfused liver. Stereoselectivity in biliary and urinary excretion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1993989/),min,130,74783,DB00143,Glutathione
>,10976660,Css,"Generally, the risk of hepatic veno-occlusive disease is increased with busulfan Css > 900 microg/L.",Plasma concentration monitoring of busulfan: does it improve clinical outcome? ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976660/),[μg] / [l],900,77929,DB00143,Glutathione
>,10976660,Css,Lower rates of relapse in chronic myelogenous leukaemia occur in patients with a busulfan Css > 917 microg/L without an increased risk of toxicity.,Plasma concentration monitoring of busulfan: does it improve clinical outcome? ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976660/),[μg] / [l],917,77930,DB00143,Glutathione
>,10976660,Css,"Busulfan Css is also related to the engraftment rate in children, and escalating busulfan doses to achieve a target Css > 600 microg/L improves graft retention.",Plasma concentration monitoring of busulfan: does it improve clinical outcome? ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976660/),[μg] / [l],600,77931,DB00143,Glutathione
,16087946,survival,Median survival for these patients was 1.3 years compared with 2.7 years for those without the variant (P = .043).,"Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087946/),years,1.3,79014,DB00143,Glutathione
,16087946,survival,Median survival for these patients was 1.3 years compared with 2.7 years for those without the variant (P = .043).,"Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087946/),years,2.7,79015,DB00143,Glutathione
,16087946,survival,Median survival for patients with deletions of glutathione-S-transferase M1 gene was 3.5 v 1.5 years for patients with one or both copies (P = .041).,"Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087946/),years,3,79016,DB00143,Glutathione
,16087946,survival,Median survival for patients with deletions of glutathione-S-transferase M1 gene was 3.5 v 1.5 years for patients with one or both copies (P = .041).,"Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087946/),years,1.5,79017,DB00143,Glutathione
,30582946,Tmax,"[14C]-BaPeq PK analysis gave plasma Tmax and Cmax values of 1.25 h and 29-82 fg/mL, respectively.",Toxicokinetics of benzo[a]pyrene in humans: Extensive metabolism as determined by UPLC-accelerator mass spectrometry following oral micro-dosing. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30582946/),h,1.25,82373,DB00143,Glutathione
,30582946,Cmax,"[14C]-BaPeq PK analysis gave plasma Tmax and Cmax values of 1.25 h and 29-82 fg/mL, respectively.",Toxicokinetics of benzo[a]pyrene in humans: Extensive metabolism as determined by UPLC-accelerator mass spectrometry following oral micro-dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30582946/),[fg] / [ml],29-,82374,DB00143,Glutathione
,30582946,LOD,"DNA, extracted from peripheral blood mononuclear cells (PBMCs) of 4 volunteers, showed measurable levels (LOD ~ 0.5 adducts/1011 nucleotides) in two individuals 2-3 h post-dose, approximately three orders of magnitude lower than smokers or occupationally-exposed individuals.",Toxicokinetics of benzo[a]pyrene in humans: Extensive metabolism as determined by UPLC-accelerator mass spectrometry following oral micro-dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30582946/),,0.5,82375,DB00143,Glutathione
,9806959,time of maximal plasma concentrations,"The time of maximal plasma concentrations for nearly all tissues was 4 hr after the dose, and the half-life of radioactivity in most tissues (8-10 hr) was similar to the half-life in plasma.","Tissue distribution and biotransformation of zopolrestat, an aldose reductase inhibitor, in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806959/),h,4,83915,DB00143,Glutathione
,9806959,half-life,"The time of maximal plasma concentrations for nearly all tissues was 4 hr after the dose, and the half-life of radioactivity in most tissues (8-10 hr) was similar to the half-life in plasma.","Tissue distribution and biotransformation of zopolrestat, an aldose reductase inhibitor, in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806959/),h,8-10,83916,DB00143,Glutathione
,10550571,rapid,"(1) WR-1065 is rapidly formed from WR-2721 and equilibrates between plasma and blood cells; (2) WR-1065 decays in plasma and blood cells with similar rapid initial half-lives of approximately 16 min; (3) WR-2721 treatment increases cysteine in plasma and blood cells, an effect similar to that of mesna; (4) WR-2721 treatment appears to increase glutathione levels in blood cells; (5) Mesna does not have a substantial effect on the fate of WR-2721 in patients.","WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550571/),min,16,83978,DB00143,Glutathione
,10550571,initial half-lives,"(1) WR-1065 is rapidly formed from WR-2721 and equilibrates between plasma and blood cells; (2) WR-1065 decays in plasma and blood cells with similar rapid initial half-lives of approximately 16 min; (3) WR-2721 treatment increases cysteine in plasma and blood cells, an effect similar to that of mesna; (4) WR-2721 treatment appears to increase glutathione levels in blood cells; (5) Mesna does not have a substantial effect on the fate of WR-2721 in patients.","WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550571/),min,16,83979,DB00143,Glutathione
,16448639,elimination constant,"At Dose 5, the heterozygous group had significantly lower elimination constant (0.176+/-0.038 vs. 0.315+/-0.021 h-1; P=0.008) and clearance corrected by bioavailability (0.118+/-0.013 vs. 0.196+/-0.011 l/h/kg; P=0.004), and significantly higher mean plasma busulfan concentration (1344+/-158 vs. 854+/-44 ng/ml; P=0.001) than the wildtype.",Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16448639/),1/[h],0.176,84364,DB00143,Glutathione
,16448639,elimination constant,"At Dose 5, the heterozygous group had significantly lower elimination constant (0.176+/-0.038 vs. 0.315+/-0.021 h-1; P=0.008) and clearance corrected by bioavailability (0.118+/-0.013 vs. 0.196+/-0.011 l/h/kg; P=0.004), and significantly higher mean plasma busulfan concentration (1344+/-158 vs. 854+/-44 ng/ml; P=0.001) than the wildtype.",Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16448639/),1/[h],0.315,84365,DB00143,Glutathione
,16448639,clearance corrected by bioavailability,"At Dose 5, the heterozygous group had significantly lower elimination constant (0.176+/-0.038 vs. 0.315+/-0.021 h-1; P=0.008) and clearance corrected by bioavailability (0.118+/-0.013 vs. 0.196+/-0.011 l/h/kg; P=0.004), and significantly higher mean plasma busulfan concentration (1344+/-158 vs. 854+/-44 ng/ml; P=0.001) than the wildtype.",Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16448639/),[l] / [h·kg],0.118,84366,DB00143,Glutathione
,16448639,clearance corrected by bioavailability,"At Dose 5, the heterozygous group had significantly lower elimination constant (0.176+/-0.038 vs. 0.315+/-0.021 h-1; P=0.008) and clearance corrected by bioavailability (0.118+/-0.013 vs. 0.196+/-0.011 l/h/kg; P=0.004), and significantly higher mean plasma busulfan concentration (1344+/-158 vs. 854+/-44 ng/ml; P=0.001) than the wildtype.",Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16448639/),[l] / [h·kg],0.196,84367,DB00143,Glutathione
,8983934,clearance,"PSP (200 mg/kg) significantly (P < 0.05) increased the clearance (controls, 19.06 +/- 2.74 ml/min/kg: PSP treated, 26.22 +/- 0.84 ml/min/kg) and volume of distribution (controls, 1.35 +/- 0.11 l/kg: PSP treated, 1.61 +/- 0.04 l/kg) of paracetamol by 37% and 21%, respectively.",Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983934/),[ml] / [kg·min],19.06,85880,DB00143,Glutathione
,8983934,clearance,"PSP (200 mg/kg) significantly (P < 0.05) increased the clearance (controls, 19.06 +/- 2.74 ml/min/kg: PSP treated, 26.22 +/- 0.84 ml/min/kg) and volume of distribution (controls, 1.35 +/- 0.11 l/kg: PSP treated, 1.61 +/- 0.04 l/kg) of paracetamol by 37% and 21%, respectively.",Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983934/),[ml] / [kg·min],26.22,85881,DB00143,Glutathione
,8983934,volume of distribution,"PSP (200 mg/kg) significantly (P < 0.05) increased the clearance (controls, 19.06 +/- 2.74 ml/min/kg: PSP treated, 26.22 +/- 0.84 ml/min/kg) and volume of distribution (controls, 1.35 +/- 0.11 l/kg: PSP treated, 1.61 +/- 0.04 l/kg) of paracetamol by 37% and 21%, respectively.",Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983934/),[l] / [kg],1.35,85882,DB00143,Glutathione
,8983934,volume of distribution,"PSP (200 mg/kg) significantly (P < 0.05) increased the clearance (controls, 19.06 +/- 2.74 ml/min/kg: PSP treated, 26.22 +/- 0.84 ml/min/kg) and volume of distribution (controls, 1.35 +/- 0.11 l/kg: PSP treated, 1.61 +/- 0.04 l/kg) of paracetamol by 37% and 21%, respectively.",Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983934/),[l] / [kg],1.61,85883,DB00143,Glutathione
,8983934,Cmax,The Cmax values of paracetamol sulphate were significantly (P < 0.01) increased by 2.4-fold from 907.8 +/- 157.7 micrograms/ml (controls) to 3061 +/- 331 micrograms/ml after PSP treatment.,Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983934/),[μg] / [ml],907.8,85884,DB00143,Glutathione
,8983934,Cmax,The Cmax values of paracetamol sulphate were significantly (P < 0.01) increased by 2.4-fold from 907.8 +/- 157.7 micrograms/ml (controls) to 3061 +/- 331 micrograms/ml after PSP treatment.,Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983934/),[μg] / [ml],3061,85885,DB00143,Glutathione
,30471374,entrapment efficiency,The PPNMs (entrapment efficiency: 96.7%) was acceptably stable in water with a mean particle size of 29.84 nm.,"Glutathione-sensitive PEGylated curcumin prodrug nanomicelles: Preparation, characterization, cellular uptake and bioavailability evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30471374/),%,96.7,86175,DB00143,Glutathione
,11131035,half-life,"Peak plasma concentrations of radiolabel and L-CPA occurred within 2 h of dosing at about 1.8 mM, and were then lost from the plasma with a half-life of 1 h.",The absence of cerebellar granule cell necrosis in the mouse following L-2-chloropropionic acid administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11131035/),h,1,87191,DB00143,Glutathione
,11131035,peak concentration,Radiolabel from L-[2-14C]-CPA was present in the cerebellum at a peak concentration of 1 mM 1-2 h after dosing and then was lost more slowly than from the plasma.,The absence of cerebellar granule cell necrosis in the mouse following L-2-chloropropionic acid administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11131035/),mM,1,87192,DB00143,Glutathione
,31125491,Tmax,"Tmax was 2-3 hour, regardless of race.","A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third-generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31125491/),h,2-3,87528,DB00143,Glutathione
,31125491,terminal half-life,"The mean terminal half-life ranged from 4.8 to 7.4 hour, with no significant differences between dose or racial groups.","A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third-generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31125491/),h,4.8 to 7.4,87529,DB00143,Glutathione
,9833606,clearance,"Median value and the corresponding 25th and 75th percentiles for the clearance of the sulphate metabolites were 93.6 (82.5-138.8) ml kg(-1)h(-1) and 77.4 (75.5-99.1), patients with ulcerative colitis and control subjects, respectively.",Paracetamol metabolism in patients with ulcerative colitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833606/),[ml] / [kg],93.6,87632,DB00143,Glutathione
,9833606,clearance,"Median value and the corresponding 25th and 75th percentiles for the clearance of the sulphate metabolites were 93.6 (82.5-138.8) ml kg(-1)h(-1) and 77.4 (75.5-99.1), patients with ulcerative colitis and control subjects, respectively.",Paracetamol metabolism in patients with ulcerative colitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833606/),,77.4,87633,DB00143,Glutathione
,32959915,recovery,"The mean recovery was 82.16%, with 2.38 and 79.78% of the radioactive dose excreted in urine and faeces, respectively.","Metabolic disposition of [14 C]-abivertinib, an epidermal growth factor receptor tyrosine kinase inhibitor: Role of glutathione conjugation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959915/),%,82.16,89201,DB00143,Glutathione
,32959915,recovery,"The mean recovery was 82.16%, with 2.38 and 79.78% of the radioactive dose excreted in urine and faeces, respectively.","Metabolic disposition of [14 C]-abivertinib, an epidermal growth factor receptor tyrosine kinase inhibitor: Role of glutathione conjugation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959915/),%,2.38,89202,DB00143,Glutathione
,32959915,recovery,"The mean recovery was 82.16%, with 2.38 and 79.78% of the radioactive dose excreted in urine and faeces, respectively.","Metabolic disposition of [14 C]-abivertinib, an epidermal growth factor receptor tyrosine kinase inhibitor: Role of glutathione conjugation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959915/),%,79.78,89203,DB00143,Glutathione
,8593476,hepatic uptake clearance,The hepatic uptake clearance was estimated to be 0.541 +/- 0.014 ml/h/g tissue or 42.4 +/- 9.8 ml/h/kg body weight.,Pharmacokinetics of glutathione-dextran macromolecular conjugate in mice. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593476/),[ml] / [g·h·tissue],0.541,89888,DB00143,Glutathione
,8593476,hepatic uptake clearance,The hepatic uptake clearance was estimated to be 0.541 +/- 0.014 ml/h/g tissue or 42.4 +/- 9.8 ml/h/kg body weight.,Pharmacokinetics of glutathione-dextran macromolecular conjugate in mice. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593476/),[ml] / [h·kg],42.4,89889,DB00143,Glutathione
,8593476,half-life,"FD--GSH accumulated in the liver for a long period, while the half-life of the conjugate in the blood circulation was 1.45h.",Pharmacokinetics of glutathione-dextran macromolecular conjugate in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593476/),h,1.45,89890,DB00143,Glutathione
,8593476,urinary,"The cumulative urinary and fecal excretions of FD-GSH were 14% and 4% of dose at 72h after the injection, respectively.",Pharmacokinetics of glutathione-dextran macromolecular conjugate in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593476/),%,14,89891,DB00143,Glutathione
,8593476,urinary,"The cumulative urinary and fecal excretions of FD-GSH were 14% and 4% of dose at 72h after the injection, respectively.",Pharmacokinetics of glutathione-dextran macromolecular conjugate in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593476/),%,4,89892,DB00143,Glutathione
,28163135,rate constant,"The maximum rate constant for DCA-induced GSTZ1-1 inactivation is estimated to be 0.96/h, which is 110 times that of the rate constant for GSTZ1-1 natural degradation (0.00875/h).",A Mechanism-Based Pharmacokinetic Enzyme Turnover Model for Dichloroacetic Acid Autoinhibition in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28163135/),1/[h],0.00875,91728,DB00143,Glutathione
,28163135,maximum enzyme inhibition (EC50),The model-predicted DCA concentration that corresponds to 50% of maximum enzyme inhibition (EC50) is 4.32 mg/L.,A Mechanism-Based Pharmacokinetic Enzyme Turnover Model for Dichloroacetic Acid Autoinhibition in Rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28163135/),[mg] / [l],4.32,91729,DB00143,Glutathione
,25119182,clearance,"Population estimates for daunorubicin clearance and volume of distribution were 116 L/m(2)/h ± 14% and 68.1 L/m(2) ± 24%, respectively.",Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25119182/),[l] / [h·m(2)],116,92436,DB00143,Glutathione
,25119182,volume of distribution,"Population estimates for daunorubicin clearance and volume of distribution were 116 L/m(2)/h ± 14% and 68.1 L/m(2) ± 24%, respectively.",Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25119182/),[l] / [m(2],68.1,92437,DB00143,Glutathione
,25119182,Apparent da,"Apparent daunorubicinol clearance and volume of distribution were 26.8 L/m(2)/h ± 5.6% and 232 L/m(2) ± 10%, respectively.",Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25119182/),[l] / [h·m(2)],26.8,92438,DB00143,Glutathione
,25119182,volume of distribution,"Apparent daunorubicinol clearance and volume of distribution were 26.8 L/m(2)/h ± 5.6% and 232 L/m(2) ± 10%, respectively.",Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25119182/),[l] / [m(2],232,92439,DB00143,Glutathione
,6745537,half-life for,The half-life for 36Cl absorption was 22.1 hr while the elimination half-life was 64.0 hr.,"Pharmacodynamics of alcide, a new antimicrobial compound, in rat and rabbit. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6745537/),h,22.1,92844,DB00143,Glutathione
,6745537,elimination half-life,The half-life for 36Cl absorption was 22.1 hr while the elimination half-life was 64.0 hr.,"Pharmacodynamics of alcide, a new antimicrobial compound, in rat and rabbit. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6745537/),h,64.0,92845,DB00143,Glutathione
,30414214,en,"The optimized TPAR-NL produced fairly stable spherical nanoparticles (˂ 200 nm) with encapsulation efficiency (%EE) of 85.77%, as well as enhanced in vitro release and improved oral bioavailability.","Preparation, optimization, and pharmacokinetic study of nanoliposomes loaded with triacylglycerol-bound punicic acid for increased antihepatotoxic activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30414214/),%,85.77,93250,DB00143,Glutathione
,29912563,half-life ( t1/2),"However, it hydrolyzed in human serum with a half-life ( t1/2) of 36 min, producing aceclofenac.","Aceclofenac-Galactose Conjugate: Design, Synthesis, Characterization, and Pharmacological and Toxicological Evaluations. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29912563/),min,36,93519,DB00143,Glutathione
,2019996,clearance,The p.o. clearance of 0.15 mmol/kg of OTC was 0.57 +/- 0.20 liters/(hr.kg) S.D..,"L-2-oxothiazolidine-4-carboxylic acid, a cysteine prodrug: pharmacokinetics and effects on thiols in plasma and lymphocytes in human. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2019996/),[l] / [hr·kg],0.57,93936,DB00143,Glutathione
,31406224,AUC,Overall there was an 11-fold variation in melphalan AUC with a median of 27.88 mg h/L (10.06-110.26).,"Impact of frailty, melphalan pharmacokinetics, and pharmacogenetics on outcomes post autologous hematopoietic cell transplantation for multiple myeloma. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31406224/),[h·mg] / [l],27.88,96076,DB00143,Glutathione
,17365284,efflux ratio,"The functional activity of the efflux pumps in Caco-2 cells and rat intestinal mucosa during the experiment was proven by the efflux ratio of saquinavir, which was 6.4 for Caco-2 cells and 2.1 for rat intestinal mucosa, respectively.",Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365284/),,6.4,96443,DB00143,Glutathione
,17365284,efflux ratio,"The functional activity of the efflux pumps in Caco-2 cells and rat intestinal mucosa during the experiment was proven by the efflux ratio of saquinavir, which was 6.4 for Caco-2 cells and 2.1 for rat intestinal mucosa, respectively.",Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365284/),,2.1,96444,DB00143,Glutathione
,14615468,AUC,Escalating doses of ifosfamide and mesna were administered; carboplatin was administered to achieve an AUC of 4 mg x min/mL.,Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14615468/),[mg·min] / [ml],4,96467,DB00143,Glutathione
,14615468,Vss,"Mean (coefficient of variation [CV%]) mesna pharmacokinetic parameter estimates were as follows: Vss of 15.3 (29) L/m2, CL of 4.6 (29) L/h/m2, and half-life of 2.2 (37) hours.",Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14615468/),[l] / [m2],15.3,96468,DB00143,Glutathione
,14615468,CL,"Mean (coefficient of variation [CV%]) mesna pharmacokinetic parameter estimates were as follows: Vss of 15.3 (29) L/m2, CL of 4.6 (29) L/h/m2, and half-life of 2.2 (37) hours.",Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14615468/),[l] / [h·m2],4.6,96469,DB00143,Glutathione
,14615468,half-life,"Mean (coefficient of variation [CV%]) mesna pharmacokinetic parameter estimates were as follows: Vss of 15.3 (29) L/m2, CL of 4.6 (29) L/h/m2, and half-life of 2.2 (37) hours.",Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14615468/),h,2.2,96470,DB00143,Glutathione
,14615468,Emax,Mean (CV%) pharmacodynamic parameter estimates were as follows: Emax of 31.7 (19) microg/mL and EC50 of 10.3 (52) microg/mL.,Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14615468/),[μg] / [ml],31.7,96471,DB00143,Glutathione
,14615468,EC50,Mean (CV%) pharmacodynamic parameter estimates were as follows: Emax of 31.7 (19) microg/mL and EC50 of 10.3 (52) microg/mL.,Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14615468/),[μg] / [ml],10.3,96472,DB00143,Glutathione
,7553617,IC50,"On the basis of an IC50 estimate of about 1.6 microM for inhibition of gamma-glutamylcysteine synthetase, the target enzyme of BSO, the population model predicted near identical GSH concentration time profiles over the dose range studied.",Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7553617/),μM,1.6,97884,DB00143,Glutathione
,30974789,maximum concentrations,"The H dose increased catechin and naringenin in plasma, with maximum concentrations of 44.3 and 19.3 ng/mL, respectively.",Polyphenols in Almond Skins after Blanching Modulate Plasma Biomarkers of Oxidative Stress in Healthy Humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30974789/),[ng] / [ml],44.3,100765,DB00143,Glutathione
,30974789,maximum concentrations,"The H dose increased catechin and naringenin in plasma, with maximum concentrations of 44.3 and 19.3 ng/mL, respectively.",Polyphenols in Almond Skins after Blanching Modulate Plasma Biomarkers of Oxidative Stress in Healthy Humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30974789/),[ng] / [ml],19.3,100766,DB00143,Glutathione
,19299526,k(inact),"TDI was observed with both compounds, with k(inact) and K(I) values of 0.08 and 0.02 min(-1) and 1.4 and 63.3 microM for TBZ and 5OH-TBZ, respectively.",In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19299526/),1/[min],0.08,101833,DB00143,Glutathione
,19299526,K(I),"TDI was observed with both compounds, with k(inact) and K(I) values of 0.08 and 0.02 min(-1) and 1.4 and 63.3 microM for TBZ and 5OH-TBZ, respectively.",In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19299526/),1/[min],0.02,101834,DB00143,Glutathione
,19299526,K(I),"TDI was observed with both compounds, with k(inact) and K(I) values of 0.08 and 0.02 min(-1) and 1.4 and 63.3 microM for TBZ and 5OH-TBZ, respectively.",In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19299526/),μM,63.3,101835,DB00143,Glutathione
,19299526,IC(50),"IC(50) determination of TBZ and 5OH-TBZ showed both compounds to be potent inhibitors, with IC(50) values of 0.83 and 13.05 microM, respectively.",In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19299526/),μM,0.83,101836,DB00143,Glutathione
,19299526,IC(50),"IC(50) determination of TBZ and 5OH-TBZ showed both compounds to be potent inhibitors, with IC(50) values of 0.83 and 13.05 microM, respectively.",In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19299526/),μM,13.05,101837,DB00143,Glutathione
,17944539,half-life,"The stability studies revealed the half-life of M1 to be about 0.85 h in HSA, 1.82 h in human plasma, and 4.48 h in phosphate-buffered saline (PBS) as determined by first-order approximation.",Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944539/),h,0.85,103134,DB00143,Glutathione
,17944539,half-life,"The stability studies revealed the half-life of M1 to be about 0.85 h in HSA, 1.82 h in human plasma, and 4.48 h in phosphate-buffered saline (PBS) as determined by first-order approximation.",Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944539/),h,1.82,103135,DB00143,Glutathione
,17944539,half-life,"The stability studies revealed the half-life of M1 to be about 0.85 h in HSA, 1.82 h in human plasma, and 4.48 h in phosphate-buffered saline (PBS) as determined by first-order approximation.",Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944539/),h,4.48,103136,DB00143,Glutathione
,17944539,rate constant k,The alkylation rate constant k for HSA was 20 M(-1) min(-1).,Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944539/),1/[M·min],20,103137,DB00143,Glutathione
,22719758,V(max⁡),"The two pathway results were comparable to previously reported values (V(max⁡) = 3.8 mg/hour, K(m) = 0.35 mg/liter, and k(GST) = 4.7 /hour).",Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in Rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22719758/),[mg] / [h],3.8,104622,DB00143,Glutathione
,22719758,K(m),"The two pathway results were comparable to previously reported values (V(max⁡) = 3.8 mg/hour, K(m) = 0.35 mg/liter, and k(GST) = 4.7 /hour).",Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in Rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22719758/),[mg] / [l],0.35,104623,DB00143,Glutathione
,22719758,k(GST),"The two pathway results were comparable to previously reported values (V(max⁡) = 3.8 mg/hour, K(m) = 0.35 mg/liter, and k(GST) = 4.7 /hour).",Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22719758/),1/[h],4.7,104624,DB00143,Glutathione
,22719758,V(max⁡(1) ),"The two binding site results were V(max⁡(1) ) = 3.7 mg/hour, K(m⁡(1) ) = 0.3 mg/hour, CL(2) = 0.047 liter/hour.",Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in Rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22719758/),[mg] / [h],3.7,104625,DB00143,Glutathione
,22719758,K(m⁡(1) ),"The two binding site results were V(max⁡(1) ) = 3.7 mg/hour, K(m⁡(1) ) = 0.3 mg/hour, CL(2) = 0.047 liter/hour.",Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in Rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22719758/),[mg] / [h],0.3,104626,DB00143,Glutathione
,22719758,CL(2),"The two binding site results were V(max⁡(1) ) = 3.7 mg/hour, K(m⁡(1) ) = 0.3 mg/hour, CL(2) = 0.047 liter/hour.",Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in Rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22719758/),[l] / [h],0.047,104627,DB00143,Glutathione
,14985147,Urinary elimination half-lives,3. Urinary elimination half-lives ranged from 5 to 6 h (rat) and from 7 to 10 h (mouse).,"Pharmacokinetics and metabolism of 14C-1,3-dichloropropene in the Fischer 344 rat and the B6C3F1 mouse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14985147/),h,5 to 6,104674,DB00143,Glutathione
,14985147,Urinary elimination half-lives,3. Urinary elimination half-lives ranged from 5 to 6 h (rat) and from 7 to 10 h (mouse).,"Pharmacokinetics and metabolism of 14C-1,3-dichloropropene in the Fischer 344 rat and the B6C3F1 mouse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14985147/),h,7 to 10,104675,DB00143,Glutathione
,12005188,Ae(Azo,"The significantly greater Ae(Azo, 0-8 h) in 4WE rats was mainly due to a significant increase in intrinsic active secretion of azosemide in renal tubules and not due to a decrease in the metabolism of azosemide.",Influence of 4-week and 8-week exercise training on the pharmacokinetics and pharmacodynamics of intravenous and oral azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12005188/),h,0-8,107367,DB00143,Glutathione
,31168820,EE,Cuminaldehyde self-emulsified nanoemulsion with acceptable characteristics (mean DS-48.83 ± 1.06 nm; PDI-0.232 ± 0.140; ZP-29.92 ± 1.66 mV; EE-91.51 ± 0.44%; and drug-loading capacity (DL)-9.77 ± 0.75%) was formulated.,Novel cuminaldehyde self-emulsified nanoemulsion for enhanced antihepatotoxicity in carbon tetrachloride-treated mice. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31168820/),%,91.51,108904,DB00143,Glutathione
,31168820,drug-loading capacity (DL),Cuminaldehyde self-emulsified nanoemulsion with acceptable characteristics (mean DS-48.83 ± 1.06 nm; PDI-0.232 ± 0.140; ZP-29.92 ± 1.66 mV; EE-91.51 ± 0.44%; and drug-loading capacity (DL)-9.77 ± 0.75%) was formulated.,Novel cuminaldehyde self-emulsified nanoemulsion for enhanced antihepatotoxicity in carbon tetrachloride-treated mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31168820/),%,9.77,108905,DB00143,Glutathione
,31168820,oral relative bioavailability,In-vitro drug release of CuA-SEN significantly increased with an oral relative bioavailability of 171.02%.,Novel cuminaldehyde self-emulsified nanoemulsion for enhanced antihepatotoxicity in carbon tetrachloride-treated mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31168820/),%,171.02,108906,DB00143,Glutathione
,17958336,"terminal elimination half-life (t1/2,lambdaz)","Upon i.v. injection, the average terminal elimination half-life (t1/2,lambdaz), AUC and AUMC were 6.4 h, 318.2 nCixh/mL and 2518 nCixh2/ mL, respectively.","Pharmacokinetics of GST-TatdMt, a recombinant fusion protein possessing potent anti-obesity activity, in mice. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17958336/),h,6.4,109047,DB00143,Glutathione
,17958336,AUC,"Upon i.v. injection, the average terminal elimination half-life (t1/2,lambdaz), AUC and AUMC were 6.4 h, 318.2 nCixh/mL and 2518 nCixh2/ mL, respectively.","Pharmacokinetics of GST-TatdMt, a recombinant fusion protein possessing potent anti-obesity activity, in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17958336/),[h·nci] / [ml],318.2,109048,DB00143,Glutathione
,17958336,AUMC,"Upon i.v. injection, the average terminal elimination half-life (t1/2,lambdaz), AUC and AUMC were 6.4 h, 318.2 nCixh/mL and 2518 nCixh2/ mL, respectively.","Pharmacokinetics of GST-TatdMt, a recombinant fusion protein possessing potent anti-obesity activity, in mice. ",AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17958336/),[h2·nci] / [ml],2518,109049,DB00143,Glutathione
,17958336,t1/2lambdaz,"The t1/2lambdaz values obtained from i.v., i.p., and oral administration were comparable from each other (range 5.8-6.4 h).","Pharmacokinetics of GST-TatdMt, a recombinant fusion protein possessing potent anti-obesity activity, in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17958336/),h,5.8-6.4,109050,DB00143,Glutathione
,17958336,absolute bioavailability,"The absolute bioavailability of 125I-GST-TatdMt was 42.8% and 60.5% after p.o. and i.p. administration, respectively.","Pharmacokinetics of GST-TatdMt, a recombinant fusion protein possessing potent anti-obesity activity, in mice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17958336/),%,42.8,109051,DB00143,Glutathione
,17958336,absolute bioavailability,"The absolute bioavailability of 125I-GST-TatdMt was 42.8% and 60.5% after p.o. and i.p. administration, respectively.","Pharmacokinetics of GST-TatdMt, a recombinant fusion protein possessing potent anti-obesity activity, in mice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17958336/),%,60.5,109052,DB00143,Glutathione
,19401458,rate of appearance,"In rats infused with [(13)C(2),(15)N-glycine]glutathione, the rate of appearance of plasma GSH was 2.1 micromol.min(-1).kg(-1), and the half-life of plasma GSH/GSSR was 6-8 min.",Dynamics of glutathione and ophthalmate traced with 2H-enriched body water in rats and humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19401458/),[μM] / [kg·min],2.1,109860,DB00143,Glutathione
,19401458,half-life,"In rats infused with [(13)C(2),(15)N-glycine]glutathione, the rate of appearance of plasma GSH was 2.1 micromol.min(-1).kg(-1), and the half-life of plasma GSH/GSSR was 6-8 min.",Dynamics of glutathione and ophthalmate traced with 2H-enriched body water in rats and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19401458/),min,6-8,109861,DB00143,Glutathione
<,19656582,uptake efficiency,"Branchial uptake efficiency was <5%, suggesting passive diffusion through aqueous channels in the gill epithelium.",Kinetics and effects of dichloroacetic acid in rainbow trout. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656582/),%,5,110554,DB00143,Glutathione
less,19656582,elimination half-lives (t(1/2)),DCA was rapidly cleared by naïve animals resulting in elimination half-lives (t(1/2)) of less than 4h.,Kinetics and effects of dichloroacetic acid in rainbow trout. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656582/),h,4,110555,DB00143,Glutathione
less,16543293,half-life,"Following oral dosing, the maximum concentration of 8-2 FTOH in plasma occurred by 1 h postdose and cleared rapidly with a half-life of less than 5 h.","Absorption, distribution, metabolism, and elimination of 8-2 fluorotelomer alcohol in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16543293/),h,5,111744,DB00143,Glutathione
,2260095,half-life,"The disappearance of inorganic arsenic from the blood showed a biphasic elimination pattern characterized first by a rapid component with a half-life of 4.5 hr and second by a slower component with a half-life of 58.0 hr in the BSO-pretreated hamsters, while these half-lives were 0.6 and 11.0 hr, respectively, in the controls.",Effects of glutathione depletion on the acute nephrotoxic potential of arsenite and on arsenic metabolism in hamsters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260095/),h,4.5,113510,DB00143,Glutathione
,2260095,half-life,"The disappearance of inorganic arsenic from the blood showed a biphasic elimination pattern characterized first by a rapid component with a half-life of 4.5 hr and second by a slower component with a half-life of 58.0 hr in the BSO-pretreated hamsters, while these half-lives were 0.6 and 11.0 hr, respectively, in the controls.",Effects of glutathione depletion on the acute nephrotoxic potential of arsenite and on arsenic metabolism in hamsters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260095/),h,58.0,113511,DB00143,Glutathione
,2260095,half-lives,"The disappearance of inorganic arsenic from the blood showed a biphasic elimination pattern characterized first by a rapid component with a half-life of 4.5 hr and second by a slower component with a half-life of 58.0 hr in the BSO-pretreated hamsters, while these half-lives were 0.6 and 11.0 hr, respectively, in the controls.",Effects of glutathione depletion on the acute nephrotoxic potential of arsenite and on arsenic metabolism in hamsters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260095/),h,0.6,113512,DB00143,Glutathione
,2260095,half-lives,"The disappearance of inorganic arsenic from the blood showed a biphasic elimination pattern characterized first by a rapid component with a half-life of 4.5 hr and second by a slower component with a half-life of 58.0 hr in the BSO-pretreated hamsters, while these half-lives were 0.6 and 11.0 hr, respectively, in the controls.",Effects of glutathione depletion on the acute nephrotoxic potential of arsenite and on arsenic metabolism in hamsters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260095/),h,11.0,113513,DB00143,Glutathione
,33805036,D50,Polymerized whey protein concentrate encapsulated GSH (PWPC-GSH) showed a diameter of roughly 1115 ± 7.07 nm (D50) and zeta potential of 30.37 ± 0.75 mV.,"Polymerized Whey Protein Concentrate-Based Glutathione Delivery System: Physicochemical Characterization, Bioavailability and Sub-Chronic Toxicity Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33805036/),nm,1115,113734,DB00143,Glutathione
,33805036,zeta potential,Polymerized whey protein concentrate encapsulated GSH (PWPC-GSH) showed a diameter of roughly 1115 ± 7.07 nm (D50) and zeta potential of 30.37 ± 0.75 mV.,"Polymerized Whey Protein Concentrate-Based Glutathione Delivery System: Physicochemical Characterization, Bioavailability and Sub-Chronic Toxicity Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33805036/),mv,30.37,113735,DB00143,Glutathione
,22768009,Total systemic normalized clearance,"Total systemic normalized clearance was 18.4 L/hr per 70 kg, with a plateau reached at approximately 2 years.","Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or Fever. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22768009/),[l] / [70·h·kg],18.4,113845,DB00143,Glutathione
,22768009,Total central,"Total central and peripheral Vds of acetaminophen were 16 and 59.5 L/70 kg, respectively.","Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or Fever. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22768009/),[l] / [70·kg],16,113846,DB00143,Glutathione
,22768009,peripheral Vds,"Total central and peripheral Vds of acetaminophen were 16 and 59.5 L/70 kg, respectively.","Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or Fever. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22768009/),[l] / [70·kg],59.5,113847,DB00143,Glutathione
<,12153755,rate of urinary elimination,Virtually all of the dose was eliminated through metabolic clearance; the rate of urinary elimination was < 1 mL/hr/kg.,Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta-depleted rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12153755/),[ml] / [h·kg],1,114318,DB00143,Glutathione
,12153755,Oral bioavailability,Oral bioavailability of DCA was 0-13% in naive and 14-75% in GST-zeta- depleted rats.,Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta-depleted rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12153755/),%,0-13,114319,DB00143,Glutathione
,12153755,Oral bioavailability,Oral bioavailability of DCA was 0-13% in naive and 14-75% in GST-zeta- depleted rats.,Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta-depleted rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12153755/),%,14-75,114320,DB00143,Glutathione
<,12153755,Oral bioavailability,Oral bioavailability of DCA in humans through consumption of drinking water was predicted to be very low and < 1%.,Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta-depleted rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12153755/),%,1,114321,DB00143,Glutathione
,43222,terminal half-life,"Following iv 6-MP administration, 6-MP levels were described by a two-compartment body model; mean terminal half-life; plasma clearance (CLp), and volume of distribution (Vdss) were 41.6 +/- 12.1 min, 48.4 +/- 15.4 ml/min/kg, and 1.76 +/- 0.64 liters/kg, respectively.",Comparative bioavailability and pharmacokinetic studies of azathioprine and 6-mercaptopurine in the rhesus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/43222/),min,41.6,114775,DB00143,Glutathione
,43222,plasma clearance (CLp),"Following iv 6-MP administration, 6-MP levels were described by a two-compartment body model; mean terminal half-life; plasma clearance (CLp), and volume of distribution (Vdss) were 41.6 +/- 12.1 min, 48.4 +/- 15.4 ml/min/kg, and 1.76 +/- 0.64 liters/kg, respectively.",Comparative bioavailability and pharmacokinetic studies of azathioprine and 6-mercaptopurine in the rhesus monkey. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/43222/),[ml] / [kg·min],48.4,114776,DB00143,Glutathione
,43222,volume of distribution (Vdss),"Following iv 6-MP administration, 6-MP levels were described by a two-compartment body model; mean terminal half-life; plasma clearance (CLp), and volume of distribution (Vdss) were 41.6 +/- 12.1 min, 48.4 +/- 15.4 ml/min/kg, and 1.76 +/- 0.64 liters/kg, respectively.",Comparative bioavailability and pharmacokinetic studies of azathioprine and 6-mercaptopurine in the rhesus monkey. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/43222/),[l] / [kg],1.76,114777,DB00143,Glutathione
,7932170,terminal half-life,"After i.v. administration, plasma EA disappearance was biphasic in seven patients and monophasic in two patients with a terminal half-life of 30 and 8 min, respectively.",Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932170/),min,30,115755,DB00143,Glutathione
,7932170,terminal half-life,"After i.v. administration, plasma EA disappearance was biphasic in seven patients and monophasic in two patients with a terminal half-life of 30 and 8 min, respectively.",Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932170/),min,8,115756,DB00143,Glutathione
,7932170,total body clearance,Mean total body clearance was high; 1405 ml/min in patients described by using a one-compartment model and 611 ml/min in those patients described by a two-compartment model.,Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932170/),[ml] / [min],1405,115757,DB00143,Glutathione
,7932170,total body clearance,Mean total body clearance was high; 1405 ml/min in patients described by using a one-compartment model and 611 ml/min in those patients described by a two-compartment model.,Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932170/),[ml] / [min],611,115758,DB00143,Glutathione
less,7932170,absolute bioavailability,"After p.o. administration, peak EA plasma concentrations were less than 10% of i.v. EA and the absolute bioavailability was less than 21% (range, 7-35%).",Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932170/),%,21,115759,DB00143,Glutathione
,27079250,t1/2,"The present account is a summary of our in vitro studies on the facile oxidative desulfurization in compound 1 to a cyclic ether metabolite M1 [5-(2,4-dimethoxyphenyl)-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-7-one] in NADPH-supplemented rats (t1/2 [half-life = mean ± S.D.] = 8.6 ± 0.4 minutes) and dog liver microsomes (t1/2 = 11.2 ± 0.4 minutes), but not in human liver microsomes (t1/2 > 120 minutes).",Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27079250/),min,8.6,119885,DB00143,Glutathione
,27079250,t1/2,"The present account is a summary of our in vitro studies on the facile oxidative desulfurization in compound 1 to a cyclic ether metabolite M1 [5-(2,4-dimethoxyphenyl)-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-7-one] in NADPH-supplemented rats (t1/2 [half-life = mean ± S.D.] = 8.6 ± 0.4 minutes) and dog liver microsomes (t1/2 = 11.2 ± 0.4 minutes), but not in human liver microsomes (t1/2 > 120 minutes).",Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27079250/),min,11.2,119886,DB00143,Glutathione
>,27079250,t1/2,"The present account is a summary of our in vitro studies on the facile oxidative desulfurization in compound 1 to a cyclic ether metabolite M1 [5-(2,4-dimethoxyphenyl)-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-7-one] in NADPH-supplemented rats (t1/2 [half-life = mean ± S.D.] = 8.6 ± 0.4 minutes) and dog liver microsomes (t1/2 = 11.2 ± 0.4 minutes), but not in human liver microsomes (t1/2 > 120 minutes).",Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27079250/),min,120,119887,DB00143,Glutathione
,27079250,Michaelis-Menten constant,"Oxidation by FMO1 followed Michaelis-Menten kinetics with Michaelis-Menten constant, maximum rate of oxidative desulfurization, and intrinsic clearance values of 209 μM, 20.4 nmol/min/mg protein, and 82.7 μl/min/mg protein, respectively.",Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27079250/),μM,209,119888,DB00143,Glutathione
,27079250,maximum rate of oxidative desulfurization,"Oxidation by FMO1 followed Michaelis-Menten kinetics with Michaelis-Menten constant, maximum rate of oxidative desulfurization, and intrinsic clearance values of 209 μM, 20.4 nmol/min/mg protein, and 82.7 μl/min/mg protein, respectively.",Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27079250/),[nM] / [mg·min],20.4,119889,DB00143,Glutathione
,27079250,intrinsic clearance,"Oxidation by FMO1 followed Michaelis-Menten kinetics with Michaelis-Menten constant, maximum rate of oxidative desulfurization, and intrinsic clearance values of 209 μM, 20.4 nmol/min/mg protein, and 82.7 μl/min/mg protein, respectively.",Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27079250/),[μl] / [mg·min],82.7,119890,DB00143,Glutathione
,27567929,relative bioavailability,"Oral administration of PAH-LNF (240mg/kg per body weight) in rats significantly enhanced solubility and relative bioavailability (270.7%) compared to the free PAH with about 2.7-, 1.5-, 1.3-, 1.3- and 1.5-fold increase in AUC, T1/2, MRT, Cmax and Tmax, respectively.",Tissue distribution and enhanced in vivo anti-hyperlipidemic-antioxidant effects of perillaldehyde-loaded liposomal nanoformulation against Poloxamer 407-induced hyperlipidemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27567929/),%,270.7,120623,DB00143,Glutathione
,26152902,intrinsic clearances,"Hepatic IFO and CAA in vitro intrinsic clearances were estimated to be 1.85 x 10(-9) μL s(-1) cell(-1) and 0.185 x 10(-9) μL s(-1) cell(-1) ,respectively (corresponding to an in vivo intrinsic IFO clearance estimate of 1.23 l h(-1) , to be compared to IFO published values ranging from 3 to 10 l h(-1) ).",Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26152902/),[μl] / [cell·s],1.85 x 10(-9),123607,DB00143,Glutathione
,26152902,intrinsic clearances,"Hepatic IFO and CAA in vitro intrinsic clearances were estimated to be 1.85 x 10(-9) μL s(-1) cell(-1) and 0.185 x 10(-9) μL s(-1) cell(-1) ,respectively (corresponding to an in vivo intrinsic IFO clearance estimate of 1.23 l h(-1) , to be compared to IFO published values ranging from 3 to 10 l h(-1) ).",Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26152902/),[μl] / [cell·s],0.185 x 10(-9),123608,DB00143,Glutathione
,26152902,intrinsic,"Hepatic IFO and CAA in vitro intrinsic clearances were estimated to be 1.85 x 10(-9) μL s(-1) cell(-1) and 0.185 x 10(-9) μL s(-1) cell(-1) ,respectively (corresponding to an in vivo intrinsic IFO clearance estimate of 1.23 l h(-1) , to be compared to IFO published values ranging from 3 to 10 l h(-1) ).",Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26152902/),[l] / [h],1.23,123609,DB00143,Glutathione
,28131081,half-life,The GSH half-life was between 2 and 3h with exposure (AUC) to increased GSH levels of 0.7 (2g γ-GC) and 1.8 (4g γ-GC) nmol.h/106 lymphocytes.,Oral administration of γ-glutamylcysteine increases intracellular glutathione levels above homeostasis in a randomised human trial pilot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28131081/),h,2 and 3,124884,DB00143,Glutathione
,28131081,AUC,The GSH half-life was between 2 and 3h with exposure (AUC) to increased GSH levels of 0.7 (2g γ-GC) and 1.8 (4g γ-GC) nmol.h/106 lymphocytes.,Oral administration of γ-glutamylcysteine increases intracellular glutathione levels above homeostasis in a randomised human trial pilot study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28131081/),,0,124885,DB00143,Glutathione
,28131081,AUC,The GSH half-life was between 2 and 3h with exposure (AUC) to increased GSH levels of 0.7 (2g γ-GC) and 1.8 (4g γ-GC) nmol.h/106 lymphocytes.,Oral administration of γ-glutamylcysteine increases intracellular glutathione levels above homeostasis in a randomised human trial pilot study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28131081/),,1.8,124886,DB00143,Glutathione
,17112692,Cmax,Serum concentration of curcumin obtained from the complex (equivalent to 1.0 g/kg of curcumin) was higher (Cmax 1.2 microg/ml) than pure curcumin (1.0 g/kg) (Cmax 0.5 microg/ml) and the complex maintained effective concentration of curcumin for a longer period of time in rat serum.,"Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112692/),[μg] / [ml],1.2,125179,DB00143,Glutathione
,17112692,Cmax,Serum concentration of curcumin obtained from the complex (equivalent to 1.0 g/kg of curcumin) was higher (Cmax 1.2 microg/ml) than pure curcumin (1.0 g/kg) (Cmax 0.5 microg/ml) and the complex maintained effective concentration of curcumin for a longer period of time in rat serum.,"Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112692/),[μg] / [ml],0.5,125180,DB00143,Glutathione
,21986100,AUC(0-8),"The AUC(0-8) (ng.min/ml) was determined to be 268848±924 and 40019±495 for CMD-Cys-DALCE and DALCE, respectively.",Development and in vivo characterization of a novel peptide drug delivery system providing extended plasma half life. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21986100/),[min·ng] / [ml],268848,125354,DB00143,Glutathione
,21986100,AUC(0-8),"The AUC(0-8) (ng.min/ml) was determined to be 268848±924 and 40019±495 for CMD-Cys-DALCE and DALCE, respectively.",Development and in vivo characterization of a novel peptide drug delivery system providing extended plasma half life. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21986100/),[min·ng] / [ml],40019,125355,DB00143,Glutathione
,21986100,mean residence time (MRT),"The mean residence time (MRT) was determined to be 256±8 and 53.1±9.5 min for CMD-Cys-DALCE and for DALCE, respectively.",Development and in vivo characterization of a novel peptide drug delivery system providing extended plasma half life. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21986100/),min,256,125356,DB00143,Glutathione
,21986100,mean residence time (MRT),"The mean residence time (MRT) was determined to be 256±8 and 53.1±9.5 min for CMD-Cys-DALCE and for DALCE, respectively.",Development and in vivo characterization of a novel peptide drug delivery system providing extended plasma half life. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21986100/),min,53.1,125357,DB00143,Glutathione
,547024,half life for the elimination,"The half life for the elimination of 36Cl from the rat was 44 hr, corresponding to a rate constant of 0.016 hr-1.","Kinetics of Cl02 and effects of Cl02, Cl02-, and Cl03- in drinking water on blood glutathione and hemolysis in rat and chicken. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/547024/),h,44,128349,DB00143,Glutathione
,547024,rate constant,"The half life for the elimination of 36Cl from the rat was 44 hr, corresponding to a rate constant of 0.016 hr-1.","Kinetics of Cl02 and effects of Cl02, Cl02-, and Cl03- in drinking water on blood glutathione and hemolysis in rat and chicken. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/547024/),1/[h],0.016,128350,DB00143,Glutathione
,10762607,half-life,"The half-life of rGSTA1/A2 mRNA in control animals was 3.6 h, whereas it was 10.2 h in phenobarbital-treated animals.",Differential lobular induction in rat liver of glutathione S-transferase A1/A2 by phenobarbital. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10762607/),h,3.6,128366,DB00143,Glutathione
,10762607,half-life,"The half-life of rGSTA1/A2 mRNA in control animals was 3.6 h, whereas it was 10.2 h in phenobarbital-treated animals.",Differential lobular induction in rat liver of glutathione S-transferase A1/A2 by phenobarbital. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10762607/),h,10.2,128367,DB00143,Glutathione
,8349826,plasma half-life,We found that intravenous administration of purified 39-kD protein to rats prolonged the plasma half-life of 125I-t-PA from 1 min to approximately 5-6 min.,39-kD protein inhibits tissue-type plasminogen activator clearance in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8349826/),min,1,129016,DB00143,Glutathione
,8349826,plasma half-life,We found that intravenous administration of purified 39-kD protein to rats prolonged the plasma half-life of 125I-t-PA from 1 min to approximately 5-6 min.,39-kD protein inhibits tissue-type plasminogen activator clearance in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8349826/),min,5-6,129017,DB00143,Glutathione
,8349826,half-lives,Clearance of 125I-39-kD protein was a biphasic process with half-lives of 30 s and 9 min and the liver was the primary organ of clearance.,39-kD protein inhibits tissue-type plasminogen activator clearance in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8349826/),s,30,129018,DB00143,Glutathione
,8349826,half-lives,Clearance of 125I-39-kD protein was a biphasic process with half-lives of 30 s and 9 min and the liver was the primary organ of clearance.,39-kD protein inhibits tissue-type plasminogen activator clearance in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8349826/),min,9,129019,DB00143,Glutathione
,8013287,Peak plasma platinum (Pt),"Peak plasma platinum (Pt) levels of 0.89 and 1.44 micrograms Pt/ml were observed at 15 min and 2 hr after administration of tetraplatin with and without GSH, respectively, and the Pt then decayed biphasically when administered with GSH and monophasically when administered alone.",Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8013287/),[pt·μg] / [ml],0.89,129102,DB00143,Glutathione
,8013287,Peak plasma platinum (Pt),"Peak plasma platinum (Pt) levels of 0.89 and 1.44 micrograms Pt/ml were observed at 15 min and 2 hr after administration of tetraplatin with and without GSH, respectively, and the Pt then decayed biphasically when administered with GSH and monophasically when administered alone.",Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8013287/),[pt·μg] / [ml],1.44,129103,DB00143,Glutathione
,31480560,CLo,"Carriers of GSTA1*B exhibited lower busulfan CLo than patients with an *A/*A genotype (p < 0.002): Busulfan CLo was 166 ± 31, 187 ± 37 vs.",Impact of GSTA1 Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31480560/),,166,131381,DB00143,Glutathione
,31480560,CLo,"Carriers of GSTA1*B exhibited lower busulfan CLo than patients with an *A/*A genotype (p < 0.002): Busulfan CLo was 166 ± 31, 187 ± 37 vs.",Impact of GSTA1 Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31480560/),,187,131382,DB00143,Glutathione
,1732127,bioactivation,"Acetaminophen glucuronide formation in subjects with Gilbert's syndrome was 31% lower than that in normal controls (0.27 +/- 0.05 vs. 0.39 +/- 0.03; P less than 0.05), and bioactivation was 1.7-fold higher (3.5% +/- 0.4% vs. 2.1% +/- 0.3%; P less than 0.05).",Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732127/),%,3.5,131650,DB00143,Glutathione
,1732127,bioactivation,"Acetaminophen glucuronide formation in subjects with Gilbert's syndrome was 31% lower than that in normal controls (0.27 +/- 0.05 vs. 0.39 +/- 0.03; P less than 0.05), and bioactivation was 1.7-fold higher (3.5% +/- 0.4% vs. 2.1% +/- 0.3%; P less than 0.05).",Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732127/),%,2.1,131651,DB00143,Glutathione
,23877690,biliary excretion,"The biliary excretion of BZL was higher (60%) in the BZL group, and urinary excretion of BZL did not show differences between groups.",Modulation of biotransformation systems and ABC transporters by benznidazole in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23877690/),%,60,133800,DB00143,Glutathione
,24141375,MTD,The MTD of GSAO was 22.0 mg/m(2)/day.,A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24141375/),[mg] / [d·m(2)],22.0,135805,DB00143,Glutathione
,3795049,hepatic extraction ratio,"The rate-limiting step in the clearance of BIU from blood most likely is glutathione conjugation as it was shown that rate-limitation is not due to flow-limited clearance in the liver (the initial extraction ratio of BIU in the perfused liver preparation was low: hepatic extraction ratio = 0.23), protein binding (60% was unbound in plasma) or enzyme saturation (linear pharmacokinetics in the dose range studied: 22-270 mumol/kg).",alpha-Bromoisovalerylurea as model substrate for studies on pharmacokinetics of glutathione conjugation in the rat. Pharmacokinetics and stereoselectivity of metabolism and excretion in vivo and in the perfused liver. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795049/),,0.23,136503,DB00143,Glutathione
,3795049,protein binding,"The rate-limiting step in the clearance of BIU from blood most likely is glutathione conjugation as it was shown that rate-limitation is not due to flow-limited clearance in the liver (the initial extraction ratio of BIU in the perfused liver preparation was low: hepatic extraction ratio = 0.23), protein binding (60% was unbound in plasma) or enzyme saturation (linear pharmacokinetics in the dose range studied: 22-270 mumol/kg).",alpha-Bromoisovalerylurea as model substrate for studies on pharmacokinetics of glutathione conjugation in the rat. Pharmacokinetics and stereoselectivity of metabolism and excretion in vivo and in the perfused liver. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795049/),%,60,136504,DB00143,Glutathione
,8377117,renal clearance,"However, for both dose groups tested, the values of renal clearance (9.96 and 11.1 mL/min.kg, respectively) were close to the value of glomerular filtration in the rat.",Biliary excretion and pharmacokinetics of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging in the rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8377117/),[ml] / [kg·min],9.96,136845,DB00143,Glutathione
,8377117,renal clearance,"However, for both dose groups tested, the values of renal clearance (9.96 and 11.1 mL/min.kg, respectively) were close to the value of glomerular filtration in the rat.",Biliary excretion and pharmacokinetics of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging in the rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8377117/),[ml] / [kg·min],11.1,136846,DB00143,Glutathione
,8377117,hepatobiliary transport maximum,A hepatobiliary transport maximum of 9.2 mumol/min.kg was evaluated by infusion studies.,Biliary excretion and pharmacokinetics of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging in the rat. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8377117/),[μM] / [kg·min],9.2,136847,DB00143,Glutathione
,22406655,area under the curve window,"For both dosing strategies, the percent of patients achieving the therapeutic area under the curve window (900-1500 μmole·min/L were 60% and 70%-90% in children <9 and ≥9 kg, respectively.",Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406655/),[min·μmole] / [l],900-1500,139080,DB00143,Glutathione
,10778956,plasma area under the curve,"Ifosfamide and mesna were infused over 24 and 36 h, respectively, at equal daily doses; carboplatin was given after ifosfamide to a target plasma area under the curve of 4 mg x min x ml(-1).",Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778956/),[mg·min] / [ml],4,140707,DB00143,Glutathione
,10778956,maximum tolerated dose,The dose of ifosfamide was escalated from 2 to 8 g/m2; the maximum tolerated dose was 6 g/m2.,Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778956/),[g] / [m2],6,140708,DB00143,Glutathione
,14988420,half-life,The plasma concentration occurred at 1 h and peaked around 20 microM at 4 h after dosing and declined with a half-life of about 2.2 h.,In vivo pharmacokinetics and regulation of gene expression profiles by isothiocyanate sulforaphane in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14988420/),h,2.2,140741,DB00143,Glutathione
,9806960,bioavailability,The bioavailability in dogs of a 2 mg/kg oral dose of zopolrestat was 97.2%.,"Bioavailability, multiple-dose pharmacokinetics, and biotransformation of the aldose reductase inhibitor zopolrestat in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806960/),%,97.2,144266,DB00143,Glutathione
,20692312,percutaneous permeability coefficient (K(p),Total urinary excretion of metabolites from in vivo rat dermal exposures was used to estimate a percutaneous permeability coefficient (K(p); 3.6×10(-5) cm/h).,Hydroquinone PBPK model refinement and application to dermal exposure. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20692312/),[cm] / [h],3.6×10(-5),144830,DB00143,Glutathione
,20692312,K(p),"The human in vivo K(p) was estimated to be 1.62×10(-4) cm/h, based on in vitro skin permeability data in rats and humans and rat in vivo values.",Hydroquinone PBPK model refinement and application to dermal exposure. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20692312/),[cm] / [h],1.62×10(-4),144831,DB00143,Glutathione
,15939501,relative bioavailability,In vivo studies demonstrated a relative bioavailability of 34.4% for the subcutaneous administration.,The use of thiolated polymers as carrier matrix in oral peptide delivery--proof of concept. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15939501/),%,34.4,144893,DB00143,Glutathione
,15939501,absolute,"The absolute and relative bioavailability was determined to be 1.1% and 3.2%, respectively.",The use of thiolated polymers as carrier matrix in oral peptide delivery--proof of concept. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15939501/),%,1.1,144894,DB00143,Glutathione
,15939501,relative bioavailability,"The absolute and relative bioavailability was determined to be 1.1% and 3.2%, respectively.",The use of thiolated polymers as carrier matrix in oral peptide delivery--proof of concept. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15939501/),%,3.2,144895,DB00143,Glutathione
,22871060,PDI,"Optimization of various process variables were carried out, and optimized formulation was found to have particle size of 520.4 ± 15.0 nm, PDI of 0.312 ± 0.062, ζ potential of +30.4 ± 5.32 mV, and encapsulation efficiency of 63.4 ± 4.26%.",Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22871060/),,0.312,145194,DB00143,Glutathione
,22871060,ζ potential,"Optimization of various process variables were carried out, and optimized formulation was found to have particle size of 520.4 ± 15.0 nm, PDI of 0.312 ± 0.062, ζ potential of +30.4 ± 5.32 mV, and encapsulation efficiency of 63.4 ± 4.26%.",Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22871060/),m,30.4,145195,DB00143,Glutathione
,22871060,encapsulation efficiency,"Optimization of various process variables were carried out, and optimized formulation was found to have particle size of 520.4 ± 15.0 nm, PDI of 0.312 ± 0.062, ζ potential of +30.4 ± 5.32 mV, and encapsulation efficiency of 63.4 ± 4.26%.",Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22871060/),%,63.4,145196,DB00143,Glutathione
,2766304,half-life,The initial phase of the plasma concentration versus time curve had a half-life of 4.9 min and accounted for 94% of the total area under the curve.,Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766304/),min,4.9,146324,DB00143,Glutathione
,2766304,half-life of the terminal phase of the curve,The half-life of the terminal phase of the curve was 36.7 min and the area accounted for only 6% of the total area under the curve.,Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766304/),min,36.7,146325,DB00143,Glutathione
,2766304,Plasma clearance,Plasma clearance of BSO was 28.1 ml/min/kg and the steady state volume of distribution was 280 ml/kg.,Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766304/),[ml] / [kg·min],28.1,146326,DB00143,Glutathione
,2766304,steady state volume of distribution,Plasma clearance of BSO was 28.1 ml/min/kg and the steady state volume of distribution was 280 ml/kg.,Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766304/),[ml] / [kg],280,146327,DB00143,Glutathione
,1361150,R/S-ratio,"GSH conjugation of BPP, catalyzed by a mixture of glutathione-S-transferases (GST's) from rat liver cytosol in vitro, was stereoselective: at a substrate concentration of 250 microM, (R)-BPP was more rapidly conjugated than (S)-BPP (R/S-ratio = 2.6).",Glutathione conjugation and pharmacokinetics of 2-bromo-3-phenylpropionic acid in vitro and in the rat in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361150/),,2.6,146442,DB00143,Glutathione
,1361150,half lives,Elimination of (R)-BPP from blood was faster than that of (S)-BPP: half lives were 9 +/- 2 min for (R)-BPP and 13 +/- 1 min for (S)-BPP.,Glutathione conjugation and pharmacokinetics of 2-bromo-3-phenylpropionic acid in vitro and in the rat in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361150/),min,9,146443,DB00143,Glutathione
,1361150,half lives,Elimination of (R)-BPP from blood was faster than that of (S)-BPP: half lives were 9 +/- 2 min for (R)-BPP and 13 +/- 1 min for (S)-BPP.,Glutathione conjugation and pharmacokinetics of 2-bromo-3-phenylpropionic acid in vitro and in the rat in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361150/),min,13,146444,DB00143,Glutathione
,1361150,Half lives of excretion,"Half lives of excretion were 13 +/- 1 for the GSH conjugate of (R)-BPP, and 11 +/- 2 for the GSH conjugate of (S)-BPP (second phase).",Glutathione conjugation and pharmacokinetics of 2-bromo-3-phenylpropionic acid in vitro and in the rat in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361150/),,13,146445,DB00143,Glutathione
,1361150,Half lives of excretion,"Half lives of excretion were 13 +/- 1 for the GSH conjugate of (R)-BPP, and 11 +/- 2 for the GSH conjugate of (S)-BPP (second phase).",Glutathione conjugation and pharmacokinetics of 2-bromo-3-phenylpropionic acid in vitro and in the rat in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361150/),,11,146446,DB00143,Glutathione
,17316863,zeta potential,"Crosslinked PEI and plasmid DNA formed stable polyplexes in a size range of 100-300 nm, with zeta potentials between +16.4 and +26.1 mV.",Crosslinked nanocarriers based upon poly(ethylene imine) for systemic plasmid delivery: in vitro characterization and in vivo studies in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17316863/),mv,16.4,146809,DB00143,Glutathione
,17316863,zeta potential,"Crosslinked PEI and plasmid DNA formed stable polyplexes in a size range of 100-300 nm, with zeta potentials between +16.4 and +26.1 mV.",Crosslinked nanocarriers based upon poly(ethylene imine) for systemic plasmid delivery: in vitro characterization and in vivo studies in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17316863/),mv,26.1,146810,DB00143,Glutathione
,8675550,minimum concentration,The minimum concentration of L-(SR)-BSO that could be determined was 10 micrograms/mL when 100-microL serum samples were used.,"Determination of L-buthionin (SR)-sulfoximine, gamma-glutamylcysteine synthetase inhibitor in rat plasma with HPLC after prelabeling with dansyl chloride. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8675550/),[μg] / [ml],10,150030,DB00143,Glutathione
,8675550,detection limit,The detection limit was 50 ng per injection volume.,"Determination of L-buthionin (SR)-sulfoximine, gamma-glutamylcysteine synthetase inhibitor in rat plasma with HPLC after prelabeling with dansyl chloride. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8675550/),[ng] / [injection·volume],50,150031,DB00143,Glutathione
,9571224,Cmax,"Following iv administration of [14C]BCB (8 mg/kg, 120 microCi/kg), no parent compound was detected in the blood; however, its debrominated metabolite, 2-methyleneglutaronitrile (2-MGN; Cmax 7.3 micrograms/ml), was observed up to 1 hr.","Metabolic and dispositional fate of 1,2-dibromo-2,4-dicyanobutane in the male fischer 344 Rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571224/),[μg] / [ml],7.3,150297,DB00143,Glutathione
,9571224,Cmax,"Although parent compound could not be detected in the blood following oral administration, 2-MGN was detected (Cmax 0. 32 micrograms/ml).","Metabolic and dispositional fate of 1,2-dibromo-2,4-dicyanobutane in the male fischer 344 Rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9571224/),[μg] / [ml],0. 32,150298,DB00143,Glutathione
,12656658,basal,"In the pharmacokinetics study, basal serum concentration of Se (75+/-6 microg/l) was within the reference range (70-125 microg/l), it promptly increased at 2 h, peaked at 4 h (147+/-17 microg/l; P<0.0001) and it was abundant in serum at 24 h.",Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12656658/),[μg] / [l],75,151472,DB00143,Glutathione
,2253201,alpha-phase half-lives,"The alpha-phase half-lives of the panel, between 0.35 and 0.71 h, were similar.","Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253201/),h,0.35 and 0.71,152526,DB00143,Glutathione
,2253201,beta-phase half-life,"The beta-phase half-life of Fib75-abrin A chain, 13.3 h, was significantly longer than the beta-phase half-lives of Fib75-ricin A chain, Fib75-gelonin, and Fib75-momordin, between 7.5 and 8.6 h.","Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253201/),h,13.3,152527,DB00143,Glutathione
,2253201,beta-phase half-lives,"The beta-phase half-life of Fib75-abrin A chain, 13.3 h, was significantly longer than the beta-phase half-lives of Fib75-ricin A chain, Fib75-gelonin, and Fib75-momordin, between 7.5 and 8.6 h.","Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253201/),h,7.5 and 8.6,152528,DB00143,Glutathione
,22057087,AUC(0→∞),"The AUC(0→∞) for RPCNG and RPTNG was found to be 928.07 ± 206.5 and 1055.99 ± 251.7 ngh/mL, respectively in comparison to 137.25 ± 31.3 and 467.15 ± 106.1 ngh/mL for RPG and oral tablet, respectively.","Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057087/),[ngh] / [ml],928.07,153188,DB00143,Glutathione
,22057087,AUC(0→∞),"The AUC(0→∞) for RPCNG and RPTNG was found to be 928.07 ± 206.5 and 1055.99 ± 251.7 ngh/mL, respectively in comparison to 137.25 ± 31.3 and 467.15 ± 106.1 ngh/mL for RPG and oral tablet, respectively.","Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057087/),[ngh] / [ml],1055.99,153189,DB00143,Glutathione
,22057087,AUC(0→∞),"The AUC(0→∞) for RPCNG and RPTNG was found to be 928.07 ± 206.5 and 1055.99 ± 251.7 ngh/mL, respectively in comparison to 137.25 ± 31.3 and 467.15 ± 106.1 ngh/mL for RPG and oral tablet, respectively.","Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057087/),[ngh] / [ml],137.25,153190,DB00143,Glutathione
,22057087,AUC(0→∞),"The AUC(0→∞) for RPCNG and RPTNG was found to be 928.07 ± 206.5 and 1055.99 ± 251.7 ngh/mL, respectively in comparison to 137.25 ± 31.3 and 467.15 ± 106.1 ngh/mL for RPG and oral tablet, respectively.","Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057087/),[ngh] / [ml],467.15,153191,DB00143,Glutathione
,8523630,total clearance,Parenteral nutrition for 10 days decreased the total clearance of acetaminophen by 23% (from 11.5 +/- 1.4 to 8.9 +/- 1.4 mL/min per kg; p < .05) and decreased the formation clearance to acetaminophen sulfate (from 6.2 +/- 0.4 to 3.9 +/- 0.5 mL/min per kg; p < .05).,The depression of hepatic drug conjugation reactions in rats after lipid-free total parenteral nutrition administered via the portal vein. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8523630/),[ml] / [kg·min],11.5,155352,DB00143,Glutathione
,8523630,total clearance,Parenteral nutrition for 10 days decreased the total clearance of acetaminophen by 23% (from 11.5 +/- 1.4 to 8.9 +/- 1.4 mL/min per kg; p < .05) and decreased the formation clearance to acetaminophen sulfate (from 6.2 +/- 0.4 to 3.9 +/- 0.5 mL/min per kg; p < .05).,The depression of hepatic drug conjugation reactions in rats after lipid-free total parenteral nutrition administered via the portal vein. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8523630/),[ml] / [kg·min],8.9,155353,DB00143,Glutathione
,8523630,formation clearance,Parenteral nutrition for 10 days decreased the total clearance of acetaminophen by 23% (from 11.5 +/- 1.4 to 8.9 +/- 1.4 mL/min per kg; p < .05) and decreased the formation clearance to acetaminophen sulfate (from 6.2 +/- 0.4 to 3.9 +/- 0.5 mL/min per kg; p < .05).,The depression of hepatic drug conjugation reactions in rats after lipid-free total parenteral nutrition administered via the portal vein. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8523630/),[ml] / [kg·min],6.2,155354,DB00143,Glutathione
,8523630,formation clearance,Parenteral nutrition for 10 days decreased the total clearance of acetaminophen by 23% (from 11.5 +/- 1.4 to 8.9 +/- 1.4 mL/min per kg; p < .05) and decreased the formation clearance to acetaminophen sulfate (from 6.2 +/- 0.4 to 3.9 +/- 0.5 mL/min per kg; p < .05).,The depression of hepatic drug conjugation reactions in rats after lipid-free total parenteral nutrition administered via the portal vein. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8523630/),[ml] / [kg·min],3.9,155355,DB00143,Glutathione
,3626590,recovery,The mean recovery of pure gossypol added to plant material was 91.1 +/- 1.1% (S.D.).,Analysis of gossypol by high performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3626590/),%,91.1,156194,DB00143,Glutathione
,3626590,sensitivity,The assay sensitivity was 5 ng/ml.,Analysis of gossypol by high performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3626590/),[ng] / [ml],5,156195,DB00143,Glutathione
,22117535,minimum effective dose,"Collectively, these findings led us to conclude that oral administration of MiADMSA was more effective than intraperitoneal administration and that the minimum effective dose with least side effects was 50 mg/kg.","Monoisoamyl 2, 3-dimercaptosuccinic acid (MiADMSA) demonstrates higher efficacy by oral route in reversing arsenic toxicity: a pharmacokinetic approach. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22117535/),,50,156683,DB00143,Glutathione
,10028198,kinetic constant,"The accretion of 3H proceeded with kinetic constant of 0.7 h, followed by monophasic decline with the half-life of about 19h.","Disposition and metabolism of 1,2-dimethylnaphthalene in rats. ",Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028198/),h,0.7,157072,DB00143,Glutathione
,10028198,half-life,"The accretion of 3H proceeded with kinetic constant of 0.7 h, followed by monophasic decline with the half-life of about 19h.","Disposition and metabolism of 1,2-dimethylnaphthalene in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10028198/),h,19,157073,DB00143,Glutathione
,2043159,clearance,"Malaria infection (MI) resulted in a significant decrease in clearance (control: 21.6 +/- 5.5 vs test: 11.8 +/- 2.9 mL/min/kg, P less than 0.005) with no change in volume of distribution and a significant prolongation of the elimination half-life (control: 30.7 +/- 6.3 vs 53.3 +/- 12.1 min, P less than 0.005) of paracetamol in malaria infected rats.",The effect of malaria infection on paracetamol disposition in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2043159/),[ml] / [kg·min],21.6,158929,DB00143,Glutathione
,2043159,clearance,"Malaria infection (MI) resulted in a significant decrease in clearance (control: 21.6 +/- 5.5 vs test: 11.8 +/- 2.9 mL/min/kg, P less than 0.005) with no change in volume of distribution and a significant prolongation of the elimination half-life (control: 30.7 +/- 6.3 vs 53.3 +/- 12.1 min, P less than 0.005) of paracetamol in malaria infected rats.",The effect of malaria infection on paracetamol disposition in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2043159/),[ml] / [kg·min],11.8,158930,DB00143,Glutathione
,2043159,elimination half-life,"Malaria infection (MI) resulted in a significant decrease in clearance (control: 21.6 +/- 5.5 vs test: 11.8 +/- 2.9 mL/min/kg, P less than 0.005) with no change in volume of distribution and a significant prolongation of the elimination half-life (control: 30.7 +/- 6.3 vs 53.3 +/- 12.1 min, P less than 0.005) of paracetamol in malaria infected rats.",The effect of malaria infection on paracetamol disposition in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2043159/),min,30.7,158931,DB00143,Glutathione
,2043159,elimination half-life,"Malaria infection (MI) resulted in a significant decrease in clearance (control: 21.6 +/- 5.5 vs test: 11.8 +/- 2.9 mL/min/kg, P less than 0.005) with no change in volume of distribution and a significant prolongation of the elimination half-life (control: 30.7 +/- 6.3 vs 53.3 +/- 12.1 min, P less than 0.005) of paracetamol in malaria infected rats.",The effect of malaria infection on paracetamol disposition in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2043159/),min,53.3,158932,DB00143,Glutathione
,2539918,half-life of decay,"The half-life of decay of the enzyme was calculated to be 4.2 and 9.1 days respectively, in those rats that had already been exposed to 3 p.p.m.",Tissue selenium levels in selenium-supplemented rats and their relevance in mammary cancer protection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2539918/),d,4.2,159061,DB00143,Glutathione
,2539918,half-life of decay,"The half-life of decay of the enzyme was calculated to be 4.2 and 9.1 days respectively, in those rats that had already been exposed to 3 p.p.m.",Tissue selenium levels in selenium-supplemented rats and their relevance in mammary cancer protection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2539918/),d,9.1,159062,DB00143,Glutathione
,19409406,bioavailability,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),%,74,160025,DB00143,Glutathione
,19409406,half-life,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),h,0.6,160026,DB00143,Glutathione
,19409406,half-life,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),[ml] / [h],0.081,160027,DB00143,Glutathione
,19409406,half-life,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),h,12,160028,DB00143,Glutathione
,19409406,half-life,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),[ml] / [h],3.80,160029,DB00143,Glutathione
,19409406,half-life,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),h,1.4,160030,DB00143,Glutathione
,19409406,half-life,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),[ml] / [h],16.8,160031,DB00143,Glutathione
,19409406,half-life,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),h,1.2,160032,DB00143,Glutathione
,19409406,half-life,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),[ml] / [h],176,160033,DB00143,Glutathione
,19409406,clearance,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),[ml] / [h],0.081,160034,DB00143,Glutathione
,19409406,clearance,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),h,12,160035,DB00143,Glutathione
,19409406,clearance,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),[ml] / [h],3.80,160036,DB00143,Glutathione
,19409406,clearance,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),h,1.4,160037,DB00143,Glutathione
,19409406,clearance,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),[ml] / [h],16.8,160038,DB00143,Glutathione
,19409406,clearance,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),h,1.2,160039,DB00143,Glutathione
,19409406,clearance,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),[ml] / [h],176,160040,DB00143,Glutathione
,31586902,zeta potential,The results showed that Tf-SS-Afa-LPNs has particle size of 103.5 ± 4.1 nm and zeta potential of -21.2 ± 2.4 mV.,"Non-small cell lung cancer-targeted, redox-sensitive lipid-polymer hybrid nanoparticles for the delivery of a second-generation irreversible epidermal growth factor inhibitor-Afatinib: In vitro and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31586902/),m,-,161479,DB00143,Glutathione
,31586902,zeta potential,The results showed that Tf-SS-Afa-LPNs has particle size of 103.5 ± 4.1 nm and zeta potential of -21.2 ± 2.4 mV.,"Non-small cell lung cancer-targeted, redox-sensitive lipid-polymer hybrid nanoparticles for the delivery of a second-generation irreversible epidermal growth factor inhibitor-Afatinib: In vitro and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31586902/),m,21.2,161480,DB00143,Glutathione
,31586902,area under the plasma concentration - time curve (AUC),"The area under the plasma concentration - time curve (AUC), peak concentration (Cmax) and terminal half life (T1/2) of Tf-SS-Afa-LPNs were 866.56 mg/L.h, 25.62 ± 3.21 L/kg/h, and 43.25 ± 2.31 h.","Non-small cell lung cancer-targeted, redox-sensitive lipid-polymer hybrid nanoparticles for the delivery of a second-generation irreversible epidermal growth factor inhibitor-Afatinib: In vitro and in vivo evaluation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31586902/),[mg] / [h·l],866.56,161481,DB00143,Glutathione
,31586902,peak concentration (Cmax),"The area under the plasma concentration - time curve (AUC), peak concentration (Cmax) and terminal half life (T1/2) of Tf-SS-Afa-LPNs were 866.56 mg/L.h, 25.62 ± 3.21 L/kg/h, and 43.25 ± 2.31 h.","Non-small cell lung cancer-targeted, redox-sensitive lipid-polymer hybrid nanoparticles for the delivery of a second-generation irreversible epidermal growth factor inhibitor-Afatinib: In vitro and in vivo evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31586902/),[l] / [h·kg],25.62,161482,DB00143,Glutathione
,31586902,terminal half life (T1/2),"The area under the plasma concentration - time curve (AUC), peak concentration (Cmax) and terminal half life (T1/2) of Tf-SS-Afa-LPNs were 866.56 mg/L.h, 25.62 ± 3.21 L/kg/h, and 43.25 ± 2.31 h.","Non-small cell lung cancer-targeted, redox-sensitive lipid-polymer hybrid nanoparticles for the delivery of a second-generation irreversible epidermal growth factor inhibitor-Afatinib: In vitro and in vivo evaluation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31586902/),h,43.25,161483,DB00143,Glutathione
,11037805,net respiratory uptake,"The average net respiratory uptake of methyl chloride was 243, 158, and 44 micromol in individuals with high, intermediate and no GSTT1 activity, respectively.",Glutathione transferase T1 phenotype affects the toxicokinetics of inhaled methyl chloride in human volunteers. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11037805/),μM,243,161654,DB00143,Glutathione
,11037805,net respiratory uptake,"The average net respiratory uptake of methyl chloride was 243, 158, and 44 micromol in individuals with high, intermediate and no GSTT1 activity, respectively.",Glutathione transferase T1 phenotype affects the toxicokinetics of inhaled methyl chloride in human volunteers. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11037805/),μM,158,161655,DB00143,Glutathione
,11037805,net respiratory uptake,"The average net respiratory uptake of methyl chloride was 243, 158, and 44 micromol in individuals with high, intermediate and no GSTT1 activity, respectively.",Glutathione transferase T1 phenotype affects the toxicokinetics of inhaled methyl chloride in human volunteers. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11037805/),μM,44,161656,DB00143,Glutathione
,11037805,Metabolic clearance,"Metabolic clearance was high (4.6 l/min) in the +/+ group, intermediate (2.4 l/min) in the +/0 group, and close to zero in 0/0 individuals, while the exhalation clearance was similar in the three groups.",Glutathione transferase T1 phenotype affects the toxicokinetics of inhaled methyl chloride in human volunteers. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11037805/),[l] / [min],4.6,161657,DB00143,Glutathione
,11037805,Metabolic clearance,"Metabolic clearance was high (4.6 l/min) in the +/+ group, intermediate (2.4 l/min) in the +/0 group, and close to zero in 0/0 individuals, while the exhalation clearance was similar in the three groups.",Glutathione transferase T1 phenotype affects the toxicokinetics of inhaled methyl chloride in human volunteers. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11037805/),[l] / [min],2.4,161658,DB00143,Glutathione
,11037805,Metabolic clearance,"Metabolic clearance was high (4.6 l/min) in the +/+ group, intermediate (2.4 l/min) in the +/0 group, and close to zero in 0/0 individuals, while the exhalation clearance was similar in the three groups.",Glutathione transferase T1 phenotype affects the toxicokinetics of inhaled methyl chloride in human volunteers. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11037805/),,zero,161659,DB00143,Glutathione
,25034010,Plasma clearance,"Plasma clearance of dolutegravir, an unboosted HIV-1 integrase inhibitor, was low in rat and monkey (0.23 and 2.12 mL/min/kg, respectively) as was the volume of distribution (0.1 and 0.28 L/kg, respectively) with terminal elimination half-life approximately 6 h.","The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034010/),[ml] / [kg·min],0.23,161778,DB00143,Glutathione
,25034010,Plasma clearance,"Plasma clearance of dolutegravir, an unboosted HIV-1 integrase inhibitor, was low in rat and monkey (0.23 and 2.12 mL/min/kg, respectively) as was the volume of distribution (0.1 and 0.28 L/kg, respectively) with terminal elimination half-life approximately 6 h.","The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034010/),[ml] / [kg·min],2.12,161779,DB00143,Glutathione
,25034010,volume of distribution,"Plasma clearance of dolutegravir, an unboosted HIV-1 integrase inhibitor, was low in rat and monkey (0.23 and 2.12 mL/min/kg, respectively) as was the volume of distribution (0.1 and 0.28 L/kg, respectively) with terminal elimination half-life approximately 6 h.","The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034010/),[l] / [kg],0.1,161780,DB00143,Glutathione
,25034010,volume of distribution,"Plasma clearance of dolutegravir, an unboosted HIV-1 integrase inhibitor, was low in rat and monkey (0.23 and 2.12 mL/min/kg, respectively) as was the volume of distribution (0.1 and 0.28 L/kg, respectively) with terminal elimination half-life approximately 6 h.","The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034010/),[l] / [kg],0.28,161781,DB00143,Glutathione
,25034010,terminal elimination half-life,"Plasma clearance of dolutegravir, an unboosted HIV-1 integrase inhibitor, was low in rat and monkey (0.23 and 2.12 mL/min/kg, respectively) as was the volume of distribution (0.1 and 0.28 L/kg, respectively) with terminal elimination half-life approximately 6 h.","The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034010/),h,6,161782,DB00143,Glutathione
,25034010,bioavailability,"Dolutegravir was rapidly absorbed from oral solution with a high bioavailability in rat and monkey (75.6 and 87.0% respectively), but solubility or dissolution rate limited when administered as suspension.","The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034010/),%,75.6,161783,DB00143,Glutathione
,25034010,bioavailability,"Dolutegravir was rapidly absorbed from oral solution with a high bioavailability in rat and monkey (75.6 and 87.0% respectively), but solubility or dissolution rate limited when administered as suspension.","The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034010/),%,87.0,161784,DB00143,Glutathione
,15927694,terminal elimination half-life,"Upon administration, the total radioactivity in serum declined bi-exponentially, with the average terminal elimination half-life ranging from 13.7 to 15.7 h.","Dose-linear pharmacokinetics, tissue distribution, and excretion of a recombinant fusion protein 125I-GST-TatdMt possessing potent anti-obesity activity. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15927694/),h,13.7 to 15.7,162007,DB00143,Glutathione
,23212688,hepatic clearance,Na followed nonlinear pharmacokinetics with hepatic clearance decreasing from 3.14 to 1.99 mL/min with increasing dose.,"Disposition of ON 01210. Na (Ex-RAD(R)), a novel radioprotectant, in the isolated perfused rat liver: probing metabolic inhibition to increase systemic exposure. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23212688/),[ml] / [min],3.14,162252,DB00143,Glutathione
,23212688,hepatic clearance,Na followed nonlinear pharmacokinetics with hepatic clearance decreasing from 3.14 to 1.99 mL/min with increasing dose.,"Disposition of ON 01210. Na (Ex-RAD(R)), a novel radioprotectant, in the isolated perfused rat liver: probing metabolic inhibition to increase systemic exposure. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23212688/),[ml] / [min],1.99,162253,DB00143,Glutathione
,27178807,elimination half-life time,"The in vivo pharmacokinetics studies displayed that DOX-loaded cRGD20/PEG-SS-PCL micelles had a prolonged elimination half-life time of 3.51h, which was comparable to that of cRGD20/PEG-PCL counterparts, indicating that disulfide bonds in the PEG-SS-PCL micelles are stable in the circulation.",cRGD-functionalized reduction-sensitive shell-sheddable biodegradable micelles mediate enhanced doxorubicin delivery to human glioma xenografts in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27178807/),h,3.51,162980,DB00143,Glutathione
,8082705,blood half-life time,"The blood half-life time of exogenously injected FTS was short (2-3 min), indicating acute internalization of FTS into pancreatic beta-cells.",Prevention of diabetes by thymic hormone in alloxan-treated rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8082705/),min,2-3,163719,DB00143,Glutathione
,20926128,P(app),"In vitro, the formulation comprising 0.5% (m/v) PAA-cysteine (100 kDa)/0.5% (m/v) GSH improved the transport of paclitaxel 6.7-fold (P(app) = 8.7 ± 1.3 × 10(-6) cm/s) in comparison to paclitaxel itself serving as buffer only control (P(app) = 1.3 ± 0.4 × 10(-6) cm/s).",Development and in vivo evaluation of an oral drug delivery system for paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926128/),[cm] / [s],8.7,165408,DB00143,Glutathione
,20926128,P(app),"In vitro, the formulation comprising 0.5% (m/v) PAA-cysteine (100 kDa)/0.5% (m/v) GSH improved the transport of paclitaxel 6.7-fold (P(app) = 8.7 ± 1.3 × 10(-6) cm/s) in comparison to paclitaxel itself serving as buffer only control (P(app) = 1.3 ± 0.4 × 10(-6) cm/s).",Development and in vivo evaluation of an oral drug delivery system for paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926128/),[cm] / [s],1.3,165409,DB00143,Glutathione
,20926128,P(app),"Moreover, in the presence of the formulation containing 0.5% (m/v) PAA-cysteine (250 kDa)/0.5% (m/v) GSH paclitaxel absorption was even 7.4-fold (P(app) = 9.7 ± 0.3 × 10(-6) cm/s) improved in comparison to the buffer only control.",Development and in vivo evaluation of an oral drug delivery system for paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926128/),[cm] / [s],9.7,165410,DB00143,Glutathione
,7910818,cellular uptake t1/2,"The observed cellular uptake t1/2 of approximately 55 min, coupled with a previously reported, rapid in vivo clearance of buthionine sulfoximine, suggest that continuous infusion would be preferable to bolus dosing.","Pharmacodynamics of prolonged treatment with L,S-buthionine sulfoximine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910818/),min,55,167110,DB00143,Glutathione
under,7910818,EC50,"Effective concentrations of L-buthionine-S-sulfoximine (24 h exposure), required to lower cellular glutathione content to 50% of control (EC50), were under 1 mM for both cell lines.","Pharmacodynamics of prolonged treatment with L,S-buthionine sulfoximine. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910818/),mM,1,167111,DB00143,Glutathione
,30496738,Peak time (Tmax),"All preparations showed slower APAP absorption than reported for humans: Peak time (Tmax) = 12 h for Intestine 2-OC and 6 h for Intestine/Liver 2-OC in both static and dynamic conditions, against reported Tmax of 0,33 to 1,4 h after oral administration to humans.",Acetaminophen absorption and metabolism in an intestine/liver microphysiological system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496738/),h,12,167114,DB00143,Glutathione
,30496738,Peak time (Tmax),"All preparations showed slower APAP absorption than reported for humans: Peak time (Tmax) = 12 h for Intestine 2-OC and 6 h for Intestine/Liver 2-OC in both static and dynamic conditions, against reported Tmax of 0,33 to 1,4 h after oral administration to humans.",Acetaminophen absorption and metabolism in an intestine/liver microphysiological system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496738/),h,6,167115,DB00143,Glutathione
,30496738,Tmax,"All preparations showed slower APAP absorption than reported for humans: Peak time (Tmax) = 12 h for Intestine 2-OC and 6 h for Intestine/Liver 2-OC in both static and dynamic conditions, against reported Tmax of 0,33 to 1,4 h after oral administration to humans.",Acetaminophen absorption and metabolism in an intestine/liver microphysiological system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496738/),h,0,167116,DB00143,Glutathione
,30496738,Tmax,"All preparations showed slower APAP absorption than reported for humans: Peak time (Tmax) = 12 h for Intestine 2-OC and 6 h for Intestine/Liver 2-OC in both static and dynamic conditions, against reported Tmax of 0,33 to 1,4 h after oral administration to humans.",Acetaminophen absorption and metabolism in an intestine/liver microphysiological system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496738/),h,"1,4",167117,DB00143,Glutathione
,30496738,half-life (T1/2),"The APAP half-life (T1/2) was 12 h in the dynamic Liver 2-OC, against T1/2 = 2 ± 0,4 h reported for humans.",Acetaminophen absorption and metabolism in an intestine/liver microphysiological system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496738/),h,12,167118,DB00143,Glutathione
,30496738,T1/2,"The APAP half-life (T1/2) was 12 h in the dynamic Liver 2-OC, against T1/2 = 2 ± 0,4 h reported for humans.",Acetaminophen absorption and metabolism in an intestine/liver microphysiological system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496738/),h,2,167119,DB00143,Glutathione
,24061863,clearance,"For the validation dataset, calculated PK parameters were as follows: clearance 0.16 ± 0.03 L/h/kg and volume of distribution 0.65 ± 0.06 L/kg (mean ± standard deviation).",Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24061863/),[l] / [h·kg],0.16,167206,DB00143,Glutathione
,24061863,volume of distribution,"For the validation dataset, calculated PK parameters were as follows: clearance 0.16 ± 0.03 L/h/kg and volume of distribution 0.65 ± 0.06 L/kg (mean ± standard deviation).",Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24061863/),[l] / [kg],0.65,167207,DB00143,Glutathione
,9511077,blood elimination half-life,"The blood elimination half-life of quinupristin was approximately 0.6 h in rats and 0.5 h in monkeys, and that of dalfopristin was approximately 0.6 h and 0.2 h, respectively.",The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9511077/),h,0.6,169459,DB00143,Glutathione
,9511077,blood elimination half-life,"The blood elimination half-life of quinupristin was approximately 0.6 h in rats and 0.5 h in monkeys, and that of dalfopristin was approximately 0.6 h and 0.2 h, respectively.",The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9511077/),h,0.5,169460,DB00143,Glutathione
,9511077,blood elimination half-life,"The blood elimination half-life of quinupristin was approximately 0.6 h in rats and 0.5 h in monkeys, and that of dalfopristin was approximately 0.6 h and 0.2 h, respectively.",The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9511077/),h,0.2,169461,DB00143,Glutathione
,9511077,elimination half-lives,Following intravenous administration both compounds are rapidly cleared from the blood with elimination half-lives of approximately 1 h for quinupristin and 0.4-0.5 h for dalfopristin.,The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9511077/),h,1,169462,DB00143,Glutathione
,9511077,elimination half-lives,Following intravenous administration both compounds are rapidly cleared from the blood with elimination half-lives of approximately 1 h for quinupristin and 0.4-0.5 h for dalfopristin.,The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9511077/),h,0.4-0.5,169463,DB00143,Glutathione
,25110055,maximum plasma concentration,"After a single 50-mg/kg administration, the maximum plasma concentration of andrographolide was 1μM which peaked at 30min.",Bioavailability of andrographolide and protection against carbon tetrachloride-induced oxidative damage in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25110055/),μM,1,170036,DB00143,Glutathione
,25110055,bioavailability,The bioavailability of andrographolide was 1.19%.,Bioavailability of andrographolide and protection against carbon tetrachloride-induced oxidative damage in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25110055/),%,1.19,170037,DB00143,Glutathione
,25110055,bioavailability,These results suggest that andrographolide is quickly absorbed in the intestinal tract in rats with a bioavailability of 1.19%.,Bioavailability of andrographolide and protection against carbon tetrachloride-induced oxidative damage in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25110055/),%,1.19,170038,DB00143,Glutathione
,24654967,volume of distribution,"The estimated pharmacokinetic population parameters were volume of distribution 0.764 ± 0.225 L/kg, elimination rate constant (ke ) 0.117 ± 0.091/h and intercompartment rate constants k12 0.607 ± 0.734/h and k21 1.105 ± 0.762/h.",Multiple intravenous doses of paracetamol result in a predictable pharmacokinetic profile in very preterm infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24654967/),[l] / [kg],0.764,170734,DB00143,Glutathione
,24654967,elimination rate constant (ke ),"The estimated pharmacokinetic population parameters were volume of distribution 0.764 ± 0.225 L/kg, elimination rate constant (ke ) 0.117 ± 0.091/h and intercompartment rate constants k12 0.607 ± 0.734/h and k21 1.105 ± 0.762/h.",Multiple intravenous doses of paracetamol result in a predictable pharmacokinetic profile in very preterm infants. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24654967/),1/[h],0.117,170735,DB00143,Glutathione
,24654967,intercompartment rate constants k12,"The estimated pharmacokinetic population parameters were volume of distribution 0.764 ± 0.225 L/kg, elimination rate constant (ke ) 0.117 ± 0.091/h and intercompartment rate constants k12 0.607 ± 0.734/h and k21 1.105 ± 0.762/h.",Multiple intravenous doses of paracetamol result in a predictable pharmacokinetic profile in very preterm infants. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24654967/),1/[h],0.607,170736,DB00143,Glutathione
,24654967,k21,"The estimated pharmacokinetic population parameters were volume of distribution 0.764 ± 0.225 L/kg, elimination rate constant (ke ) 0.117 ± 0.091/h and intercompartment rate constants k12 0.607 ± 0.734/h and k21 1.105 ± 0.762/h.",Multiple intravenous doses of paracetamol result in a predictable pharmacokinetic profile in very preterm infants. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24654967/),1/[h],1.105,170737,DB00143,Glutathione
>,27620474,50% inhibitory concentrations [IC50s],In vitro studies suggest minimal interaction with recombinant cytochrome P450 enzymes (50% inhibitory concentrations [IC50s] of >10 μM).,"Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27620474/),μM,10,171003,DB00143,Glutathione
,29157071,half-life,Blood 14 C was maximal at 3-8 h and decreased with a half-life of 52-163 h.,"Metabolism of metofluthrin in rats: II. Excretion, distribution and amount of metabolites. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29157071/),h,52-163,171874,DB00143,Glutathione
,30442651,clearance,A human [14C] microtracer bioavailability study in healthy subjects revealed moderate intravenous clearance (39.4 l/h) and an absolute bioavailability of 25.3% ± 14.3% (n = 8).,"Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30442651/),[l] / [h],39.4,172069,DB00143,Glutathione
,30442651,absolute bioavailability,A human [14C] microtracer bioavailability study in healthy subjects revealed moderate intravenous clearance (39.4 l/h) and an absolute bioavailability of 25.3% ± 14.3% (n = 8).,"Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30442651/),%,25.3,172070,DB00143,Glutathione
<,30442651,elimination half-life,"Absorption and elimination of acalabrutinib after a 100 mg [14C] microtracer acalabrutinib oral dose was rapid, with the maximum concentration reached in <1 hour and elimination half-life values of <2 hours.","Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30442651/),h,2,172071,DB00143,Glutathione
,30442651,Total radioactivity recovery,"Total radioactivity recovery was 95.7% ± 4.6% (n = 6), with 12.0% of dose in urine and 83.5% in feces.","Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30442651/),%,95.7,172072,DB00143,Glutathione
,30442651,Total radioactivity recovery,"Total radioactivity recovery was 95.7% ± 4.6% (n = 6), with 12.0% of dose in urine and 83.5% in feces.","Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30442651/),%,12.0,172073,DB00143,Glutathione
,30442651,Total radioactivity recovery,"Total radioactivity recovery was 95.7% ± 4.6% (n = 6), with 12.0% of dose in urine and 83.5% in feces.","Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30442651/),%,83.5,172074,DB00143,Glutathione
,2732949,blood elimination half-lives,"The blood elimination half-lives of (R)- or (S)-BIU were 8 and 38 min, respectively.",Stereoselectivity of glutathione conjugation: blood elimination of alpha-bromoisovalerylurea enantiomers and biliary excretion of the conjugates in unanesthetized normal or congenitally jaundiced rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732949/),min,8,173144,DB00143,Glutathione
,2732949,blood elimination half-lives,"The blood elimination half-lives of (R)- or (S)-BIU were 8 and 38 min, respectively.",Stereoselectivity of glutathione conjugation: blood elimination of alpha-bromoisovalerylurea enantiomers and biliary excretion of the conjugates in unanesthetized normal or congenitally jaundiced rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732949/),min,38,173145,DB00143,Glutathione
,2732949,T1/2,"The excretion half-lives of the GSH conjugates in bile in normal rats showed a similar difference: (R)-BIU yielded exclusively (S)-IU-S-G with a T1/2 of 12 min, and (S)-BIU yielded only (R)-IU-S-G with a T1/2 of 36 min.",Stereoselectivity of glutathione conjugation: blood elimination of alpha-bromoisovalerylurea enantiomers and biliary excretion of the conjugates in unanesthetized normal or congenitally jaundiced rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732949/),min,12,173146,DB00143,Glutathione
,2732949,T1/2,"The excretion half-lives of the GSH conjugates in bile in normal rats showed a similar difference: (R)-BIU yielded exclusively (S)-IU-S-G with a T1/2 of 12 min, and (S)-BIU yielded only (R)-IU-S-G with a T1/2 of 36 min.",Stereoselectivity of glutathione conjugation: blood elimination of alpha-bromoisovalerylurea enantiomers and biliary excretion of the conjugates in unanesthetized normal or congenitally jaundiced rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732949/),min,36,173147,DB00143,Glutathione
<,30340896,IC50s,"Many potent inhibitors (30, 39, 41, 42, 44, 45 and 58) were identified with low nanomolar activity (IC50s: <15 nM) along with adequate metabolic stability.","Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340896/),nM,15,173996,DB00143,Glutathione
,3970952,plasma clearance,"However, plasma clearance of taurocholate was significantly larger in analbuminemic (68.3 ml/min per kg of body weight) than in normal rats (29.8 ml/min per kg of body weight) at a dose of 8 mumol/kg of body weight.",Transhepatic transport of taurocholic acid in normal and mutant analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3970952/),[ml] / [kg·min],68.3,174232,DB00143,Glutathione
,3970952,plasma clearance,"However, plasma clearance of taurocholate was significantly larger in analbuminemic (68.3 ml/min per kg of body weight) than in normal rats (29.8 ml/min per kg of body weight) at a dose of 8 mumol/kg of body weight.",Transhepatic transport of taurocholic acid in normal and mutant analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3970952/),[ml] / [kg·min],29.8,174233,DB00143,Glutathione
,2775620,t1/2,"2. A pronounced stereoselectivity was observed: the mercapturate formed from R-BIU was excreted with a t1/2 of 1.5 +/- 0.4 h, while that from S-BIU showed a t1/2 of 3.1 +/- 1.3 h.",Stereoselectivity in the urinary excretion of the mercapturates of (R-) and (S-) alpha-bromoisovalerylurea in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775620/),h,1.5,174575,DB00143,Glutathione
,2775620,t1/2,"2. A pronounced stereoselectivity was observed: the mercapturate formed from R-BIU was excreted with a t1/2 of 1.5 +/- 0.4 h, while that from S-BIU showed a t1/2 of 3.1 +/- 1.3 h.",Stereoselectivity in the urinary excretion of the mercapturates of (R-) and (S-) alpha-bromoisovalerylurea in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775620/),h,3.1,174576,DB00143,Glutathione
,23517808,MTD,The MTD of capecitabine was determined to be 825 mg/m(2) b.i.d.,Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23517808/),[mg] / [m],825,174735,DB00143,Glutathione
,6431641,Initial,Initial and terminal half-lives of unchanged TCP in the blood were 0.29 and 23 hr.,"Disposition of 1,2,3-trichloropropane in the Fischer 344 rat: conventional and physiological pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6431641/),h,0.29,176064,DB00143,Glutathione
,6431641,terminal half-lives,Initial and terminal half-lives of unchanged TCP in the blood were 0.29 and 23 hr.,"Disposition of 1,2,3-trichloropropane in the Fischer 344 rat: conventional and physiological pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6431641/),h,23,176065,DB00143,Glutathione
,29523601,distribution volume,"Senkyunolide I exhibited a large distribution volume (1.32 l/kg) and was moderately bound in plasma (54% unbound), whereas senkyunolide G exhibited a small distribution volume (0.10 l/kg) and was extensively bound in plasma (3% unbound).","Pharmacokinetics-Based Identification of Potential Therapeutic Phthalides from XueBiJing, a Chinese Herbal Injection Used in Sepsis Management. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29523601/),[l] / [kg],1.32,176257,DB00143,Glutathione
,29523601,distribution volume,"Senkyunolide I exhibited a large distribution volume (1.32 l/kg) and was moderately bound in plasma (54% unbound), whereas senkyunolide G exhibited a small distribution volume (0.10 l/kg) and was extensively bound in plasma (3% unbound).","Pharmacokinetics-Based Identification of Potential Therapeutic Phthalides from XueBiJing, a Chinese Herbal Injection Used in Sepsis Management. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29523601/),[l] / [kg],0.10,176258,DB00143,Glutathione
,20705133,area under concentration-time curve,The area under concentration-time curve in rat plasma from 0 to 24h with PCP-Cys/GSH/sodium decanoate gel was 135.3μgmin/ml and 1.3-fold improved with the tablets.,Development and in vivo bioavailability study of an oral fondaparinux delivery system. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20705133/),[μgmin] / [ml],135.3,176643,DB00143,Glutathione
,20705133,C(max),"C(max) value of mini-tablets was 0.23μg/ml and the absolute bioavailability of 4.4% was 6.2-fold improved, while the control solution was not absorbed orally.",Development and in vivo bioavailability study of an oral fondaparinux delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20705133/),[μg] / [ml],0.23,176644,DB00143,Glutathione
,20705133,absolute bioavailability,"C(max) value of mini-tablets was 0.23μg/ml and the absolute bioavailability of 4.4% was 6.2-fold improved, while the control solution was not absorbed orally.",Development and in vivo bioavailability study of an oral fondaparinux delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20705133/),%,4.4,176645,DB00143,Glutathione
,20601034,clearance,"Dose- and weight-corrected Bu PK parameters (clearance, 0.173 ± 0.051 L/hour · kg; volume of distribution, 0.71 ± 0.17 L/kg; half-life time, 3.0 ± 0.7 hours) did not differ among treatment protocols (all P >.14) and remained stable between the first and mid-cycle doses.",Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20601034/),[l] / [h·kg],0.173,177221,DB00143,Glutathione
,20601034,volume of distribution,"Dose- and weight-corrected Bu PK parameters (clearance, 0.173 ± 0.051 L/hour · kg; volume of distribution, 0.71 ± 0.17 L/kg; half-life time, 3.0 ± 0.7 hours) did not differ among treatment protocols (all P >.14) and remained stable between the first and mid-cycle doses.",Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20601034/),[l] / [kg],0.71,177222,DB00143,Glutathione
,20601034,half-life time,"Dose- and weight-corrected Bu PK parameters (clearance, 0.173 ± 0.051 L/hour · kg; volume of distribution, 0.71 ± 0.17 L/kg; half-life time, 3.0 ± 0.7 hours) did not differ among treatment protocols (all P >.14) and remained stable between the first and mid-cycle doses.",Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20601034/),h,3.0,177223,DB00143,Glutathione
,9193867,recoveries,"After intravenous dosing of 10 mg/kg [14C]toborinone, fecal and urinary recoveries of the 14C dose were approximately 70% and 26-30%, respectively, in both rats and dogs.",Biotransformation of the novel inotropic agent toborinone (OPC-18790) in rats and dogs. Evidence for the formation of novel glutathione and two cysteine conjugates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193867/),%,70,177387,DB00143,Glutathione
,9193867,recoveries,"After intravenous dosing of 10 mg/kg [14C]toborinone, fecal and urinary recoveries of the 14C dose were approximately 70% and 26-30%, respectively, in both rats and dogs.",Biotransformation of the novel inotropic agent toborinone (OPC-18790) in rats and dogs. Evidence for the formation of novel glutathione and two cysteine conjugates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193867/),%,26-30,177388,DB00143,Glutathione
,6705446,ClAP,"In contrast, sulfinpyrazone pretreatment increased ClAP by 23% (from 5.70 +/- 0.21 to 7.00 +/- 0.39 ml/min/kg) and ClAP was 46% greater in the epileptic subjects who received anticonvulsant drugs than in the control group (8.32 +/- 0.45 and 5.70 +/- 0.21 ml/ml/kg).",Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705446/),[ml] / [kg·min],5.70,180973,DB00143,Glutathione
,6705446,ClAP,"In contrast, sulfinpyrazone pretreatment increased ClAP by 23% (from 5.70 +/- 0.21 to 7.00 +/- 0.39 ml/min/kg) and ClAP was 46% greater in the epileptic subjects who received anticonvulsant drugs than in the control group (8.32 +/- 0.45 and 5.70 +/- 0.21 ml/ml/kg).",Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705446/),[ml] / [kg·min],7.00,180974,DB00143,Glutathione
,6705446,ClAP,"In contrast, sulfinpyrazone pretreatment increased ClAP by 23% (from 5.70 +/- 0.21 to 7.00 +/- 0.39 ml/min/kg) and ClAP was 46% greater in the epileptic subjects who received anticonvulsant drugs than in the control group (8.32 +/- 0.45 and 5.70 +/- 0.21 ml/ml/kg).",Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705446/),[ml] / [kg·ml],8.32,180975,DB00143,Glutathione
,6705446,ClAP,"In contrast, sulfinpyrazone pretreatment increased ClAP by 23% (from 5.70 +/- 0.21 to 7.00 +/- 0.39 ml/min/kg) and ClAP was 46% greater in the epileptic subjects who received anticonvulsant drugs than in the control group (8.32 +/- 0.45 and 5.70 +/- 0.21 ml/ml/kg).",Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705446/),[ml] / [kg·ml],5.70,180976,DB00143,Glutathione
,21950150,half-life,"After i.v. injection of [phenyl ring-U-14C]TAK-242 to rats and dogs, the 14C concentrations in dogs declined slowly with a half-life of about 1 week although that in rats was about 6 h.",Investigation of the unique metabolic fate of ethyl (6R)-6- [N- (2-chloro-4-fluorophenyl) sulfamoyl] cyclohex-1-ene-1-carboxylate (TAK-242) in rats and dogs using two types of 14C-labeled compounds having different labeled positions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950150/),week,1,180984,DB00143,Glutathione
,21950150,half-life,"After i.v. injection of [phenyl ring-U-14C]TAK-242 to rats and dogs, the 14C concentrations in dogs declined slowly with a half-life of about 1 week although that in rats was about 6 h.",Investigation of the unique metabolic fate of ethyl (6R)-6- [N- (2-chloro-4-fluorophenyl) sulfamoyl] cyclohex-1-ene-1-carboxylate (TAK-242) in rats and dogs using two types of 14C-labeled compounds having different labeled positions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950150/),h,6,180985,DB00143,Glutathione
,11174078,flow rate,"The livers were perfused in a single-pass way at a flow rate of 15 ml/min using a perfusate which consisted of Krebs-Henseleit buffer containing glucose, taurocholate, bovine albumin and erythrocytes.",No effect of phenobarbital pretreatment of rats on methotrexate pharmacokinetics in the isolated liver perfused in a single-pass way. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11174078/),[ml] / [min],15,181550,DB00143,Glutathione
,11174078,steady-state biliary clearance,"During the perfusion with 50 micromol/l MTX, the steady-state biliary clearance (1.26 +/- 0.24 ml/min) in 7 nonpretreated rats accounted for a major proportion of the hepatic clearance (1.30 +/- 0.33 ml/min), metabolism of MTX to 7- OHMTX was minor (partial metabolic clearance = 0.041 +/- 0.023 ml/min).",No effect of phenobarbital pretreatment of rats on methotrexate pharmacokinetics in the isolated liver perfused in a single-pass way. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11174078/),[ml] / [min],1.26,181551,DB00143,Glutathione
,11174078,hepatic clearance,"During the perfusion with 50 micromol/l MTX, the steady-state biliary clearance (1.26 +/- 0.24 ml/min) in 7 nonpretreated rats accounted for a major proportion of the hepatic clearance (1.30 +/- 0.33 ml/min), metabolism of MTX to 7- OHMTX was minor (partial metabolic clearance = 0.041 +/- 0.023 ml/min).",No effect of phenobarbital pretreatment of rats on methotrexate pharmacokinetics in the isolated liver perfused in a single-pass way. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11174078/),[ml] / [min],1.30,181552,DB00143,Glutathione
,11174078,partial metabolic clearance,"During the perfusion with 50 micromol/l MTX, the steady-state biliary clearance (1.26 +/- 0.24 ml/min) in 7 nonpretreated rats accounted for a major proportion of the hepatic clearance (1.30 +/- 0.33 ml/min), metabolism of MTX to 7- OHMTX was minor (partial metabolic clearance = 0.041 +/- 0.023 ml/min).",No effect of phenobarbital pretreatment of rats on methotrexate pharmacokinetics in the isolated liver perfused in a single-pass way. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11174078/),[ml] / [min],0.041,181553,DB00143,Glutathione
,17175039,absolute bioavailability,"The absolute bioavailability calculated as dose-normalized AUC(extravascular)/AUC(i.v.) was 98.0, 75.8, and 87.1% after nasal, s.c., and oral administration, respectively.","Pharmacokinetics of 125I-GST-TatdMt, a recombinant fusion protein possessing potent anti-obesity activity, after intravenous, nasal, oral, and subcutaneous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175039/),%,98.0,182386,DB00143,Glutathione
,17175039,absolute bioavailability,"The absolute bioavailability calculated as dose-normalized AUC(extravascular)/AUC(i.v.) was 98.0, 75.8, and 87.1% after nasal, s.c., and oral administration, respectively.","Pharmacokinetics of 125I-GST-TatdMt, a recombinant fusion protein possessing potent anti-obesity activity, after intravenous, nasal, oral, and subcutaneous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175039/),%,75.8,182387,DB00143,Glutathione
,17175039,absolute bioavailability,"The absolute bioavailability calculated as dose-normalized AUC(extravascular)/AUC(i.v.) was 98.0, 75.8, and 87.1% after nasal, s.c., and oral administration, respectively.","Pharmacokinetics of 125I-GST-TatdMt, a recombinant fusion protein possessing potent anti-obesity activity, after intravenous, nasal, oral, and subcutaneous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175039/),%,87.1,182388,DB00143,Glutathione
,21422190,plasma half-life,Odanacatib was characterized by low systemic clearance in all species and by a long plasma half-life in monkeys (18 h) and dogs (64 h).,"Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422190/),h,18,183182,DB00143,Glutathione
,21422190,plasma half-life,Odanacatib was characterized by low systemic clearance in all species and by a long plasma half-life in monkeys (18 h) and dogs (64 h).,"Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422190/),h,64,183183,DB00143,Glutathione
,21422190,oral bioavailability,"The oral bioavailability was dependent on the vehicle used and ranged from 18% (monkey) to ~100% (dog) at doses of 1 to 5 mg/kg, using nonaqueous vehicles.","Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422190/),%,18,183184,DB00143,Glutathione
,21422190,oral bioavailability,"The oral bioavailability was dependent on the vehicle used and ranged from 18% (monkey) to ~100% (dog) at doses of 1 to 5 mg/kg, using nonaqueous vehicles.","Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422190/),%,100,183185,DB00143,Glutathione
>,15100180,mean plasma concentrations,"Lumiracoxib was rapidly absorbed, achieving mean plasma concentrations >1 microg/ml within 1 h of dosing.",Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15100180/),[μg] / [ml],1,183734,DB00143,Glutathione
,15100180,terminal half-life,The terminal half-life of lumiracoxib in plasma was 6.5 h.,Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15100180/),h,6.5,183735,DB00143,Glutathione
,30274288,LOD (limit of detection),The LOD (limit of detection) was 1.5 ng/mL.,Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),[ng] / [ml],1.5,184012,DB00143,Glutathione
,30274288,recoveries,The recoveries were in the range 85.66~92.90%.,Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),%,85.66~92.90,184013,DB00143,Glutathione
,30274288,Tmax,"The results showed that RPDQ exhibited slow oral absorption (Tmax = 7.0 h, 7.5 h, and 7.0 h, respectively), low elimination (t1/2 = 12.59 h, 12.83 h, and 13.74 h, respectively) and poor absolute bioavailability (5.55, 5.15, and 6.08%, respectively).",Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),h,7.0,184014,DB00143,Glutathione
,30274288,Tmax,"The results showed that RPDQ exhibited slow oral absorption (Tmax = 7.0 h, 7.5 h, and 7.0 h, respectively), low elimination (t1/2 = 12.59 h, 12.83 h, and 13.74 h, respectively) and poor absolute bioavailability (5.55, 5.15, and 6.08%, respectively).",Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),h,7.5,184015,DB00143,Glutathione
,30274288,elimination (t1/2,"The results showed that RPDQ exhibited slow oral absorption (Tmax = 7.0 h, 7.5 h, and 7.0 h, respectively), low elimination (t1/2 = 12.59 h, 12.83 h, and 13.74 h, respectively) and poor absolute bioavailability (5.55, 5.15, and 6.08%, respectively).",Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),h,12.59,184016,DB00143,Glutathione
,30274288,elimination (t1/2,"The results showed that RPDQ exhibited slow oral absorption (Tmax = 7.0 h, 7.5 h, and 7.0 h, respectively), low elimination (t1/2 = 12.59 h, 12.83 h, and 13.74 h, respectively) and poor absolute bioavailability (5.55, 5.15, and 6.08%, respectively).",Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),h,12.83,184017,DB00143,Glutathione
,30274288,elimination (t1/2,"The results showed that RPDQ exhibited slow oral absorption (Tmax = 7.0 h, 7.5 h, and 7.0 h, respectively), low elimination (t1/2 = 12.59 h, 12.83 h, and 13.74 h, respectively) and poor absolute bioavailability (5.55, 5.15, and 6.08%, respectively).",Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),h,13.74,184018,DB00143,Glutathione
,30274288,absolute bioavailability,"The results showed that RPDQ exhibited slow oral absorption (Tmax = 7.0 h, 7.5 h, and 7.0 h, respectively), low elimination (t1/2 = 12.59 h, 12.83 h, and 13.74 h, respectively) and poor absolute bioavailability (5.55, 5.15, and 6.08%, respectively).",Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),%,5.55,184019,DB00143,Glutathione
,30274288,absolute bioavailability,"The results showed that RPDQ exhibited slow oral absorption (Tmax = 7.0 h, 7.5 h, and 7.0 h, respectively), low elimination (t1/2 = 12.59 h, 12.83 h, and 13.74 h, respectively) and poor absolute bioavailability (5.55, 5.15, and 6.08%, respectively).",Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),%,5.15,184020,DB00143,Glutathione
,30274288,absolute bioavailability,"The results showed that RPDQ exhibited slow oral absorption (Tmax = 7.0 h, 7.5 h, and 7.0 h, respectively), low elimination (t1/2 = 12.59 h, 12.83 h, and 13.74 h, respectively) and poor absolute bioavailability (5.55, 5.15, and 6.08%, respectively).",Pharmacokinetic and Metabolism Studies of 12-Riboside-Pseudoginsengenin DQ by UPLC-MS/MS and UPLC-QTOF-MSE. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30274288/),%,6.08,184021,DB00143,Glutathione
,2582712,Ki,"Studies in microsomes prepared from two human organ donors indicated that cimetidine inhibited acetaminophen reactive metabolite formation noncompetitively, with Ki values of 0.35 mmol/L and 0.32 mmol/L for the respective livers, which is 5 to 10 times the putative cimetidine concentration required for therapeutic effect.",Lack of effect of cimetidine on acetaminophen disposition in humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2582712/),[mM] / [l],0.35,184247,DB00143,Glutathione
,2582712,Ki,"Studies in microsomes prepared from two human organ donors indicated that cimetidine inhibited acetaminophen reactive metabolite formation noncompetitively, with Ki values of 0.35 mmol/L and 0.32 mmol/L for the respective livers, which is 5 to 10 times the putative cimetidine concentration required for therapeutic effect.",Lack of effect of cimetidine on acetaminophen disposition in humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2582712/),[mM] / [l],0.32,184248,DB00143,Glutathione
,24120542,IC50,"Early lead isoquinoline 1 suffered from modest cell potency (cellular IC50=0.71 μM measuring pMCM2), low selectivity against structurally related kinases, and high IV clearance in rats (CL=18 L/h/kg).",The optimization of aminooxadiazoles as orally active inhibitors of Cdc7. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120542/),μM,0.71,184289,DB00143,Glutathione
,24120542,CL,"Early lead isoquinoline 1 suffered from modest cell potency (cellular IC50=0.71 μM measuring pMCM2), low selectivity against structurally related kinases, and high IV clearance in rats (CL=18 L/h/kg).",The optimization of aminooxadiazoles as orally active inhibitors of Cdc7. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120542/),[l] / [h·kg],18,184290,DB00143,Glutathione
,24120542,IC50,"Extensive optimization resulted in azaindole 26 (Cdc7 IC50=1.1 nM, pMCM2 IC50=32 nM) that demonstrated robust lowering of pMCM2 in a mouse pharmacodynamic (PD) model when dosed orally.",The optimization of aminooxadiazoles as orally active inhibitors of Cdc7. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120542/),nM,1.1,184291,DB00143,Glutathione
,24120542,IC50,"Extensive optimization resulted in azaindole 26 (Cdc7 IC50=1.1 nM, pMCM2 IC50=32 nM) that demonstrated robust lowering of pMCM2 in a mouse pharmacodynamic (PD) model when dosed orally.",The optimization of aminooxadiazoles as orally active inhibitors of Cdc7. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120542/),nM,32,184292,DB00143,Glutathione
,22115772,IC(50),Indeed was found in an in vitro assay that DFO was an effective Cr(VI) chelator with an IC(50) of 800μg.,Deferoxamine pretreatment prevents Cr(VI)-induced nephrotoxicity and oxidant stress: role of Cr(VI) chelation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22115772/),μg,800,187804,DB00143,Glutathione
,23262165,absolute bioavailability,Thiolated formulations provided an absolute bioavailability of 0.89%.,Development and in vivo evaluation of an oral vitamin B12 delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23262165/),%,0.89,187920,DB00143,Glutathione
,11396777,apparent absorption,The apparent absorption of selenium from shrimps was 83 +/- 4%.,Absorption and retention of selenium from shrimps in man. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396777/),%,83,188317,DB00143,Glutathione
,11396777,excretion,"Faecal and urinary selenium excretion was 32.5 +/- 17.0 microg/d and 21.2 +/- 9.0 microg/d, respectively and the total retention of selenium was 3.1 +/- 1.1 mg.",Absorption and retention of selenium from shrimps in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396777/),[μg] / [d],32.5,188318,DB00143,Glutathione
,11396777,excretion,"Faecal and urinary selenium excretion was 32.5 +/- 17.0 microg/d and 21.2 +/- 9.0 microg/d, respectively and the total retention of selenium was 3.1 +/- 1.1 mg.",Absorption and retention of selenium from shrimps in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396777/),[μg] / [d],21.2,188319,DB00143,Glutathione
,11396777,total retention,"Faecal and urinary selenium excretion was 32.5 +/- 17.0 microg/d and 21.2 +/- 9.0 microg/d, respectively and the total retention of selenium was 3.1 +/- 1.1 mg.",Absorption and retention of selenium from shrimps in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396777/),mg,3.1,188320,DB00143,Glutathione
,939381,biliary transport maximum,"The biliary transport maximum for sulfobromophthalein, on the other hand, decreased by almost 70% from 153 to 52 nmoles per min per min per 100 g after portacaval anastomosis.","Hepatic functional deterioration after portacaval shunt in the rat. Effects on sulfobromophthalein transport-maximum, indocyanine green clearance and galactose elimination capacity. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/939381/),[nmoles] / [100·g·min·min],153,193149,DB00143,Glutathione
,939381,biliary transport maximum,"The biliary transport maximum for sulfobromophthalein, on the other hand, decreased by almost 70% from 153 to 52 nmoles per min per min per 100 g after portacaval anastomosis.","Hepatic functional deterioration after portacaval shunt in the rat. Effects on sulfobromophthalein transport-maximum, indocyanine green clearance and galactose elimination capacity. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/939381/),[nmoles] / [100·g·min·min],52,193150,DB00143,Glutathione
,10725314,maximum plasma concentrations,"After an i.v. or oral administration of 0.3 mg/kg of [(14)C]moxonidine, the maximum plasma concentrations of moxonidine were determined to be 146.0 and 4.0 ng/ml, respectively, and the elimination half-lives were 0.9 and 1.1 h, respectively.",Metabolism and disposition of moxonidine in Fischer 344 rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10725314/),[ng] / [ml],146.0,193625,DB00143,Glutathione
,10725314,maximum plasma concentrations,"After an i.v. or oral administration of 0.3 mg/kg of [(14)C]moxonidine, the maximum plasma concentrations of moxonidine were determined to be 146.0 and 4.0 ng/ml, respectively, and the elimination half-lives were 0.9 and 1.1 h, respectively.",Metabolism and disposition of moxonidine in Fischer 344 rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10725314/),[ng] / [ml],4.0,193626,DB00143,Glutathione
,10725314,elimination half-lives,"After an i.v. or oral administration of 0.3 mg/kg of [(14)C]moxonidine, the maximum plasma concentrations of moxonidine were determined to be 146.0 and 4.0 ng/ml, respectively, and the elimination half-lives were 0.9 and 1.1 h, respectively.",Metabolism and disposition of moxonidine in Fischer 344 rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10725314/),h,0.9,193627,DB00143,Glutathione
,10725314,elimination half-lives,"After an i.v. or oral administration of 0.3 mg/kg of [(14)C]moxonidine, the maximum plasma concentrations of moxonidine were determined to be 146.0 and 4.0 ng/ml, respectively, and the elimination half-lives were 0.9 and 1.1 h, respectively.",Metabolism and disposition of moxonidine in Fischer 344 rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10725314/),h,1.1,193628,DB00143,Glutathione
,10725314,oral bioavailability,The oral bioavailability of moxonidine was determined to be 5.1%.,Metabolism and disposition of moxonidine in Fischer 344 rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10725314/),%,5.1,193629,DB00143,Glutathione
,33691596,serum half-life,Albumin has a serum half-life of 3 weeks in humans.,Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33691596/),weeks,3,194083,DB00143,Glutathione
,12817900,absolute bioavailability,For tablets being based on the thiomer/GSH system an absolute bioavailability of 19.9 +/- 9.3% (means +/- SD; n = 5) vs. intravenous injection could be achieved.,Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12817900/),%,19.9,194455,DB00143,Glutathione
,30871097,bioavailability,"In this study, we first determined the content of the main polyphenols in a brown propolis extract obtained using a patented extraction method (Multi Dinamic Extraction-M.E.D.) by RP-HPLC-UV-PDA-MSn analysis, followed by the bioavailability of galangin and chrysin, the most abundant polyphenols in the mixture (7.8% and 7.5% respectively), following acute (single bolus of 500 mg/kg containing about 3.65 mg of the polyphenol mixture) and prolonged (100, 250 and 500 mg/kg body for 30 days) oral administration in 30 male 8 weeks old C57BL/6 wild-type mice.",Bioavailability and In Vivo Antioxidant Activity of a Standardized Polyphenol Mixture Extracted from Brown Propolis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30871097/),%,7.8,194852,DB00143,Glutathione
,30871097,bioavailability,"In this study, we first determined the content of the main polyphenols in a brown propolis extract obtained using a patented extraction method (Multi Dinamic Extraction-M.E.D.) by RP-HPLC-UV-PDA-MSn analysis, followed by the bioavailability of galangin and chrysin, the most abundant polyphenols in the mixture (7.8% and 7.5% respectively), following acute (single bolus of 500 mg/kg containing about 3.65 mg of the polyphenol mixture) and prolonged (100, 250 and 500 mg/kg body for 30 days) oral administration in 30 male 8 weeks old C57BL/6 wild-type mice.",Bioavailability and In Vivo Antioxidant Activity of a Standardized Polyphenol Mixture Extracted from Brown Propolis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30871097/),%,7.5,194853,DB00143,Glutathione
,8825192,peak concentrations in bile,"Analysis of radioactivity in bile, urine, and feces showed that U-91502-related radioactivity was rapidly excreted, predominantly in bile, achieving peak concentrations in bile of 1250 +/- 622 micrograms-eq/g during first 3 hr after a 10 mg/kg dose.",Metabolism of the bisphosphonate ester U-91502 in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8825192/),[μgrams-eq] / [g],1250,195044,DB00143,Glutathione
greater,32283195,plasma apparent half-life,"Also, a trend to a higher plasma apparent half-life (greater than24 h) was observed for the oleogel-loaded-CoQ10.",Bioavailability of coenzyme Q10 loaded in an oleogel formulation for oral therapy: Comparison with a commercial-grade solid formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32283195/),h,24,196764,DB00143,Glutathione
,1676649,half-life,"In vivo and in vitro values were close in adults and newborns for half-life (average 5.2 vs. 5.4 and 27 vs. 35 hr, respectively) and intrinsic clearance of TH (13 vs. 11 and 0.032 vs. 0.021 ml/min).",Pharmacokinetics of theophylline in the newborn and adult rabbit. In vivo and isolated perfused liver approaches. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676649/),h,5.2,199024,DB00143,Glutathione
,1676649,half-life,"In vivo and in vitro values were close in adults and newborns for half-life (average 5.2 vs. 5.4 and 27 vs. 35 hr, respectively) and intrinsic clearance of TH (13 vs. 11 and 0.032 vs. 0.021 ml/min).",Pharmacokinetics of theophylline in the newborn and adult rabbit. In vivo and isolated perfused liver approaches. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676649/),h,5.4,199025,DB00143,Glutathione
,1676649,half-life,"In vivo and in vitro values were close in adults and newborns for half-life (average 5.2 vs. 5.4 and 27 vs. 35 hr, respectively) and intrinsic clearance of TH (13 vs. 11 and 0.032 vs. 0.021 ml/min).",Pharmacokinetics of theophylline in the newborn and adult rabbit. In vivo and isolated perfused liver approaches. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676649/),h,27,199026,DB00143,Glutathione
,1676649,half-life,"In vivo and in vitro values were close in adults and newborns for half-life (average 5.2 vs. 5.4 and 27 vs. 35 hr, respectively) and intrinsic clearance of TH (13 vs. 11 and 0.032 vs. 0.021 ml/min).",Pharmacokinetics of theophylline in the newborn and adult rabbit. In vivo and isolated perfused liver approaches. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676649/),h,35,199027,DB00143,Glutathione
,1676649,intrinsic clearance,"In vivo and in vitro values were close in adults and newborns for half-life (average 5.2 vs. 5.4 and 27 vs. 35 hr, respectively) and intrinsic clearance of TH (13 vs. 11 and 0.032 vs. 0.021 ml/min).",Pharmacokinetics of theophylline in the newborn and adult rabbit. In vivo and isolated perfused liver approaches. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676649/),[ml] / [min],13,199028,DB00143,Glutathione
,1676649,intrinsic clearance,"In vivo and in vitro values were close in adults and newborns for half-life (average 5.2 vs. 5.4 and 27 vs. 35 hr, respectively) and intrinsic clearance of TH (13 vs. 11 and 0.032 vs. 0.021 ml/min).",Pharmacokinetics of theophylline in the newborn and adult rabbit. In vivo and isolated perfused liver approaches. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676649/),[ml] / [min],11,199029,DB00143,Glutathione
,1676649,intrinsic clearance,"In vivo and in vitro values were close in adults and newborns for half-life (average 5.2 vs. 5.4 and 27 vs. 35 hr, respectively) and intrinsic clearance of TH (13 vs. 11 and 0.032 vs. 0.021 ml/min).",Pharmacokinetics of theophylline in the newborn and adult rabbit. In vivo and isolated perfused liver approaches. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676649/),[ml] / [min],0.032,199030,DB00143,Glutathione
,1676649,intrinsic clearance,"In vivo and in vitro values were close in adults and newborns for half-life (average 5.2 vs. 5.4 and 27 vs. 35 hr, respectively) and intrinsic clearance of TH (13 vs. 11 and 0.032 vs. 0.021 ml/min).",Pharmacokinetics of theophylline in the newborn and adult rabbit. In vivo and isolated perfused liver approaches. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676649/),[ml] / [min],0.021,199031,DB00143,Glutathione
less,33938357,Tmax,Pictilisib was rapidly absorbed with Tmax less than 2 h across species.,"Absorption, metabolism and excretion of pictilisib, a potent pan-class I phosphatidylinositol-3-Kinase (PI3K) inhibitor, in rats, dogs, and humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33938357/),h,2,202873,DB00143,Glutathione
,2878990,plasma clearance,"With increasing dose, the rate constant for drug elimination and plasma clearance increased from 0.84 to 2.44 ml min-1 and the half-life of the elimination phase decreased from 52.4 to 11.4 min.",Pharmacokinetics of intravenously administered glutathione in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878990/),[ml] / [min],0.84 to 2.44,205313,DB00143,Glutathione
,2878990,half-life of the elimination phase,"With increasing dose, the rate constant for drug elimination and plasma clearance increased from 0.84 to 2.44 ml min-1 and the half-life of the elimination phase decreased from 52.4 to 11.4 min.",Pharmacokinetics of intravenously administered glutathione in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878990/),min,52.4 to 11.4,205314,DB00143,Glutathione
,2878990,apparent volume of distribution,"Both the apparent volume of distribution and the degree of penetration of GSH into the tissues were diminished with increasing dose (from 3.78 to 1.33 litres kg-1 and from 6.00 to 0.51 as k12/k21, respectively).",Pharmacokinetics of intravenously administered glutathione in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878990/),[l] / [kg],3.78 to 1.33,205315,DB00143,Glutathione
,2878990,penetration,"Both the apparent volume of distribution and the degree of penetration of GSH into the tissues were diminished with increasing dose (from 3.78 to 1.33 litres kg-1 and from 6.00 to 0.51 as k12/k21, respectively).",Pharmacokinetics of intravenously administered glutathione in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878990/),,6.00 to 0.51,205316,DB00143,Glutathione
,2878990,k12/k21,"Both the apparent volume of distribution and the degree of penetration of GSH into the tissues were diminished with increasing dose (from 3.78 to 1.33 litres kg-1 and from 6.00 to 0.51 as k12/k21, respectively).",Pharmacokinetics of intravenously administered glutathione in the rat. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878990/),,6.00 to 0.51,205317,DB00143,Glutathione
,30843439,Particle size,"Particle size of F1 and F5 was 167.8 ± 0.9 and 175.9 ± 2.0 nm, and zeta potential of F1 and F5 was -8.1 ± 0.7 and 21.1 ± 2.0 mV, respectively.","Design of novel proliposome formulation for antioxidant peptide, glutathione with enhanced oral bioavailability and stability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30843439/),nm,167.8,205718,DB00143,Glutathione
,30843439,Particle size,"Particle size of F1 and F5 was 167.8 ± 0.9 and 175.9 ± 2.0 nm, and zeta potential of F1 and F5 was -8.1 ± 0.7 and 21.1 ± 2.0 mV, respectively.","Design of novel proliposome formulation for antioxidant peptide, glutathione with enhanced oral bioavailability and stability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30843439/),nm,175.9,205719,DB00143,Glutathione
,30843439,zeta potential,"Particle size of F1 and F5 was 167.8 ± 0.9 and 175.9 ± 2.0 nm, and zeta potential of F1 and F5 was -8.1 ± 0.7 and 21.1 ± 2.0 mV, respectively.","Design of novel proliposome formulation for antioxidant peptide, glutathione with enhanced oral bioavailability and stability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30843439/),mv,-8.1,205720,DB00143,Glutathione
,30843439,zeta potential,"Particle size of F1 and F5 was 167.8 ± 0.9 and 175.9 ± 2.0 nm, and zeta potential of F1 and F5 was -8.1 ± 0.7 and 21.1 ± 2.0 mV, respectively.","Design of novel proliposome formulation for antioxidant peptide, glutathione with enhanced oral bioavailability and stability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30843439/),mv,21.1,205721,DB00143,Glutathione
,30843439,Encapsulation efficiency,"Encapsulation efficiency of F1 and F5 was 58.6% and 54.7%, respectively.","Design of novel proliposome formulation for antioxidant peptide, glutathione with enhanced oral bioavailability and stability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30843439/),%,58.6,205722,DB00143,Glutathione
,30843439,Encapsulation efficiency,"Encapsulation efficiency of F1 and F5 was 58.6% and 54.7%, respectively.","Design of novel proliposome formulation for antioxidant peptide, glutathione with enhanced oral bioavailability and stability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30843439/),%,54.7,205723,DB00143,Glutathione
,25697421,MAC,"The mean MAC was similar for generic and original sevoflurane (median [range], 0.93 [0.67-1.29] vs 0.94 [0.63-1.5] vol%).",An Open-label Comparison of a New Generic Sevoflurane Formulation With Original Sevoflurane in Patients Scheduled for Elective Surgery Under General Anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697421/),vol%,0.93,206295,DB00143,Glutathione
,25697421,MAC,"The mean MAC was similar for generic and original sevoflurane (median [range], 0.93 [0.67-1.29] vs 0.94 [0.63-1.5] vol%).",An Open-label Comparison of a New Generic Sevoflurane Formulation With Original Sevoflurane in Patients Scheduled for Elective Surgery Under General Anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697421/),vol%,0.94,206296,DB00143,Glutathione
,25697421,AUClast,"Adverse event rates were similar (90.3% vs 84.3%), as were the AUClast of inorganic fluoride (333.7 [112.7-1264.7] vs 311.9 [81.5-1266.5] hours·μmol/L) and compound A (51.8 [6.3-204.5] vs 55.3 [10.8-270.6] hours·ppm).",An Open-label Comparison of a New Generic Sevoflurane Formulation With Original Sevoflurane in Patients Scheduled for Elective Surgery Under General Anesthesia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697421/),[h·μM] / [l],333.7,206297,DB00143,Glutathione
,25697421,AUClast,"Adverse event rates were similar (90.3% vs 84.3%), as were the AUClast of inorganic fluoride (333.7 [112.7-1264.7] vs 311.9 [81.5-1266.5] hours·μmol/L) and compound A (51.8 [6.3-204.5] vs 55.3 [10.8-270.6] hours·ppm).",An Open-label Comparison of a New Generic Sevoflurane Formulation With Original Sevoflurane in Patients Scheduled for Elective Surgery Under General Anesthesia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697421/),[h·μM] / [l],311.9,206298,DB00143,Glutathione
,25697421,AUClast,"Adverse event rates were similar (90.3% vs 84.3%), as were the AUClast of inorganic fluoride (333.7 [112.7-1264.7] vs 311.9 [81.5-1266.5] hours·μmol/L) and compound A (51.8 [6.3-204.5] vs 55.3 [10.8-270.6] hours·ppm).",An Open-label Comparison of a New Generic Sevoflurane Formulation With Original Sevoflurane in Patients Scheduled for Elective Surgery Under General Anesthesia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697421/),h·ppm,51.8,206299,DB00143,Glutathione
,25697421,AUClast,"Adverse event rates were similar (90.3% vs 84.3%), as were the AUClast of inorganic fluoride (333.7 [112.7-1264.7] vs 311.9 [81.5-1266.5] hours·μmol/L) and compound A (51.8 [6.3-204.5] vs 55.3 [10.8-270.6] hours·ppm).",An Open-label Comparison of a New Generic Sevoflurane Formulation With Original Sevoflurane in Patients Scheduled for Elective Surgery Under General Anesthesia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697421/),h·ppm,55.3,206300,DB00143,Glutathione
,6820913,t 1/2 beta,"The blood level of MMC decreased relative by rapidly, t 1/2 beta in iv dose of 30, 20 and 10 mg/body to man was 50, 41 and 33 minutes, respectively.",[Pharmacokinetics of mitomycin C and its derivative (KW-2083)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6820913/),min,50,206390,DB00143,Glutathione
,6820913,t 1/2 beta,"The blood level of MMC decreased relative by rapidly, t 1/2 beta in iv dose of 30, 20 and 10 mg/body to man was 50, 41 and 33 minutes, respectively.",[Pharmacokinetics of mitomycin C and its derivative (KW-2083)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6820913/),min,41,206391,DB00143,Glutathione
,6820913,t 1/2 beta,"The blood level of MMC decreased relative by rapidly, t 1/2 beta in iv dose of 30, 20 and 10 mg/body to man was 50, 41 and 33 minutes, respectively.",[Pharmacokinetics of mitomycin C and its derivative (KW-2083)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6820913/),min,33,206392,DB00143,Glutathione
,6820913,T 1/2 beta,"T 1/2 beta of KW-2083 in patients after iv injection at 70, 40 and 20 mg/body was about 18 minutes.",[Pharmacokinetics of mitomycin C and its derivative (KW-2083)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6820913/),min,18,206393,DB00143,Glutathione
,12682786,time lag,"A significant depletion of cysteine occurred with a time lag of about 2 h after the end of BNP7787 infusion, while a reversible depletion of GSH and homocysteine occurred immediately following the start of BNP7787 infusion, with the plasma thiol/disulfide nadir corresponding to the end of infusion.",Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682786/),h,2,206523,DB00143,Glutathione
,12682786,half-life,"The mean half-life of cysteine depletion following BNP7787 administration was 2.2 h, significantly longer than for homocysteine (0.23 h), or GSH (0.18 h; P<0.05 for both).",Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682786/),h,2.2,206524,DB00143,Glutathione
,12682786,half-life,"The mean half-life of cysteine depletion following BNP7787 administration was 2.2 h, significantly longer than for homocysteine (0.23 h), or GSH (0.18 h; P<0.05 for both).",Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682786/),h,0.23,206525,DB00143,Glutathione
,12682786,half-life,"The mean half-life of cysteine depletion following BNP7787 administration was 2.2 h, significantly longer than for homocysteine (0.23 h), or GSH (0.18 h; P<0.05 for both).",Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682786/),h,0.18,206526,DB00143,Glutathione
,29978489,flow rate,"Analytes were eluted by a binary gradient mobile phase composed of water (phase A) and methanol containing 0.1% formic acid (phase B) at a flow rate of 0.3 mL/min, which was performed on a CAPCELL PAK C18 MG II column.","A reliable LC-MS/MS method for the quantification of N-acetyl-p-benzoquinoneimine, acetaminophen glutathione and acetaminophen glucuronide in mouse plasma, liver and kidney: Method validation and application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29978489/),[ml] / [min],0.3,206836,DB00143,Glutathione
,22883407,inhibitory concentration 50%,The inhibitory concentration 50% values of different pairs of L-OHP-sensitive and -resistant cells were 7.2 and 89.00.,[Effects of medicated serum prepared with Chinese herbal medicine Changweiqing on pharmacokinetics of oxaliplatin in colon cancer cells]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22883407/),,7.2,207520,DB00143,Glutathione
,22883407,inhibitory concentration 50%,The inhibitory concentration 50% values of different pairs of L-OHP-sensitive and -resistant cells were 7.2 and 89.00.,[Effects of medicated serum prepared with Chinese herbal medicine Changweiqing on pharmacokinetics of oxaliplatin in colon cancer cells]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22883407/),,89.00,207521,DB00143,Glutathione
,22883407,resistance index,The resistance index of HCT116/L-OHP cells was 12.36.,[Effects of medicated serum prepared with Chinese herbal medicine Changweiqing on pharmacokinetics of oxaliplatin in colon cancer cells]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22883407/),,12.36,207522,DB00143,Glutathione
,11543642,elimination half-life,Results indicated that the elimination half-life of (-)-BCA was 0.07 compared to 0.40 h for (+)-BCA in naive rats.,Stereospecific toxicokinetics of bromochloro- and chlorofluoroacetate: effect of GST-zeta depletion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11543642/),h,0.07,207616,DB00143,Glutathione
,11543642,elimination half-life,Results indicated that the elimination half-life of (-)-BCA was 0.07 compared to 0.40 h for (+)-BCA in naive rats.,Stereospecific toxicokinetics of bromochloro- and chlorofluoroacetate: effect of GST-zeta depletion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11543642/),h,0.40,207617,DB00143,Glutathione
,11543642,elimination half-life,A comparable difference in elimination half-life was also observed for the CFA stereoisomers (0.79 vs 0.11 h).,Stereospecific toxicokinetics of bromochloro- and chlorofluoroacetate: effect of GST-zeta depletion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11543642/),h,0.79,207618,DB00143,Glutathione
,11543642,elimination half-life,A comparable difference in elimination half-life was also observed for the CFA stereoisomers (0.79 vs 0.11 h).,Stereospecific toxicokinetics of bromochloro- and chlorofluoroacetate: effect of GST-zeta depletion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11543642/),h,0.11,207619,DB00143,Glutathione
,11543642,elimination half-life,"In GST-zeta-depleted rats, stereospecific elimination of (-),(+)-BCA was absent, with both stereoisomers having an elimination half-life of approximately 0.4 h.",Stereospecific toxicokinetics of bromochloro- and chlorofluoroacetate: effect of GST-zeta depletion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11543642/),h,0.4,207620,DB00143,Glutathione
,11543642,intrinsic metabolic clearance,"Results of in vitro metabolism experiments indicated (-)-BCA was affected by modulating GST-zeta activity, with the intrinsic metabolic clearance decreasing from 2.81 to 0.15 ml h(-1) mg.protein(-1) (naive, GST-zeta depleted) compared with values for (+)-BCA (0.30 and 0.31 ml h(-1) mg.protein(-1)).",Stereospecific toxicokinetics of bromochloro- and chlorofluoroacetate: effect of GST-zeta depletion. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11543642/),[-1·mg·ml] / [h],2.81,207621,DB00143,Glutathione
,11543642,intrinsic metabolic clearance,"Results of in vitro metabolism experiments indicated (-)-BCA was affected by modulating GST-zeta activity, with the intrinsic metabolic clearance decreasing from 2.81 to 0.15 ml h(-1) mg.protein(-1) (naive, GST-zeta depleted) compared with values for (+)-BCA (0.30 and 0.31 ml h(-1) mg.protein(-1)).",Stereospecific toxicokinetics of bromochloro- and chlorofluoroacetate: effect of GST-zeta depletion. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11543642/),[-1·mg·ml] / [h],0.15,207622,DB00143,Glutathione
,11543642,intrinsic metabolic clearance,"Results of in vitro metabolism experiments indicated (-)-BCA was affected by modulating GST-zeta activity, with the intrinsic metabolic clearance decreasing from 2.81 to 0.15 ml h(-1) mg.protein(-1) (naive, GST-zeta depleted) compared with values for (+)-BCA (0.30 and 0.31 ml h(-1) mg.protein(-1)).",Stereospecific toxicokinetics of bromochloro- and chlorofluoroacetate: effect of GST-zeta depletion. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11543642/),[-1·mg·ml] / [h],0.30,207623,DB00143,Glutathione
,11543642,intrinsic metabolic clearance,"Results of in vitro metabolism experiments indicated (-)-BCA was affected by modulating GST-zeta activity, with the intrinsic metabolic clearance decreasing from 2.81 to 0.15 ml h(-1) mg.protein(-1) (naive, GST-zeta depleted) compared with values for (+)-BCA (0.30 and 0.31 ml h(-1) mg.protein(-1)).",Stereospecific toxicokinetics of bromochloro- and chlorofluoroacetate: effect of GST-zeta depletion. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11543642/),[-1·mg·ml] / [h],0.31,207624,DB00143,Glutathione
,17075317,half-life,"By investigating the pharmacokinetics of imexon, we also found that imexon undergoes rapid clearance from plasma in a dose-independent fashion with a half-life of 12-15 min.","Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17075317/),min,12-15,207773,DB00143,Glutathione
,8558205,half-lives,"Harmonic mean half-lives were 1.39 hours and 1.89 hours for R-BSO and S-BSO, respectively.",Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558205/),h,1.39,208766,DB00143,Glutathione
,8558205,half-lives,"Harmonic mean half-lives were 1.39 hours and 1.89 hours for R-BSO and S-BSO, respectively.",Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558205/),h,1.89,208767,DB00143,Glutathione
,11401302,recovery,The recovery of PEITC assessed on multiple days was 96.6 +/- 1.5% and was 100% for PEITC--GSH and PEITC--NAC.,High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401302/),%,96.6,211431,DB00143,Glutathione
,11401302,recovery,The recovery of PEITC assessed on multiple days was 96.6 +/- 1.5% and was 100% for PEITC--GSH and PEITC--NAC.,High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401302/),%,100,211432,DB00143,Glutathione
,11401302,plasma ITC,"In clinical studies, mean plasma ITC level of 413 +/- 193 nM PEITC equivalents was determined for a non-dietary-controlled group of 23 subjects.",High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401302/),nM,413,211433,DB00143,Glutathione
,8545826,rapid-phase half-life,"The respiratory epithelium had an apparent biphasic rate of GSH turnover, with a rapid-phase half-life of 4.4 hr and a slow-phase half-life of 34 hr.",Glutathione content and turnover in rat nasal epithelia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8545826/),h,4.4,213066,DB00143,Glutathione
,8545826,slow-phase half-life,"The respiratory epithelium had an apparent biphasic rate of GSH turnover, with a rapid-phase half-life of 4.4 hr and a slow-phase half-life of 34 hr.",Glutathione content and turnover in rat nasal epithelia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8545826/),h,34,213067,DB00143,Glutathione
greater,8545826,half-lives,"The other epithelia had slower rates of GSH turnover, with half-lives greater than 30 hr.",Glutathione content and turnover in rat nasal epithelia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8545826/),h,30,213068,DB00143,Glutathione
,8511787,half-lives,"For example, both the liver and the kidney had rapid turnover rates with half-lives of 1-5 hr, while those for heart, skeletal muscle, and blood were much slower with half-lives of 68-118 hr.",Apparent rates of glutathione turnover in rat tissues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8511787/),h,1-5,213284,DB00143,Glutathione
,8511787,half-lives,"For example, both the liver and the kidney had rapid turnover rates with half-lives of 1-5 hr, while those for heart, skeletal muscle, and blood were much slower with half-lives of 68-118 hr.",Apparent rates of glutathione turnover in rat tissues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8511787/),h,68-118,213285,DB00143,Glutathione
,8511787,half-life,"[35S]GSH had a half-life in lung and skin of approximately 63 and 50 hr, respectively.",Apparent rates of glutathione turnover in rat tissues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8511787/),h,63,213286,DB00143,Glutathione
,8511787,half-life,"[35S]GSH had a half-life in lung and skin of approximately 63 and 50 hr, respectively.",Apparent rates of glutathione turnover in rat tissues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8511787/),h,50,213287,DB00143,Glutathione
a,19005591,half-life,"Here we report the design, synthesis, and characterization of an azobenzene derivative that absorbs between 400-450 nm in aqueous solution to produce the cis isomer, and relaxes back to the trans isomer with a half-life of a few seconds at room temperature.","Photo-control of peptide conformation on a timescale of seconds with a conformationally constrained, blue-absorbing, photo-switchable linker. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19005591/),seconds,few,213364,DB00143,Glutathione
,1440617,peak plasma concentrations,RHA/jj rats demonstrated respective 230- and 7-fold increases in the peak plasma concentrations of ALT (17144 +/- 1014 vs 75 +/- 10) and BUN (128 +/- 23 vs 18.4 +/- 0.2) compared to congenic normal controls (RHA/++) (p < 0.05).,Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1440617/),,17144,214135,DB00143,Glutathione
,1440617,peak plasma concentrations,RHA/jj rats demonstrated respective 230- and 7-fold increases in the peak plasma concentrations of ALT (17144 +/- 1014 vs 75 +/- 10) and BUN (128 +/- 23 vs 18.4 +/- 0.2) compared to congenic normal controls (RHA/++) (p < 0.05).,Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1440617/),,75,214136,DB00143,Glutathione
,1440617,peak plasma concentrations,RHA/jj rats demonstrated respective 230- and 7-fold increases in the peak plasma concentrations of ALT (17144 +/- 1014 vs 75 +/- 10) and BUN (128 +/- 23 vs 18.4 +/- 0.2) compared to congenic normal controls (RHA/++) (p < 0.05).,Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1440617/),,128,214137,DB00143,Glutathione
,1440617,peak plasma concentrations,RHA/jj rats demonstrated respective 230- and 7-fold increases in the peak plasma concentrations of ALT (17144 +/- 1014 vs 75 +/- 10) and BUN (128 +/- 23 vs 18.4 +/- 0.2) compared to congenic normal controls (RHA/++) (p < 0.05).,Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1440617/),,18.4,214138,DB00143,Glutathione
,3416297,g,In vitro mean glutathione-S-transferase values were 91.52 nmol/min/mg protein in TE-671 and 50.31 nmol/min/mg protein in Daoy.,"Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416297/),[nM] / [mg·min],91.52,214176,DB00143,Glutathione
,3416297,g,In vitro mean glutathione-S-transferase values were 91.52 nmol/min/mg protein in TE-671 and 50.31 nmol/min/mg protein in Daoy.,"Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416297/),[nM] / [mg·min],50.31,214177,DB00143,Glutathione
,3416297,Km,"Transport studies revealed kinetic parameters of Km = 108.3 microM, Vmax = 363.1 pmol/10(6) cells/min in TE-671 and Km = 111.7 microM, Vmax = 180.6 pmol/10(6) cells/min in Daoy.","Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416297/),μM,108.3,214178,DB00143,Glutathione
,3416297,Vmax,"Transport studies revealed kinetic parameters of Km = 108.3 microM, Vmax = 363.1 pmol/10(6) cells/min in TE-671 and Km = 111.7 microM, Vmax = 180.6 pmol/10(6) cells/min in Daoy.","Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416297/),[pM] / [10(6)·cells·min],363.1,214179,DB00143,Glutathione
,3416297,Km,"Transport studies revealed kinetic parameters of Km = 108.3 microM, Vmax = 363.1 pmol/10(6) cells/min in TE-671 and Km = 111.7 microM, Vmax = 180.6 pmol/10(6) cells/min in Daoy.","Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416297/),μM,111.7,214180,DB00143,Glutathione
,3416297,Vmax,"Transport studies revealed kinetic parameters of Km = 108.3 microM, Vmax = 363.1 pmol/10(6) cells/min in TE-671 and Km = 111.7 microM, Vmax = 180.6 pmol/10(6) cells/min in Daoy.","Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416297/),[pM] / [10(6)·cells·min],180.6,214181,DB00143,Glutathione
,3416297,half-life,"The mean plasma concentration in mice given a 10% lethal dose (71.3 mg/m2) of melphalan i.p. was 50.3 microM at 10 min, with the half-life of 29.9 min.","Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416297/),min,29.9,214182,DB00143,Glutathione
>,29717617,Brain:blood ratio,"Brain:blood ratio of 2.207 > 0.093 of selegiline-loaded nanoemulsion (intranasally administered) > selegiline solution (administered intravenously), respectively, at 0.5 hours showed direct nose-to-brain delivery of drug bypassing blood-brain barrier.",Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29717617/),,2.207,214678,DB00143,Glutathione
>,29717617,Brain:blood ratio,"Brain:blood ratio of 2.207 > 0.093 of selegiline-loaded nanoemulsion (intranasally administered) > selegiline solution (administered intravenously), respectively, at 0.5 hours showed direct nose-to-brain delivery of drug bypassing blood-brain barrier.",Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29717617/),,0.093,214679,DB00143,Glutathione
,28552692,polydispersity index,"Formulations optimized using statistical hybrid-design approach exhibited particle size of 152.0 ± 1.78 and 248.8 ± 1.83 nm, polydispersity index of 0.183 ± 0.021 and 0.225 ± 0.018 with zeta potential of -26.8 ± 0.76 and -23.3 ± 0.22 mV and percentage entrapment efficiency (% EE) of 92.3 ± 4.99% and 94.7 ± 5.67%, for GCBMs and PCBMs, respectively.",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),,0.183,216930,DB00143,Glutathione
,28552692,polydispersity index,"Formulations optimized using statistical hybrid-design approach exhibited particle size of 152.0 ± 1.78 and 248.8 ± 1.83 nm, polydispersity index of 0.183 ± 0.021 and 0.225 ± 0.018 with zeta potential of -26.8 ± 0.76 and -23.3 ± 0.22 mV and percentage entrapment efficiency (% EE) of 92.3 ± 4.99% and 94.7 ± 5.67%, for GCBMs and PCBMs, respectively.",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),,0.225,216931,DB00143,Glutathione
,28552692,zeta potential,"Formulations optimized using statistical hybrid-design approach exhibited particle size of 152.0 ± 1.78 and 248.8 ± 1.83 nm, polydispersity index of 0.183 ± 0.021 and 0.225 ± 0.018 with zeta potential of -26.8 ± 0.76 and -23.3 ± 0.22 mV and percentage entrapment efficiency (% EE) of 92.3 ± 4.99% and 94.7 ± 5.67%, for GCBMs and PCBMs, respectively.",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),mv,-,216932,DB00143,Glutathione
,28552692,zeta potential,"Formulations optimized using statistical hybrid-design approach exhibited particle size of 152.0 ± 1.78 and 248.8 ± 1.83 nm, polydispersity index of 0.183 ± 0.021 and 0.225 ± 0.018 with zeta potential of -26.8 ± 0.76 and -23.3 ± 0.22 mV and percentage entrapment efficiency (% EE) of 92.3 ± 4.99% and 94.7 ± 5.67%, for GCBMs and PCBMs, respectively.",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),mv,26.8,216933,DB00143,Glutathione
,28552692,zeta potential,"Formulations optimized using statistical hybrid-design approach exhibited particle size of 152.0 ± 1.78 and 248.8 ± 1.83 nm, polydispersity index of 0.183 ± 0.021 and 0.225 ± 0.018 with zeta potential of -26.8 ± 0.76 and -23.3 ± 0.22 mV and percentage entrapment efficiency (% EE) of 92.3 ± 4.99% and 94.7 ± 5.67%, for GCBMs and PCBMs, respectively.",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),mv,23.3,216934,DB00143,Glutathione
,28552692,percentage entrapment efficiency (% EE),"Formulations optimized using statistical hybrid-design approach exhibited particle size of 152.0 ± 1.78 and 248.8 ± 1.83 nm, polydispersity index of 0.183 ± 0.021 and 0.225 ± 0.018 with zeta potential of -26.8 ± 0.76 and -23.3 ± 0.22 mV and percentage entrapment efficiency (% EE) of 92.3 ± 4.99% and 94.7 ± 5.67%, for GCBMs and PCBMs, respectively.",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),%,92.3,216935,DB00143,Glutathione
,28552692,percentage entrapment efficiency (% EE),"Formulations optimized using statistical hybrid-design approach exhibited particle size of 152.0 ± 1.78 and 248.8 ± 1.83 nm, polydispersity index of 0.183 ± 0.021 and 0.225 ± 0.018 with zeta potential of -26.8 ± 0.76 and -23.3 ± 0.22 mV and percentage entrapment efficiency (% EE) of 92.3 ± 4.99% and 94.7 ± 5.67%, for GCBMs and PCBMs, respectively.",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),%,94.7,216936,DB00143,Glutathione
,28552692,AUC0→∞,"The comparative bioavailability profiles of UDC from GCBMs and PCBMs (AUC0→∞ = 19,546.8 ± 512.88 ng·h/L for GCBMs and 27,961.99 ± 602.46 ng·h/L for PCBMs) were approximately 6.5- and 7.0-fold higher than that of UDC suspension (AUC0→∞ = 3132.806 ± 405.44 ng·h/L).",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),[h·ng] / [l],"19,546.8",216937,DB00143,Glutathione
,28552692,AUC0→∞,"The comparative bioavailability profiles of UDC from GCBMs and PCBMs (AUC0→∞ = 19,546.8 ± 512.88 ng·h/L for GCBMs and 27,961.99 ± 602.46 ng·h/L for PCBMs) were approximately 6.5- and 7.0-fold higher than that of UDC suspension (AUC0→∞ = 3132.806 ± 405.44 ng·h/L).",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),[h·ng] / [l],"27,961.99",216938,DB00143,Glutathione
,28552692,AUC0→∞,"The comparative bioavailability profiles of UDC from GCBMs and PCBMs (AUC0→∞ = 19,546.8 ± 512.88 ng·h/L for GCBMs and 27,961.99 ± 602.46 ng·h/L for PCBMs) were approximately 6.5- and 7.0-fold higher than that of UDC suspension (AUC0→∞ = 3132.806 ± 405.44 ng·h/L).",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),[h·ng] / [l],3132.806,216939,DB00143,Glutathione
,16411147,absolute bioavailability,"Formulations A and B led to an absolute bioavailability of 1%, whereas PACAP did not reach the systemic circulation when administered via formulations C and D.",Thiolated chitosans: design and in vivo evaluation of a mucoadhesive buccal peptide drug delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411147/),%,1,224196,DB00143,Glutathione
,21135089,clearance,The average (± standard deviation) busulfan clearance was 3.2 ± 0.56 mL/min/kg in the separate population of 95 patients who received oral busulfan and 103 ± 24 ml/min/m(2) in the 57 patients who received IV busulfan.,Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21135089/),[ml] / [kg·min],3.2,224534,DB00143,Glutathione
,21135089,clearance,The average (± standard deviation) busulfan clearance was 3.2 ± 0.56 mL/min/kg in the separate population of 95 patients who received oral busulfan and 103 ± 24 ml/min/m(2) in the 57 patients who received IV busulfan.,Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21135089/),[min·ml] / [m(2],103,224535,DB00143,Glutathione
,25505606,systemic clearance rate,Intravenous administration of MM-433593 to cynomolgus monkeys produced a rapid distribution phase and slower elimination phase with a mean systemic clearance rate of 8-11 mL/min/kg.,"Metabolism and disposition of MM-433593, a selective FAAH-1 inhibitor, in monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25505606/),[ml] / [kg·min],8-11,226352,DB00143,Glutathione
,25505606,Absolute oral bioavailability,Absolute oral bioavailability was determined to be 14-21% with maximum plasma concentrations reached ∼3 h (T max) following a 10 mg/kg oral dose.,"Metabolism and disposition of MM-433593, a selective FAAH-1 inhibitor, in monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25505606/),%,14-21,226353,DB00143,Glutathione
,25505606,terminal half-life,"The average terminal half-life of MM-433593 was 17-20 h, and there were no qualitative sex differences in the metabolite profile of MM-433593.","Metabolism and disposition of MM-433593, a selective FAAH-1 inhibitor, in monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25505606/),h,17-20,226354,DB00143,Glutathione
,27028877,Ki,"These studies revealed that AM-1-124, possessing a 2,3,5,6-tetrafluorophenylsulfonamide group, retained STAT3 protein affinity (Ki =15 μm), as well as selectivity over STAT1 (Ki >250 μm).",Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27028877/),μm,15,228942,DB00143,Glutathione
>,27028877,Ki,"These studies revealed that AM-1-124, possessing a 2,3,5,6-tetrafluorophenylsulfonamide group, retained STAT3 protein affinity (Ki =15 μm), as well as selectivity over STAT1 (Ki >250 μm).",Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27028877/),μm,250,228943,DB00143,Glutathione
,27028877,t1/2,"Moreover, in both hepatocytes and in in vivo pharmacokinetic studies (CD-1 mice), AM-1-124 was found to be dramatically more stable than SH-4-054 (t1/2 =1.42 h cf. 10 min, respectively).",Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27028877/),h,1.42,228944,DB00143,Glutathione
,27028877,t1/2,"Moreover, in both hepatocytes and in in vivo pharmacokinetic studies (CD-1 mice), AM-1-124 was found to be dramatically more stable than SH-4-054 (t1/2 =1.42 h cf. 10 min, respectively).",Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27028877/),min,10,228945,DB00143,Glutathione
,22352389,total recovery,"TH-302 was extensively metabolized with total recovery of 75.1%, with 47.5% and 25.3% excreted through the urine and through the bile into the feces, respectively.",Metabolism and excretion of TH-302 in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22352389/),%,75.1,231141,DB00143,Glutathione
,22352389,total recovery,"TH-302 was extensively metabolized with total recovery of 75.1%, with 47.5% and 25.3% excreted through the urine and through the bile into the feces, respectively.",Metabolism and excretion of TH-302 in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22352389/),%,47.5,231142,DB00143,Glutathione
,22352389,total recovery,"TH-302 was extensively metabolized with total recovery of 75.1%, with 47.5% and 25.3% excreted through the urine and through the bile into the feces, respectively.",Metabolism and excretion of TH-302 in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22352389/),%,25.3,231143,DB00143,Glutathione
,11420329,absorption half life (t(abs)),"After modelling of the data, the following pharmacokinetic variables were calculated: absorption half life (t(abs)), 0.51 hours; volume of distribution (V/F(oral)), 0.80 litres/kg; clearance (CL/F(oral)), 0.22 litres/h; they were consistent with population pharmacokinetic studies.",Paracetamol overdose in a preterm neonate. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420329/),h,0.51,231594,DB00143,Glutathione
,11420329,volume of distribution (V/F(oral)),"After modelling of the data, the following pharmacokinetic variables were calculated: absorption half life (t(abs)), 0.51 hours; volume of distribution (V/F(oral)), 0.80 litres/kg; clearance (CL/F(oral)), 0.22 litres/h; they were consistent with population pharmacokinetic studies.",Paracetamol overdose in a preterm neonate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420329/),[l] / [kg],0.80,231595,DB00143,Glutathione
,11420329,clearance (CL/F(oral)),"After modelling of the data, the following pharmacokinetic variables were calculated: absorption half life (t(abs)), 0.51 hours; volume of distribution (V/F(oral)), 0.80 litres/kg; clearance (CL/F(oral)), 0.22 litres/h; they were consistent with population pharmacokinetic studies.",Paracetamol overdose in a preterm neonate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420329/),[l] / [h],0.22,231596,DB00143,Glutathione
,11420329,plasma half life (Tbeta),"The increased plasma half life (Tbeta) of 5.69 hours thus reflected normal slower metabolism in infants, rather than toxicity.",Paracetamol overdose in a preterm neonate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420329/),h,5.69,231597,DB00143,Glutathione
,7853160,rate,GSHE added to rat plasma at a concentration of 10 mM was hydrolyzed to GSH at a rate of 0.1 mumol/min.,Disposition of glutathione monoethyl ester in the rat: glutathione ester is a slow release form of extracellular glutathione. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853160/),[μM] / [min],0.1,232050,DB00143,Glutathione
,8422741,plasma clearance,"The plasma clearance of R-bromisovalum was about 12 times higher than that of S-bromisovalum (9.3 +/- 3.7 and 0.78 +/- 0.38 L/min, respectively), which was in agreement with the higher urinary cumulative excretion for the mercapturate derived from R-bromisovalum: 26% +/- 4% of the dose versus 8% +/- 3% of the dose for the mercapturate derived from S-bromisovalum.",Characterization of glutathione conjugation in humans: stereoselectivity in plasma elimination pharmacokinetics and urinary excretion of (R)- and (S)-2-bromoisovalerylurea in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422741/),[l] / [min],9.3,233535,DB00143,Glutathione
,8422741,plasma clearance,"The plasma clearance of R-bromisovalum was about 12 times higher than that of S-bromisovalum (9.3 +/- 3.7 and 0.78 +/- 0.38 L/min, respectively), which was in agreement with the higher urinary cumulative excretion for the mercapturate derived from R-bromisovalum: 26% +/- 4% of the dose versus 8% +/- 3% of the dose for the mercapturate derived from S-bromisovalum.",Characterization of glutathione conjugation in humans: stereoselectivity in plasma elimination pharmacokinetics and urinary excretion of (R)- and (S)-2-bromoisovalerylurea in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422741/),[l] / [min],0.78,233536,DB00143,Glutathione
,12738715,elimination half-life,"Pharmacokinetic studies of TLK286 on cycle 1 revealed a mean elimination half-life of 18 min (95% confidence interval, 16.1-19.9).",Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12738715/),min,18,233960,DB00143,Glutathione
,10972486,peak value,"Intravenous administration of CHG(Et)2 resulted in the rapid appearance of CHG(Et)2 in the plasma of tumor-bearing mice with a peak value of 40-60 microM, followed by a first-order decrease with a half-life of about 10 min.",Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972486/),μM,40-60,234017,DB00143,Glutathione
,10972486,half-life,"Intravenous administration of CHG(Et)2 resulted in the rapid appearance of CHG(Et)2 in the plasma of tumor-bearing mice with a peak value of 40-60 microM, followed by a first-order decrease with a half-life of about 10 min.",Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972486/),min,10,234018,DB00143,Glutathione
,10972486,maximum concentration,"There was a corresponding increase in the concentration of inhibitory CHG in the B16 tumors, with a maximum concentration in the range 30-60 microM occurring at 15 min, followed by a decrease to a plateau value of about 6 microM after 120 min.",Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972486/),μM,30-60,234019,DB00143,Glutathione
,10972486,maximum concentration,"There was a corresponding increase in the concentration of inhibitory CHG in the B16 tumors, with a maximum concentration in the range 30-60 microM occurring at 15 min, followed by a decrease to a plateau value of about 6 microM after 120 min.",Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972486/),,6,234020,DB00143,Glutathione
,24046333,apparent K(m),"The apparent K(m) and V(max) values of M10 formation were 174 ± 8 µM and 14.0 ± 0.3 pmol•min(-1)•mg protein(-1) in human and 132 ± 9 µM and 131 ± 4 pmol•min(-1)•mg protein(-1) in monkey, respectively.","Metabolism and excretion of 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine, an HSP90 inhibitor, in rats and dogs and assessment of its metabolic profile in plasma of humans. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24046333/),μM,174,234085,DB00143,Glutathione
,24046333,apparent K(m),"The apparent K(m) and V(max) values of M10 formation were 174 ± 8 µM and 14.0 ± 0.3 pmol•min(-1)•mg protein(-1) in human and 132 ± 9 µM and 131 ± 4 pmol•min(-1)•mg protein(-1) in monkey, respectively.","Metabolism and excretion of 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine, an HSP90 inhibitor, in rats and dogs and assessment of its metabolic profile in plasma of humans. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24046333/),μM,132,234086,DB00143,Glutathione
,24046333,V(max),"The apparent K(m) and V(max) values of M10 formation were 174 ± 8 µM and 14.0 ± 0.3 pmol•min(-1)•mg protein(-1) in human and 132 ± 9 µM and 131 ± 4 pmol•min(-1)•mg protein(-1) in monkey, respectively.","Metabolism and excretion of 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine, an HSP90 inhibitor, in rats and dogs and assessment of its metabolic profile in plasma of humans. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24046333/),[-1·mg·pM] / [min],14.0,234087,DB00143,Glutathione
,24046333,V(max),"The apparent K(m) and V(max) values of M10 formation were 174 ± 8 µM and 14.0 ± 0.3 pmol•min(-1)•mg protein(-1) in human and 132 ± 9 µM and 131 ± 4 pmol•min(-1)•mg protein(-1) in monkey, respectively.","Metabolism and excretion of 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine, an HSP90 inhibitor, in rats and dogs and assessment of its metabolic profile in plasma of humans. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24046333/),[-1·mg·pM] / [min],131,234088,DB00143,Glutathione
,18496131,area under the curve,"A cohort of 124 Caucasian patients received a high-dose chemotherapy combination consisting of cyclophosphamide (4-6 g/m2), thiotepa (320-480 mg/m2) and carboplatin (area under the curve 13-20 mg x min/ml) as intravenous infusions over 4 consecutive days.","Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18496131/),[mg·min] / [ml],13-20,234196,DB00143,Glutathione
,6857680,alpha,"A linear two-compartment open model described the blood MeCl data: alpha and beta phase elimination half-times corresponded to approximately 4 and 15 min, respectively, in rats, and 8 and 40 min in dogs.",Pharmacokinetics and metabolism of inhaled methyl chloride in the rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6857680/),min,4,234224,DB00143,Glutathione
,6857680,alpha,"A linear two-compartment open model described the blood MeCl data: alpha and beta phase elimination half-times corresponded to approximately 4 and 15 min, respectively, in rats, and 8 and 40 min in dogs.",Pharmacokinetics and metabolism of inhaled methyl chloride in the rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6857680/),min,15,234225,DB00143,Glutathione
,6857680,alpha,"A linear two-compartment open model described the blood MeCl data: alpha and beta phase elimination half-times corresponded to approximately 4 and 15 min, respectively, in rats, and 8 and 40 min in dogs.",Pharmacokinetics and metabolism of inhaled methyl chloride in the rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6857680/),min,8,234226,DB00143,Glutathione
,6857680,beta phase elimination half-times,"A linear two-compartment open model described the blood MeCl data: alpha and beta phase elimination half-times corresponded to approximately 4 and 15 min, respectively, in rats, and 8 and 40 min in dogs.",Pharmacokinetics and metabolism of inhaled methyl chloride in the rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6857680/),min,15,234227,DB00143,Glutathione
,6857680,beta phase elimination half-times,"A linear two-compartment open model described the blood MeCl data: alpha and beta phase elimination half-times corresponded to approximately 4 and 15 min, respectively, in rats, and 8 and 40 min in dogs.",Pharmacokinetics and metabolism of inhaled methyl chloride in the rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6857680/),min,8,234228,DB00143,Glutathione
,6857680,beta phase elimination half-times,"A linear two-compartment open model described the blood MeCl data: alpha and beta phase elimination half-times corresponded to approximately 4 and 15 min, respectively, in rats, and 8 and 40 min in dogs.",Pharmacokinetics and metabolism of inhaled methyl chloride in the rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6857680/),min,40,234229,DB00143,Glutathione
,2069422,half-life (t1/2),"Total radioactivity eliminated in water indicated three phases with a calculated half-life (t1/2) of 7 days and predicted 90 and 95% clearance of 162 and 211 days, respectively.",Biotransformation and disposition of hexachlorocyclopentadiene in fish. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069422/),d,7,235151,DB00143,Glutathione
,2069422,clearance,"Total radioactivity eliminated in water indicated three phases with a calculated half-life (t1/2) of 7 days and predicted 90 and 95% clearance of 162 and 211 days, respectively.",Biotransformation and disposition of hexachlorocyclopentadiene in fish. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069422/),d,162,235152,DB00143,Glutathione
,2069422,clearance,"Total radioactivity eliminated in water indicated three phases with a calculated half-life (t1/2) of 7 days and predicted 90 and 95% clearance of 162 and 211 days, respectively.",Biotransformation and disposition of hexachlorocyclopentadiene in fish. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069422/),d,211,235153,DB00143,Glutathione
,2069422,t1/2,"For a static system, two phases of elimination were detected with a calculated t1/2 of 9 days and predicted 90 and 95% clearance of 77 and 107 days, respectively.",Biotransformation and disposition of hexachlorocyclopentadiene in fish. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069422/),d,9,235154,DB00143,Glutathione
,2069422,90,"For a static system, two phases of elimination were detected with a calculated t1/2 of 9 days and predicted 90 and 95% clearance of 77 and 107 days, respectively.",Biotransformation and disposition of hexachlorocyclopentadiene in fish. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069422/),d,77,235155,DB00143,Glutathione
,2069422,95,"For a static system, two phases of elimination were detected with a calculated t1/2 of 9 days and predicted 90 and 95% clearance of 77 and 107 days, respectively.",Biotransformation and disposition of hexachlorocyclopentadiene in fish. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069422/),d,77,235156,DB00143,Glutathione
,2069422,clearance,"For a static system, two phases of elimination were detected with a calculated t1/2 of 9 days and predicted 90 and 95% clearance of 77 and 107 days, respectively.",Biotransformation and disposition of hexachlorocyclopentadiene in fish. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069422/),d,77,235157,DB00143,Glutathione
,2069422,clearance,"For a static system, two phases of elimination were detected with a calculated t1/2 of 9 days and predicted 90 and 95% clearance of 77 and 107 days, respectively.",Biotransformation and disposition of hexachlorocyclopentadiene in fish. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069422/),d,107,235158,DB00143,Glutathione
,20237319,area under the concentration-versus-time curve (AUC),Intravenous Bu was administered every 6 hours as part of a conditioning regimen with PK-based dose adjustment to target a conservative area under the concentration-versus-time curve (AUC) range (900-1350 microMol*min).,Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20237319/),min·μMol,900-1350,235615,DB00143,Glutathione
>,14570767,IC50,"In the absence of preincubation, the racemate was found to be a weak inhibitor (IC50 > 100 microM) of phenacetin O-deethylation (POD) (CYP1A2), paclitaxel 6alpha-hydroxylation (CYP2C8), diclofenac 4'-hydroxylation (CYP2C9), (S)-mephenytoin 4'-hydroxylation (CYP2C19), bufuralol 1'-hydroxylation (CYP2D6), testosterone 6beta-hydroxylation (CYP3A4), chlorzoxazone 6-hydroxylation (CYP2E1), and bupropion hydroxylation (CYP2B6).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,100,238065,DB00143,Glutathione
,14570767,kinact,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238066,DB00143,Glutathione
,14570767,apparent KI,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238067,DB00143,Glutathione
,14570767,kinact/KIratio,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0003,238068,DB00143,Glutathione
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.037,238069,DB00143,Glutathione
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,98.2,238070,DB00143,Glutathione
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0004,238071,DB00143,Glutathione
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.012,238072,DB00143,Glutathione
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,66.6,238073,DB00143,Glutathione
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0002,238074,DB00143,Glutathione
,8398704,terminal half-life,The mean terminal half-life at each dose level ranged from 5.1-5.8 h.,Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398704/),h,5.1-5.8,238754,DB00143,Glutathione
,8398704,total body clearance,"The mean area under the plasma concentration-time curve was linearly related to dose, and mean total body clearance ranged from 46.6-94.0 ml-1 min-1 m-2; renal clearance accounted for 65.7-79.3%.",Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398704/),1/[(m)^2·min·ml],46.6-94.0,238755,DB00143,Glutathione
,26523356,critical micelle concentrations,"Both DCM and DEM had an average size of around 130 nm, camptothecin (CPT) loadings of around 7.7% and critical micelle concentrations of around 0.95 μg/ml.",Pharmacokinetics and antitumor efficacy of micelles assembled from multiarmed amphiphilic copolymers with drug conjugates in comparison with drug-encapsulated micelles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26523356/),[μg] / [ml],0.95,239942,DB00143,Glutathione
,1907548,volume of distribution,The volume of distribution of exogenous glutathione was 176 +/- 107 ml kg-1 and the elimination rate constant was 0.063 +/- 0.027 min-1 corresponding to a half-life of 14.1 +/- 9.2 min.,High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1907548/),[ml] / [kg],176,241257,DB00143,Glutathione
,1907548,elimination rate constant,The volume of distribution of exogenous glutathione was 176 +/- 107 ml kg-1 and the elimination rate constant was 0.063 +/- 0.027 min-1 corresponding to a half-life of 14.1 +/- 9.2 min.,High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1907548/),1/[min],0.063,241258,DB00143,Glutathione
,1907548,half-life,The volume of distribution of exogenous glutathione was 176 +/- 107 ml kg-1 and the elimination rate constant was 0.063 +/- 0.027 min-1 corresponding to a half-life of 14.1 +/- 9.2 min.,High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1907548/),min,14.1,241259,DB00143,Glutathione
,12969965,clearance,"On day 29, etoposide clearance was higher (47.4 versus 29.2 mL/min/m2, P <.0001) than at week 54.",Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12969965/),[ml] / [m2·min],47.4,241630,DB00143,Glutathione
,12969965,clearance,"On day 29, etoposide clearance was higher (47.4 versus 29.2 mL/min/m2, P <.0001) than at week 54.",Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12969965/),[ml] / [m2·min],29.2,241631,DB00143,Glutathione
,26419450,clearance,"The typical value of clearance and volume of distribution were 11.0 l/h and 42.4 l, respectively.",Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26419450/),[l] / [h],11.0,242062,DB00143,Glutathione
,26419450,volume of distribution,"The typical value of clearance and volume of distribution were 11.0 l/h and 42.4 l, respectively.",Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26419450/),l,42.4,242063,DB00143,Glutathione
,33358433,max concentration,"After oral administration, lusianthridin was quickly absorbed into plasma and reached the max concentration of 236.22 ng/mL at 22.00 min.","Pharmacokinetic, bioavailability, and metabolism studies of lusianthridin, a dihydrophenanthrene compound, in rats by liquid chromatography/electrospray ionization tandem mass spectrometry. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33358433/),[ng] / [ml],236.22,242064,DB00143,Glutathione
,33358433,elimination half life,The elimination half life of lusianthridin from plasma was approximately 83.05-104.47 min and the oral absolute bioavailability was calculated as 30.93 %.,"Pharmacokinetic, bioavailability, and metabolism studies of lusianthridin, a dihydrophenanthrene compound, in rats by liquid chromatography/electrospray ionization tandem mass spectrometry. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33358433/),min,83.05-104.47,242065,DB00143,Glutathione
,33358433,oral absolute bioavailability,The elimination half life of lusianthridin from plasma was approximately 83.05-104.47 min and the oral absolute bioavailability was calculated as 30.93 %.,"Pharmacokinetic, bioavailability, and metabolism studies of lusianthridin, a dihydrophenanthrene compound, in rats by liquid chromatography/electrospray ionization tandem mass spectrometry. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33358433/),%,30.93,242066,DB00143,Glutathione
,26851241,IC50,IC50 values from recombinant enzymes indicated that an interaction is most probable for CYP2A6 (IC50 = 6.1 µM).,Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851241/),μM,6.1,242385,DB00143,Glutathione
,26851241,KS,t-CA is a type I ligand for CYP2A6 (KS = 14.9 µM).,Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851241/),μM,14.9,242386,DB00143,Glutathione
,26851241,K(I),"Using a static model and mechanism-based inhibition parameters (K(I) = 18.0 µM; k(inact) = 0.056 minute(-1)), changes in the area under the concentration-time curve (AUC) for nicotine and letrozole were predicted in the presence of t-CA (0.1 and 1 µM).",Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851241/),μM,18.0,242387,DB00143,Glutathione
,26851241,k(inact),"Using a static model and mechanism-based inhibition parameters (K(I) = 18.0 µM; k(inact) = 0.056 minute(-1)), changes in the area under the concentration-time curve (AUC) for nicotine and letrozole were predicted in the presence of t-CA (0.1 and 1 µM).",Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851241/),1/[minute],0.056,242388,DB00143,Glutathione
,26851241,AUC fold-change,The AUC fold-change ranged from 1.1 to 3.6.,Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851241/),,1.1,242389,DB00143,Glutathione
,21701126,maximum plasma concentration (C(max)),"After single oral administration, the maximum plasma concentration (C(max)) and area under the curve (AUC(0-∞)) were 84.7 ± 25.2 µmol/L and 2,676.4 ± 708.3 µmol/L·h, respectively.",Single dose administration of L-carnitine improves antioxidant activities in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21701126/),[μM] / [l],84.7,242391,DB00143,Glutathione
,21701126,area under the curve (AUC(0-∞)),"After single oral administration, the maximum plasma concentration (C(max)) and area under the curve (AUC(0-∞)) were 84.7 ± 25.2 µmol/L and 2,676.4 ± 708.3 µmol/L·h, respectively.",Single dose administration of L-carnitine improves antioxidant activities in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21701126/),[μM] / [h·l],"2,676.4",242392,DB00143,Glutathione
,21701126,half-life,"The half-life and the time required to reach the C(max) was 60.3 ± 15.0 min and 3.4 ± 0.46 h, respectively.",Single dose administration of L-carnitine improves antioxidant activities in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21701126/),min,60.3,242393,DB00143,Glutathione
,21701126,time required to reach the C(max),"The half-life and the time required to reach the C(max) was 60.3 ± 15.0 min and 3.4 ± 0.46 h, respectively.",Single dose administration of L-carnitine improves antioxidant activities in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21701126/),h,3.4,242394,DB00143,Glutathione
,28399620,MED,"Mean MED in pre-Lin-GSH arm was superior to mean MED in placebo arm (135±5.53 mJ/cm2 vs. 105±7.64 mJ/cm2, P=0.0003).","Efficacy and safety of S-acyl glutathione 2% cream vs. placebo against UVB-induced erythema: a randomized, double-blinded clinical trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399620/),[mj] / [cm2],135,242901,DB00143,Glutathione
,28399620,MED,"Mean MED in pre-Lin-GSH arm was superior to mean MED in placebo arm (135±5.53 mJ/cm2 vs. 105±7.64 mJ/cm2, P=0.0003).","Efficacy and safety of S-acyl glutathione 2% cream vs. placebo against UVB-induced erythema: a randomized, double-blinded clinical trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399620/),[mj] / [cm2],105,242902,DB00143,Glutathione
,15005638,maximal plasma concentration,Single-dose administration of 7.5 mg/kg produced a maximal plasma concentration of 2.3-2.7 mg/L for quinupristin and 6.1-8.2 mg/L for dalfopristin.,Clinical pharmacokinetics of quinupristin/dalfopristin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),[mg] / [l],2.3-2.7,243865,DB00143,Glutathione
,15005638,maximal plasma concentration,Single-dose administration of 7.5 mg/kg produced a maximal plasma concentration of 2.3-2.7 mg/L for quinupristin and 6.1-8.2 mg/L for dalfopristin.,Clinical pharmacokinetics of quinupristin/dalfopristin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),[mg] / [l],6.1-8.2,243866,DB00143,Glutathione
,15005638,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) obtained with the same dose was 2.7-3.3 and 6.5-7.7 mg.,Clinical pharmacokinetics of quinupristin/dalfopristin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),mg,2.7-3.3,243867,DB00143,Glutathione
,15005638,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) obtained with the same dose was 2.7-3.3 and 6.5-7.7 mg.,Clinical pharmacokinetics of quinupristin/dalfopristin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),mg,6.5-7.7,243868,DB00143,Glutathione
,15005638,steady-state volumes of distribution,"Quinupristin and dalfopristin exhibit steady-state volumes of distribution of 0.46-0.54 and 0.24-0.30 L/kg, respectively.",Clinical pharmacokinetics of quinupristin/dalfopristin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),[l] / [kg],0.46-0.54,243869,DB00143,Glutathione
,15005638,steady-state volumes of distribution,"Quinupristin and dalfopristin exhibit steady-state volumes of distribution of 0.46-0.54 and 0.24-0.30 L/kg, respectively.",Clinical pharmacokinetics of quinupristin/dalfopristin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),[l] / [kg],0.24-0.30,243870,DB00143,Glutathione
,15005638,protein binding,"Quinupristin exhibits higher protein binding (55-78%) than dalfopristin (11-26%), though both entities distribute well into tissues.",Clinical pharmacokinetics of quinupristin/dalfopristin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),%,55-78,243871,DB00143,Glutathione
,15005638,protein binding,"Quinupristin exhibits higher protein binding (55-78%) than dalfopristin (11-26%), though both entities distribute well into tissues.",Clinical pharmacokinetics of quinupristin/dalfopristin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),%,11-26,243872,DB00143,Glutathione
,15005638,Extravascular penetration,"Extravascular penetration, as measured in blister fluid, is 40-80%.",Clinical pharmacokinetics of quinupristin/dalfopristin. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),%,40-80,243873,DB00143,Glutathione
,15005638,elimination half-lives,"The elimination half-lives of quinupristin and dalfopristin are similar, and are 0.7-1.3 hours after single doses.",Clinical pharmacokinetics of quinupristin/dalfopristin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),h,0.7-1.3,243874,DB00143,Glutathione
,15005638,half-lives,"The metabolites have slightly longer half-lives, ranging from 1.2 to 1.8 hours.",Clinical pharmacokinetics of quinupristin/dalfopristin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),h,1.2 to 1.8,243875,DB00143,Glutathione
,15005638,clearances,"With repeated doses, plasma clearance of quinupristin and dalfopristin is reduced by approximately 20% compared with single doses, resulting in clearances of 0.7-0.8 L/h/kg.",Clinical pharmacokinetics of quinupristin/dalfopristin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),[l] / [h·kg],0.7-0.8,243876,DB00143,Glutathione
,9590463,peak plasma concentration,"Single-dose administration of OTC resulted in measurable plasma levels at all dosages, with a mean peak plasma concentration of 734 +/- 234 nmol/mL at the highest dosage studied.",A phase I/II evaluation of oral L-2-oxothiazolidine-4-carboxylic acid in asymptomatic patients infected with human immunodeficiency virus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9590463/),[nM] / [ml],734,244691,DB00143,Glutathione
,25565670,steady-state concentration (Css),Bu doses were adjusted to obtain an average steady-state concentration (Css) of 900 mcg/L.,Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25565670/),[mcg] / [l],900,245166,DB00143,Glutathione
,25565670,Css,Median first dose Bu Css was 1000 mcg/L (600-1780 mcg/L).,Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25565670/),[mcg] / [l],1000,245167,DB00143,Glutathione
,25565670,Mortality,"Mortality ≤3 months was associated with higher first dose Bu exposure (1090 versus 980 mcg/L, P = 0.021).",Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25565670/),,109,245168,DB00143,Glutathione
,25565670,Mortality,"Mortality ≤3 months was associated with higher first dose Bu exposure (1090 versus 980 mcg/L, P = 0.021).",Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25565670/),,980,245169,DB00143,Glutathione
,25375771,permeability coefficient,"Having a permeability coefficient of 2.49 × 10(-6) cm s(-1), it was classified as discrete BBB-permeable compound.",Synthesis of a novel cyclic prodrug of S-allyl-glutathione able to attenuate LPS-induced ROS production through the inhibition of MAPK pathways in U937 cells. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25375771/),[cm] / [s],2.49 × 10(-6),245808,DB00143,Glutathione
,1933869,50% inhibitory concentration,Ethacrynic acid inhibits the isoenzymes of GSH transferase with 50% inhibitory concentration values ranging from 0.3 to 6.0 microM and has been shown to restore sensitivity to alkylating agents in drug-resistant animal tumor models.,Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1933869/),μM,0.3 to 6.0,246876,DB00143,Glutathione
,1933869,terminal half-life,The plasma disappearance of thiotepa fit a two-compartment open model with a terminal half-life of approximately 2 h.,Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1933869/),h,2,246877,DB00143,Glutathione
,1933869,terminal half-life,"The harmonic mean terminal half-life of TEPA was 10.4 h, and the TEPA area under the curve (AUC) did not increase with increasing thiotepa dose.",Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1933869/),h,10.4,246878,DB00143,Glutathione
,6632001,percent of,The percent of the administered dose excreted in the urine during the first 6 h was 17.5 for the male rat versus 24.5 for the female rat.,Hepatotoxicity and metabolism of acetaminophen in male and female rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6632001/),,17.5,247435,DB00143,Glutathione
,6632001,percent of,The percent of the administered dose excreted in the urine during the first 6 h was 17.5 for the male rat versus 24.5 for the female rat.,Hepatotoxicity and metabolism of acetaminophen in male and female rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6632001/),,24.5,247436,DB00143,Glutathione
,6632001,excreted,The percent of the administered dose excreted in the urine during the first 6 h was 17.5 for the male rat versus 24.5 for the female rat.,Hepatotoxicity and metabolism of acetaminophen in male and female rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6632001/),,17.5,247437,DB00143,Glutathione
,6632001,excreted,The percent of the administered dose excreted in the urine during the first 6 h was 17.5 for the male rat versus 24.5 for the female rat.,Hepatotoxicity and metabolism of acetaminophen in male and female rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6632001/),,24.5,247438,DB00143,Glutathione
,9475855,apparent half-lives,"[SP-C]2 was removed more slowly than SP-C, with apparent half-lives of 30 and 18 h, respectively.",Removal of a dimeric form of surfactant protein C from mouse lungs: its acceleration by reduction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9475855/),h,30,252322,DB00143,Glutathione
,9475855,apparent half-lives,"[SP-C]2 was removed more slowly than SP-C, with apparent half-lives of 30 and 18 h, respectively.",Removal of a dimeric form of surfactant protein C from mouse lungs: its acceleration by reduction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9475855/),h,18,252323,DB00143,Glutathione
,9475855,conversion rate,"A significant amount of [SP-C]2 was removed as SP-C, and the conversion rate was 0.22 micrograms.h-1.mouse-1.",Removal of a dimeric form of surfactant protein C from mouse lungs: its acceleration by reduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9475855/),[μg] / [h·mouse],0.22,252324,DB00143,Glutathione
,9475855,half-life,"By correcting the removal as SP-C, we obtained 38 h for a possible half-life of [SP-C]2.",Removal of a dimeric form of surfactant protein C from mouse lungs: its acceleration by reduction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9475855/),h,38,252325,DB00143,Glutathione
,21964316,P(app),"Due to the addition of gel formulations comprising 0.5% (m/v) unmodified chitosan/0.5% (m/v) GSH and 0.5% (m/v) chitosan-TGA/0.5% (m/v) GSH, the transport of leuprolide across excised mucosa was improved up to 2.06-fold and 3.79-fold, respectively, in comparison with leuprolide applied in buffer (P(app)=2.87 ± 0.77 × 10⁻⁶ cm/s).",Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21964316/),[cm] / [s],2.87,252533,DB00143,Glutathione
,21964316,relative bioavailability,"With the oral gel formulation comprising 8 mg of chitosan-TGA, a relative bioavailability (versus s.c. injection) of 4.5% was achieved in contrast to the control displaying a relative bioavailability of 1.2%.",Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21964316/),%,4.5,252534,DB00143,Glutathione
,21964316,relative bioavailability,"With the oral gel formulation comprising 8 mg of chitosan-TGA, a relative bioavailability (versus s.c. injection) of 4.5% was achieved in contrast to the control displaying a relative bioavailability of 1.2%.",Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21964316/),%,1.2,252535,DB00143,Glutathione
,22668502,oral bioavailability (BA),"After oral and intravenous administration, SEI was quickly eliminated from plasma and its oral bioavailability (BA) was about 37.25%, which was smaller than intraportal BA (81.17%), but similar to intraduodenal BA (36.91%), suggesting that gastric first-pass effect of SEI is negligible, and hepatic first-pass effect was approximately 18.83%.","Pharmacokinetics, tissue distribution and metabolism of senkyunolide I, a major bioactive component in Ligusticum chuanxiong Hort. (Umbelliferae). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22668502/),%,37.25,253662,DB00143,Glutathione
,22668502,oral bioavailability (BA),"After oral and intravenous administration, SEI was quickly eliminated from plasma and its oral bioavailability (BA) was about 37.25%, which was smaller than intraportal BA (81.17%), but similar to intraduodenal BA (36.91%), suggesting that gastric first-pass effect of SEI is negligible, and hepatic first-pass effect was approximately 18.83%.","Pharmacokinetics, tissue distribution and metabolism of senkyunolide I, a major bioactive component in Ligusticum chuanxiong Hort. (Umbelliferae). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22668502/),%,81.17,253663,DB00143,Glutathione
,22668502,oral bioavailability (BA),"After oral and intravenous administration, SEI was quickly eliminated from plasma and its oral bioavailability (BA) was about 37.25%, which was smaller than intraportal BA (81.17%), but similar to intraduodenal BA (36.91%), suggesting that gastric first-pass effect of SEI is negligible, and hepatic first-pass effect was approximately 18.83%.","Pharmacokinetics, tissue distribution and metabolism of senkyunolide I, a major bioactive component in Ligusticum chuanxiong Hort. (Umbelliferae). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22668502/),%,36.91,253664,DB00143,Glutathione
,30685819,peak concentration,The results showed that the Se reached the peak concentration of (0.2451 ± 0.0123) μg mL-1 at (0.4237 ± 0.0185) h following intramuscular injection administration and (0.1781 ± 0.0142) μg mL-1 at (2.1517 ± 0.1806) h following oral administration in the plasma.,Pharmacokinetics of Selenium in Healthy Piglets After Different Routes of Administration: Application of Pharmacokinetic Data to the Risk Assessment of Selenium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30685819/),[μg] / [ml],0.2451,254093,DB00143,Glutathione
,30685819,peak concentration,The results showed that the Se reached the peak concentration of (0.2451 ± 0.0123) μg mL-1 at (0.4237 ± 0.0185) h following intramuscular injection administration and (0.1781 ± 0.0142) μg mL-1 at (2.1517 ± 0.1806) h following oral administration in the plasma.,Pharmacokinetics of Selenium in Healthy Piglets After Different Routes of Administration: Application of Pharmacokinetic Data to the Risk Assessment of Selenium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30685819/),[μg] / [ml],0.1781,254094,DB00143,Glutathione
,30685819,AUC,"The average AUC of sodium selenite following intramuscular injection and oral administrations was (31.7260 ± 1.3574) and (75.1460 ± 3.4127) mg L-1 h-1, respectively.",Pharmacokinetics of Selenium in Healthy Piglets After Different Routes of Administration: Application of Pharmacokinetic Data to the Risk Assessment of Selenium. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30685819/),[mg] / [h·l],31.7260,254095,DB00143,Glutathione
,30685819,AUC,"The average AUC of sodium selenite following intramuscular injection and oral administrations was (31.7260 ± 1.3574) and (75.1460 ± 3.4127) mg L-1 h-1, respectively.",Pharmacokinetics of Selenium in Healthy Piglets After Different Routes of Administration: Application of Pharmacokinetic Data to the Risk Assessment of Selenium. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30685819/),[mg] / [h·l],75.1460,254096,DB00143,Glutathione
,16896064,urinary,"The mean urinary and fecal excretion of radioactivity up to 144 h were 71.2 and 2.9%, respectively, indicating renal excretion was the major route of elimination of [14C]irofulven.","Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16896064/),%,71.2,254518,DB00143,Glutathione
,16896064,urinary,"The mean urinary and fecal excretion of radioactivity up to 144 h were 71.2 and 2.9%, respectively, indicating renal excretion was the major route of elimination of [14C]irofulven.","Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16896064/),%,2.9,254519,DB00143,Glutathione
,16896064,C(max),"The C(max), AUC(0-infinity), and terminal half-life values for total radioactivity were 1130 ng-Eq/ml, 24,400 ng-Eq . h/ml, and 116.5 h, respectively, and the corresponding values for irofulven were 82.7 ng/ml, 65.5 ng .","Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16896064/),[ng-eq] / [ml],1130,254520,DB00143,Glutathione
,16896064,C(max),"The C(max), AUC(0-infinity), and terminal half-life values for total radioactivity were 1130 ng-Eq/ml, 24,400 ng-Eq . h/ml, and 116.5 h, respectively, and the corresponding values for irofulven were 82.7 ng/ml, 65.5 ng .","Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16896064/),[ng] / [ml],82.7,254521,DB00143,Glutathione
,16896064,AUC(0-infinity),"The C(max), AUC(0-infinity), and terminal half-life values for total radioactivity were 1130 ng-Eq/ml, 24,400 ng-Eq . h/ml, and 116.5 h, respectively, and the corresponding values for irofulven were 82.7 ng/ml, 65.5 ng .","Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16896064/),[h·ng-eq] / [ml],"24,400",254522,DB00143,Glutathione
,16896064,AUC(0-infinity),"The C(max), AUC(0-infinity), and terminal half-life values for total radioactivity were 1130 ng-Eq/ml, 24,400 ng-Eq . h/ml, and 116.5 h, respectively, and the corresponding values for irofulven were 82.7 ng/ml, 65.5 ng .","Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16896064/),[ng] / [ml],82.7,254523,DB00143,Glutathione
,16896064,AUC(0-infinity),"The C(max), AUC(0-infinity), and terminal half-life values for total radioactivity were 1130 ng-Eq/ml, 24,400 ng-Eq . h/ml, and 116.5 h, respectively, and the corresponding values for irofulven were 82.7 ng/ml, 65.5 ng .","Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16896064/),ng,65.5,254524,DB00143,Glutathione
,16896064,terminal half-life,"The C(max), AUC(0-infinity), and terminal half-life values for total radioactivity were 1130 ng-Eq/ml, 24,400 ng-Eq . h/ml, and 116.5 h, respectively, and the corresponding values for irofulven were 82.7 ng/ml, 65.5 ng .","Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16896064/),h,116.5,254525,DB00143,Glutathione
,16896064,terminal half-life,"The C(max), AUC(0-infinity), and terminal half-life values for total radioactivity were 1130 ng-Eq/ml, 24,400 ng-Eq . h/ml, and 116.5 h, respectively, and the corresponding values for irofulven were 82.7 ng/ml, 65.5 ng .","Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16896064/),[ng] / [ml],82.7,254526,DB00143,Glutathione
,16896064,terminal half-life,"The C(max), AUC(0-infinity), and terminal half-life values for total radioactivity were 1130 ng-Eq/ml, 24,400 ng-Eq . h/ml, and 116.5 h, respectively, and the corresponding values for irofulven were 82.7 ng/ml, 65.5 ng .","Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16896064/),ng,65.5,254527,DB00143,Glutathione
,11758635,blood-to-plasma ratio,"Levocetirizine and/or its metabolites were not, or only very poorly, associated with blood cells, as the blood-to-plasma ratio was 0.51 to 0.68.","Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758635/),,0.51 to 0.68,254748,DB00143,Glutathione
,11758635,apparent volume of distribution (Vz/F),The mean apparent volume of distribution (Vz/F) was 26.9 1 (0.3 l/kg) indicating that the distribution of levocetirizine is restrictive.,"Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758635/),1,26.9,254749,DB00143,Glutathione
,11758635,protein binding,The protein binding of radiolabelled levocetirizine was 96.1% l h after administration.,"Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758635/),%·h·l,96.1,254750,DB00143,Glutathione
,11758635,protein binding,"In vitro, at concentrations ranging from 0.2 microg/ml to 1 microg/ml, the protein binding was 94.8% to 95.0%.","Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758635/),%,94.8,254751,DB00143,Glutathione
,11758635,protein binding,"In vitro, at concentrations ranging from 0.2 microg/ml to 1 microg/ml, the protein binding was 94.8% to 95.0%.","Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758635/),%,95.0,254752,DB00143,Glutathione
,8104113,t 1/2,Elimination of Mz from all tissues including the tumor was first order with a t 1/2 ranging from 1.52 to 2.03 hr.,Biodistribution and metabolism of orally administered mitozolomide in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104113/),h,1.52 to 2.03,255306,DB00143,Glutathione
less,8270977,half-life (t1/2),"The pattern of GCS inhibition mirrored the plasma BSO concentrations with peak values (level 6, 4 to 8 mmol/L L,R+L,S BSO) observed at the end of the infusion with a rapid decrease in plasma concentrations with an estimated half-life (t1/2) of less than 2 hours.",Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8270977/),h,2,258888,DB00143,Glutathione
,8216377,t 1/2 beta,SR2508 plasma pharmacokinetics in this model were similar to those described previously (t 1/2 beta = 5.83 hr).,SR2508 (etanidazole) pharmacokinetics and biochemical effects in tumor and normal tissues of scid mice bearing HT-29 human colon adenocarcinoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216377/),h,5.83,259004,DB00143,Glutathione
,8216377,volume of distribution,The volume of distribution of 0.32 L/kg suggests minimal tissue binding.,SR2508 (etanidazole) pharmacokinetics and biochemical effects in tumor and normal tissues of scid mice bearing HT-29 human colon adenocarcinoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216377/),[l] / [kg],0.32,259005,DB00143,Glutathione
,25007236,Activity,"Subsequent age-dependent maturation ratio resulted in three different age groups: Activity of busulfan-glutathione conjugate formation was 80%, 61%, and 89% in comparison to adults for children with an age of up to 2 years, > 2-6 years, and > 6-18 years, respectively.",Predictive performance of a physiologically based pharmacokinetic model of busulfan in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25007236/),%,80,260183,DB00143,Glutathione
,25007236,Activity,"Subsequent age-dependent maturation ratio resulted in three different age groups: Activity of busulfan-glutathione conjugate formation was 80%, 61%, and 89% in comparison to adults for children with an age of up to 2 years, > 2-6 years, and > 6-18 years, respectively.",Predictive performance of a physiologically based pharmacokinetic model of busulfan in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25007236/),%,61,260184,DB00143,Glutathione
,25007236,Activity,"Subsequent age-dependent maturation ratio resulted in three different age groups: Activity of busulfan-glutathione conjugate formation was 80%, 61%, and 89% in comparison to adults for children with an age of up to 2 years, > 2-6 years, and > 6-18 years, respectively.",Predictive performance of a physiologically based pharmacokinetic model of busulfan in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25007236/),%,89,260185,DB00143,Glutathione
,28844183,PDI,"Optimized formulation (A10) showed spherical droplets with mean diameter of 60.00 ± 15 nm, PDI of 0.121 ± 0.053, and zeta potential values of -24.40 ± 0.16 mV.",Attenuation of Oxidative Damage by Coenzyme Q10 Loaded Nanoemulsion Through Oral Route for the Management of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28844183/),,0.121,260891,DB00143,Glutathione
,28844183,zeta potential,"Optimized formulation (A10) showed spherical droplets with mean diameter of 60.00 ± 15 nm, PDI of 0.121 ± 0.053, and zeta potential values of -24.40 ± 0.16 mV.",Attenuation of Oxidative Damage by Coenzyme Q10 Loaded Nanoemulsion Through Oral Route for the Management of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28844183/),mv,-24.40,260892,DB00143,Glutathione
,28844183,transmittance,"Prepared nanoemulsion exhibited good transmittance (100.50% ± 0.86%), refractive index (1.41 ± 0.02), and viscosity (30.54 ± 2.86 cP).",Attenuation of Oxidative Damage by Coenzyme Q10 Loaded Nanoemulsion Through Oral Route for the Management of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28844183/),%,100.50,260893,DB00143,Glutathione
,28844183,refractive index,"Prepared nanoemulsion exhibited good transmittance (100.50% ± 0.86%), refractive index (1.41 ± 0.02), and viscosity (30.54 ± 2.86 cP).",Attenuation of Oxidative Damage by Coenzyme Q10 Loaded Nanoemulsion Through Oral Route for the Management of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28844183/),,1.41,260894,DB00143,Glutathione
,28844183,viscosity,"Prepared nanoemulsion exhibited good transmittance (100.50% ± 0.86%), refractive index (1.41 ± 0.02), and viscosity (30.54 ± 2.86 cP).",Attenuation of Oxidative Damage by Coenzyme Q10 Loaded Nanoemulsion Through Oral Route for the Management of Parkinson's Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28844183/),cp,30.54,260895,DB00143,Glutathione
,19449806,C(max),"The serum concentration of EA obtained from the complex (equivalent to 80 mg/kg of EA) was higher (C(max) = 0.54 microg/mL) than that of pure EA (80 mg/kg) (C(max) = 0.21 microg/mL), and the complex maintained effective concentration for a longer period of time in serum.",Enhanced oral bioavailability and antioxidant profile of ellagic acid by phospholipids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19449806/),[μg] / [ml],0.54,261705,DB00143,Glutathione
,19449806,C(max),"The serum concentration of EA obtained from the complex (equivalent to 80 mg/kg of EA) was higher (C(max) = 0.54 microg/mL) than that of pure EA (80 mg/kg) (C(max) = 0.21 microg/mL), and the complex maintained effective concentration for a longer period of time in serum.",Enhanced oral bioavailability and antioxidant profile of ellagic acid by phospholipids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19449806/),[μg] / [ml],0.21,261706,DB00143,Glutathione
,18229623,Tmax,"The pharmacokinetic parameters of LYC oil and L-LYC in a single dose were 4.45 and 7.45 h for Tmax; 0.473 and 0.654 microg x mL(-1) for Cmax; 12.38 and 21.67 mirog x h x mL(-1) for AUC,respectively.",[Lycopene liposomes: lycopene release in vitro and pharmaceutical behaviors and antioxidation in vivo]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18229623/),h,4.45,262200,DB00143,Glutathione
,18229623,Tmax,"The pharmacokinetic parameters of LYC oil and L-LYC in a single dose were 4.45 and 7.45 h for Tmax; 0.473 and 0.654 microg x mL(-1) for Cmax; 12.38 and 21.67 mirog x h x mL(-1) for AUC,respectively.",[Lycopene liposomes: lycopene release in vitro and pharmaceutical behaviors and antioxidation in vivo]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18229623/),h,7.45,262201,DB00143,Glutathione
,18229623,Cmax,"The pharmacokinetic parameters of LYC oil and L-LYC in a single dose were 4.45 and 7.45 h for Tmax; 0.473 and 0.654 microg x mL(-1) for Cmax; 12.38 and 21.67 mirog x h x mL(-1) for AUC,respectively.",[Lycopene liposomes: lycopene release in vitro and pharmaceutical behaviors and antioxidation in vivo]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18229623/),[μg] / [ml],0.473,262202,DB00143,Glutathione
,18229623,Cmax,"The pharmacokinetic parameters of LYC oil and L-LYC in a single dose were 4.45 and 7.45 h for Tmax; 0.473 and 0.654 microg x mL(-1) for Cmax; 12.38 and 21.67 mirog x h x mL(-1) for AUC,respectively.",[Lycopene liposomes: lycopene release in vitro and pharmaceutical behaviors and antioxidation in vivo]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18229623/),[μg] / [ml],0.654,262203,DB00143,Glutathione
,18229623,AUC,"The pharmacokinetic parameters of LYC oil and L-LYC in a single dose were 4.45 and 7.45 h for Tmax; 0.473 and 0.654 microg x mL(-1) for Cmax; 12.38 and 21.67 mirog x h x mL(-1) for AUC,respectively.",[Lycopene liposomes: lycopene release in vitro and pharmaceutical behaviors and antioxidation in vivo]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18229623/),[h·mirog] / [ml],12.38,262204,DB00143,Glutathione
,18229623,AUC,"The pharmacokinetic parameters of LYC oil and L-LYC in a single dose were 4.45 and 7.45 h for Tmax; 0.473 and 0.654 microg x mL(-1) for Cmax; 12.38 and 21.67 mirog x h x mL(-1) for AUC,respectively.",[Lycopene liposomes: lycopene release in vitro and pharmaceutical behaviors and antioxidation in vivo]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18229623/),[h·mirog] / [ml],21.67,262205,DB00143,Glutathione
,25730183,BU,"BU were calculated as 4.02 mL/min per kg and 3380.77 μM/min, respectively.",Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25730183/),[ml] / [kg·min],4.02,262249,DB00143,Glutathione
,25730183,BU,"BU were calculated as 4.02 mL/min per kg and 3380.77 μM/min, respectively.",Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25730183/),[μM] / [min],3380.77,262250,DB00143,Glutathione
,25730183,Cmax,The estimated Cmax was 1.031±0.0325 μg/mL.,Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25730183/),[μg] / [ml],1.031,262251,DB00143,Glutathione
,25730183,t1/2,The estimated t1/2 and Vd values were 3.618±0.1932 h and 1.212±0.0352 L/kg.,Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25730183/),h,3.618,262252,DB00143,Glutathione
,25730183,Vd,The estimated t1/2 and Vd values were 3.618±0.1932 h and 1.212±0.0352 L/kg.,Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25730183/),[l] / [kg],1.212,262253,DB00143,Glutathione
,32953880,retention times,"The HPLC/UV analysis of the decoction revealed the presence of dihydroxycoumarin, quinine, and scopoletin with the following retention times: 2.6, 5.1, and 7.01 min, respectively.",Hepatoprotective Activity of Leptadenia hastata (Asclepiadaceae) on Acetaminophen-Induced Toxicity in Mice: In Vivo Study and Characterization of Bioactive Compounds through Molecular Docking Approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32953880/),min,2.6,263341,DB00143,Glutathione
,32953880,retention times,"The HPLC/UV analysis of the decoction revealed the presence of dihydroxycoumarin, quinine, and scopoletin with the following retention times: 2.6, 5.1, and 7.01 min, respectively.",Hepatoprotective Activity of Leptadenia hastata (Asclepiadaceae) on Acetaminophen-Induced Toxicity in Mice: In Vivo Study and Characterization of Bioactive Compounds through Molecular Docking Approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32953880/),min,5.1,263342,DB00143,Glutathione
,32953880,retention times,"The HPLC/UV analysis of the decoction revealed the presence of dihydroxycoumarin, quinine, and scopoletin with the following retention times: 2.6, 5.1, and 7.01 min, respectively.",Hepatoprotective Activity of Leptadenia hastata (Asclepiadaceae) on Acetaminophen-Induced Toxicity in Mice: In Vivo Study and Characterization of Bioactive Compounds through Molecular Docking Approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32953880/),min,7.01,263343,DB00143,Glutathione
,18661531,Maximum FD(4) concentration,Maximum FD(4) concentration in blood of the patch system was 46.1 +/- 8.9 ng/mL and was reached 3 h after administration.,Design and in vivo evaluation of a patch system based on thiolated polymers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18661531/),[ng] / [ml],46.1,266014,DB00143,Glutathione
,18661531,c(max),In contrast c(max) of control tablets displayed 50.5 +/- 14.9 ng/mL after 2 h and the absorption of FD(4) after administration in oral solution was negligible.,Design and in vivo evaluation of a patch system based on thiolated polymers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18661531/),[ng] / [ml],50.5,266015,DB00143,Glutathione
,18661531,absolute bioavailability,The absolute bioavailability of orally administered patch systems and control tablets was 0.54% and 0.32% respectively.,Design and in vivo evaluation of a patch system based on thiolated polymers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18661531/),%,0.54,266016,DB00143,Glutathione
,18661531,absolute bioavailability,The absolute bioavailability of orally administered patch systems and control tablets was 0.54% and 0.32% respectively.,Design and in vivo evaluation of a patch system based on thiolated polymers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18661531/),%,0.32,266017,DB00143,Glutathione
,9923751,maximal content,"Male subjects exposed to 100 ppm Tri exhibited a maximal content of DCVG in the blood at 2 h after the start of the exposure of 46.1 +/- 14.2 nmol/ml (n = 8), whereas female subjects exposed to 100 ppm Tri exhibited a maximal content of DCVG in the blood at 4 h after the start of the exposure of only 13.4 /- 6.6 nmol/ml (n = 8).","Identification of S-(1,2-dichlorovinyl)glutathione in the blood of human volunteers exposed to trichloroethylene. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923751/),[nM] / [ml],13.4,266079,DB00143,Glutathione
,23669385,time to peak concentration,"Dolutegravir was well tolerated, and absorption of dolutegravir from the suspension formulation was rapid (median time to peak concentration, 0.5 h), declining in a biphasic fashion.","Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23669385/),h,0.5,266812,DB00143,Glutathione
,23669385,terminal plasma half-lives (t1/2),"Dolutegravir and the radioactivity had similar terminal plasma half-lives (t1/2) (15.6 versus 15.7 h), indicating metabolism was formation rate limited with no long-lived metabolites.","Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23669385/),h,15.6,266813,DB00143,Glutathione
,23669385,terminal plasma half-lives (t1/2),"Dolutegravir and the radioactivity had similar terminal plasma half-lives (t1/2) (15.6 versus 15.7 h), indicating metabolism was formation rate limited with no long-lived metabolites.","Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23669385/),h,15.7,266814,DB00143,Glutathione
,32890709,maximum plasma concentration (Cmax),"PK parameters such as maximum plasma concentration (Cmax), 16.78 ± 5.32 ng/mL; time of maximum concentration (Tmax), 18 ± 0.12min; half-life (T1/2) 61.20 ± 9.87min; mean residual time (MRT), 7.53 h s; area under the concentration versus time curve (AUC0-1), 1678 ± 34.13 ng/mL; area under the concentration versus time curve from zero to infinity (AUC0-∞), 1705 ± 28.87 ng/mL; total clearance (CL), 290.67 ± 15.89 mL/min and volume of distribution (Vd) 0.054 L were calculated.",Pharmacological and pharmacokinetic effect of a polyherbal combination with Withania somnifera (L.) Dunal for the management of anxiety. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32890709/),[ng] / [ml],16.78,270021,DB00143,Glutathione
,32890709,time of maximum concentration (Tmax),"PK parameters such as maximum plasma concentration (Cmax), 16.78 ± 5.32 ng/mL; time of maximum concentration (Tmax), 18 ± 0.12min; half-life (T1/2) 61.20 ± 9.87min; mean residual time (MRT), 7.53 h s; area under the concentration versus time curve (AUC0-1), 1678 ± 34.13 ng/mL; area under the concentration versus time curve from zero to infinity (AUC0-∞), 1705 ± 28.87 ng/mL; total clearance (CL), 290.67 ± 15.89 mL/min and volume of distribution (Vd) 0.054 L were calculated.",Pharmacological and pharmacokinetic effect of a polyherbal combination with Withania somnifera (L.) Dunal for the management of anxiety. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32890709/),min,18,270022,DB00143,Glutathione
,32890709,half-life (T1/2),"PK parameters such as maximum plasma concentration (Cmax), 16.78 ± 5.32 ng/mL; time of maximum concentration (Tmax), 18 ± 0.12min; half-life (T1/2) 61.20 ± 9.87min; mean residual time (MRT), 7.53 h s; area under the concentration versus time curve (AUC0-1), 1678 ± 34.13 ng/mL; area under the concentration versus time curve from zero to infinity (AUC0-∞), 1705 ± 28.87 ng/mL; total clearance (CL), 290.67 ± 15.89 mL/min and volume of distribution (Vd) 0.054 L were calculated.",Pharmacological and pharmacokinetic effect of a polyherbal combination with Withania somnifera (L.) Dunal for the management of anxiety. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32890709/),min,61.20,270023,DB00143,Glutathione
,32890709,residual time (MRT),"PK parameters such as maximum plasma concentration (Cmax), 16.78 ± 5.32 ng/mL; time of maximum concentration (Tmax), 18 ± 0.12min; half-life (T1/2) 61.20 ± 9.87min; mean residual time (MRT), 7.53 h s; area under the concentration versus time curve (AUC0-1), 1678 ± 34.13 ng/mL; area under the concentration versus time curve from zero to infinity (AUC0-∞), 1705 ± 28.87 ng/mL; total clearance (CL), 290.67 ± 15.89 mL/min and volume of distribution (Vd) 0.054 L were calculated.",Pharmacological and pharmacokinetic effect of a polyherbal combination with Withania somnifera (L.) Dunal for the management of anxiety. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32890709/),h·s,7.53,270024,DB00143,Glutathione
,32890709,area under the concentration versus time curve (AUC0-1),"PK parameters such as maximum plasma concentration (Cmax), 16.78 ± 5.32 ng/mL; time of maximum concentration (Tmax), 18 ± 0.12min; half-life (T1/2) 61.20 ± 9.87min; mean residual time (MRT), 7.53 h s; area under the concentration versus time curve (AUC0-1), 1678 ± 34.13 ng/mL; area under the concentration versus time curve from zero to infinity (AUC0-∞), 1705 ± 28.87 ng/mL; total clearance (CL), 290.67 ± 15.89 mL/min and volume of distribution (Vd) 0.054 L were calculated.",Pharmacological and pharmacokinetic effect of a polyherbal combination with Withania somnifera (L.) Dunal for the management of anxiety. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32890709/),[ng] / [ml],1678,270025,DB00143,Glutathione
,32890709,area under the concentration versus time curve from zero to infinity (AUC0-∞),"PK parameters such as maximum plasma concentration (Cmax), 16.78 ± 5.32 ng/mL; time of maximum concentration (Tmax), 18 ± 0.12min; half-life (T1/2) 61.20 ± 9.87min; mean residual time (MRT), 7.53 h s; area under the concentration versus time curve (AUC0-1), 1678 ± 34.13 ng/mL; area under the concentration versus time curve from zero to infinity (AUC0-∞), 1705 ± 28.87 ng/mL; total clearance (CL), 290.67 ± 15.89 mL/min and volume of distribution (Vd) 0.054 L were calculated.",Pharmacological and pharmacokinetic effect of a polyherbal combination with Withania somnifera (L.) Dunal for the management of anxiety. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32890709/),[ng] / [ml],1705,270026,DB00143,Glutathione
,32890709,total clearance (CL),"PK parameters such as maximum plasma concentration (Cmax), 16.78 ± 5.32 ng/mL; time of maximum concentration (Tmax), 18 ± 0.12min; half-life (T1/2) 61.20 ± 9.87min; mean residual time (MRT), 7.53 h s; area under the concentration versus time curve (AUC0-1), 1678 ± 34.13 ng/mL; area under the concentration versus time curve from zero to infinity (AUC0-∞), 1705 ± 28.87 ng/mL; total clearance (CL), 290.67 ± 15.89 mL/min and volume of distribution (Vd) 0.054 L were calculated.",Pharmacological and pharmacokinetic effect of a polyherbal combination with Withania somnifera (L.) Dunal for the management of anxiety. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32890709/),[ml] / [min],290.67,270027,DB00143,Glutathione
,32890709,volume of distribution (Vd),"PK parameters such as maximum plasma concentration (Cmax), 16.78 ± 5.32 ng/mL; time of maximum concentration (Tmax), 18 ± 0.12min; half-life (T1/2) 61.20 ± 9.87min; mean residual time (MRT), 7.53 h s; area under the concentration versus time curve (AUC0-1), 1678 ± 34.13 ng/mL; area under the concentration versus time curve from zero to infinity (AUC0-∞), 1705 ± 28.87 ng/mL; total clearance (CL), 290.67 ± 15.89 mL/min and volume of distribution (Vd) 0.054 L were calculated.",Pharmacological and pharmacokinetic effect of a polyherbal combination with Withania somnifera (L.) Dunal for the management of anxiety. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32890709/),l,0.054,270028,DB00143,Glutathione
,14555815,effective concentrations,"Further pharmacokinetic study into the systemic administration of these antioxidants is necessary, using effective concentrations of 5-40 mM for both N-acetyl-L-cysteine and glutathione, and 1-50 units of catalase.",Effects of N-acetyl-L-cysteine and glutathione on antioxidant status of human serum and 3T3 fibroblasts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555815/),m,5-40,273151,DB00143,Glutathione
